{ "version": "2.2", "instance": { "legn-20231231.htm": { "nsprefix": "legn", "nsuri": "http://legendbiotech.com/20231231", "dts": { "inline": { "local": [ "legn-20231231.htm" ] }, "schema": { "local": [ "legn-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "legn-20231231_cal.xml" ] }, "definitionLink": { "local": [ "legn-20231231_def.xml" ] }, "labelLink": { "local": [ "legn-20231231_lab.xml" ] }, "presentationLink": { "local": [ "legn-20231231_pre.xml" ] } }, "keyStandard": 323, "keyCustom": 189, "axisStandard": 30, "axisCustom": 0, "memberStandard": 50, "memberCustom": 97, "hidden": { "total": 8, "http://legendbiotech.com/20231231": 3, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 610, "entityCount": 1, "segmentCount": 157, "elementCount": 867, "unitCount": 10, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 1476, "http://xbrl.sec.gov/dei/2023": 45 }, "report": { "R1": { "role": "http://legendbiotech.com/role/COVER", "longName": "0000001 - Document - COVER", "shortName": "COVER", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R2": { "role": "http://legendbiotech.com/role/AUDITINFORMATION", "longName": "0000002 - Document - AUDIT INFORMATION", "shortName": "AUDIT INFORMATION", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R3": { "role": "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME", "longName": "0000003 - Statement - CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME", "shortName": "CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-1", "name": "legn:RevenueFromLicensingOfIntellectualProperty", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:CostOfSales", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R4": { "role": "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "legn:AdvancePaymentsForPropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R5": { "role": "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-12", "name": "ifrs-full:Equity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "ifrs-full:Equity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R6": { "role": "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AdjustmentsForFinanceIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R7": { "role": "http://legendbiotech.com/role/CORPORATEINFORMATION", "longName": "0000007 - Disclosure - CORPORATE INFORMATION", "shortName": "CORPORATE INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R8": { "role": "http://legendbiotech.com/role/BASISOFPREPARATION", "longName": "0000008 - Disclosure - BASIS OF PREPARATION", "shortName": "BASIS OF PREPARATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R9": { "role": "http://legendbiotech.com/role/CHANGESINACCOUNTINGPOLICIESANDDISCLOSURES", "longName": "0000009 - Disclosure - CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES", "shortName": "CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DescriptionOfVoluntaryChangeInAccountingPolicy", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DescriptionOfVoluntaryChangeInAccountingPolicy", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R10": { "role": "http://legendbiotech.com/role/ISSUEDBUTNOTYETEFFECTIVEINTERNATIONALFINANCIALREPORTINGSTANDARDS", "longName": "0000010 - Disclosure - ISSUED BUT NOT YET EFFECTIVE INTERNATIONAL FINANCIAL REPORTING STANDARDS", "shortName": "ISSUED BUT NOT YET EFFECTIVE INTERNATIONAL FINANCIAL REPORTING STANDARDS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R11": { "role": "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "0000011 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R12": { "role": "http://legendbiotech.com/role/SIGNIFICANTACCOUNTINGJUDGEMENTSANDESTIMATES", "longName": "0000012 - Disclosure - SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES", "shortName": "SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R13": { "role": "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATION", "longName": "0000013 - Disclosure - OPERATING SEGMENT INFORMATION", "shortName": "OPERATING SEGMENT INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R14": { "role": "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINS", "longName": "0000014 - Disclosure - REVENUE, OTHER INCOME AND GAINS", "shortName": "REVENUE, OTHER INCOME AND GAINS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfRevenueOtherIncomeAndGainsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfRevenueOtherIncomeAndGainsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R15": { "role": "http://legendbiotech.com/role/LOSSBEFORETAX", "longName": "0000015 - Disclosure - LOSS BEFORE TAX", "shortName": "LOSS BEFORE TAX", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R16": { "role": "http://legendbiotech.com/role/FINANCECOSTS", "longName": "0000016 - Disclosure - FINANCE COSTS", "shortName": "FINANCE COSTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "legn:EntireDisclosureOfFinanceCostsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:EntireDisclosureOfFinanceCostsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R17": { "role": "http://legendbiotech.com/role/INCOMETAX", "longName": "0000017 - Disclosure - INCOME TAX", "shortName": "INCOME TAX", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R18": { "role": "http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENT", "longName": "0000018 - Disclosure - LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT", "shortName": "LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R19": { "role": "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENT", "longName": "0000019 - Disclosure - PROPERTY, PLANT AND EQUIPMENT", "shortName": "PROPERTY, PLANT AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R20": { "role": "http://legendbiotech.com/role/INTANGIBLEASSETS", "longName": "0000020 - Disclosure - INTANGIBLE ASSETS", "shortName": "INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R21": { "role": "http://legendbiotech.com/role/OTHERNONCURRENTASSETS", "longName": "0000021 - Disclosure - OTHER NON-CURRENT ASSETS", "shortName": "OTHER NON-CURRENT ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R22": { "role": "http://legendbiotech.com/role/LEASES", "longName": "0000022 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R23": { "role": "http://legendbiotech.com/role/COLLABORATIONINVENTORIES", "longName": "0000023 - Disclosure - COLLABORATION INVENTORIES", "shortName": "COLLABORATION INVENTORIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R24": { "role": "http://legendbiotech.com/role/TRADERECEIVABLES", "longName": "0000024 - Disclosure - TRADE RECEIVABLES", "shortName": "TRADE RECEIVABLES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R25": { "role": "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS", "longName": "0000025 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS", "shortName": "PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R26": { "role": "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITS", "longName": "0000026 - Disclosure - CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS", "shortName": "CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R27": { "role": "http://legendbiotech.com/role/TRADEPAYABLES", "longName": "0000027 - Disclosure - TRADE PAYABLES", "shortName": "TRADE PAYABLES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R28": { "role": "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALS", "longName": "0000028 - Disclosure - OTHER PAYABLES AND ACCRUALS", "shortName": "OTHER PAYABLES AND ACCRUALS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R29": { "role": "http://legendbiotech.com/role/DEFERREDTAX", "longName": "0000029 - Disclosure - DEFERRED TAX", "shortName": "DEFERRED TAX", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R30": { "role": "http://legendbiotech.com/role/WARRANTLIABILITY", "longName": "0000030 - Disclosure - WARRANT LIABILITY", "shortName": "WARRANT LIABILITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfWarrantLiabilityExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfWarrantLiabilityExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R31": { "role": "http://legendbiotech.com/role/GOVERNMENTGRANTS", "longName": "0000031 - Disclosure - GOVERNMENT GRANTS", "shortName": "GOVERNMENT GRANTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R32": { "role": "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDING", "longName": "0000032 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING", "shortName": "COLLABORATION INTEREST-BEARING ADVANCED FUNDING", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R33": { "role": "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUM", "longName": "0000033 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM", "shortName": "SHARE CAPITAL AND SHARE PREMIUM", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R34": { "role": "http://legendbiotech.com/role/SHAREOPTIONSCHEME", "longName": "0000034 - Disclosure - SHARE OPTION SCHEME", "shortName": "SHARE OPTION SCHEME", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R35": { "role": "http://legendbiotech.com/role/RESTRICTEDSHAREUNITS", "longName": "0000035 - Disclosure - RESTRICTED SHARE UNITS", "shortName": "RESTRICTED SHARE UNITS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "legn:RestrictedStockUnitsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:RestrictedStockUnitsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R36": { "role": "http://legendbiotech.com/role/RESERVES", "longName": "0000036 - Disclosure - RESERVES", "shortName": "RESERVES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R37": { "role": "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWS", "longName": "0000037 - Disclosure - NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS", "shortName": "NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R38": { "role": "http://legendbiotech.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "0000038 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R39": { "role": "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONS", "longName": "0000039 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R40": { "role": "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORY", "longName": "0000040 - Disclosure - FINANCIAL INSTRUMENTS BY CATEGORY", "shortName": "FINANCIAL INSTRUMENTS BY CATEGORY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R41": { "role": "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTS", "longName": "0000041 - Disclosure - FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS", "shortName": "FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R42": { "role": "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIES", "longName": "0000042 - Disclosure - FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES", "shortName": "FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R43": { "role": "http://legendbiotech.com/role/SUBSEQUENTEVENT", "longName": "0000043 - Disclosure - SUBSEQUENT EVENT", "shortName": "SUBSEQUENT EVENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R44": { "role": "http://legendbiotech.com/role/APPROVALOFTHECONSOLIDATEDFINANCIALSTATEMENTS", "longName": "0000044 - Disclosure - APPROVAL OF THE CONSOLIDATED FINANCIAL STATEMENTS", "shortName": "APPROVAL OF THE CONSOLIDATED FINANCIAL STATEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R45": { "role": "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R46": { "role": "http://legendbiotech.com/role/CORPORATEINFORMATIONTables", "longName": "9954472 - Disclosure - CORPORATE INFORMATION (Tables)", "shortName": "CORPORATE INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R47": { "role": "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "longName": "9954473 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R48": { "role": "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONTables", "longName": "9954474 - Disclosure - OPERATING SEGMENT INFORMATION (Tables)", "shortName": "OPERATING SEGMENT INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R49": { "role": "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTables", "longName": "9954475 - Disclosure - REVENUE, OTHER INCOME AND GAINS (Tables)", "shortName": "REVENUE, OTHER INCOME AND GAINS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R50": { "role": "http://legendbiotech.com/role/LOSSBEFORETAXTables", "longName": "9954476 - Disclosure - LOSS BEFORE TAX (Tables)", "shortName": "LOSS BEFORE TAX (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfProfitLossBeforeTaxArrivedAfterChargingTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfProfitLossBeforeTaxArrivedAfterChargingTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R51": { "role": "http://legendbiotech.com/role/FINANCECOSTSTables", "longName": "9954477 - Disclosure - FINANCE COSTS (Tables)", "shortName": "FINANCE COSTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinanceCostExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinanceCostExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R52": { "role": "http://legendbiotech.com/role/INCOMETAXTables", "longName": "9954478 - Disclosure - INCOME TAX (Tables)", "shortName": "INCOME TAX (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "legn:DetailedDisclosureOfTaxChargesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DetailedDisclosureOfTaxChargesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R53": { "role": "http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTTables", "longName": "9954479 - Disclosure - LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT (Tables)", "shortName": "LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R54": { "role": "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTTables", "longName": "9954480 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R55": { "role": "http://legendbiotech.com/role/INTANGIBLEASSETSTables", "longName": "9954481 - Disclosure - INTANGIBLE ASSETS (Tables)", "shortName": "INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R56": { "role": "http://legendbiotech.com/role/OTHERNONCURRENTASSETSTables", "longName": "9954482 - Disclosure - OTHER NON-CURRENT ASSETS (Tables)", "shortName": "OTHER NON-CURRENT ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R57": { "role": "http://legendbiotech.com/role/LEASESTables", "longName": "9954483 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R58": { "role": "http://legendbiotech.com/role/COLLABORATIONINVENTORIESTables", "longName": "9954484 - Disclosure - COLLABORATION INVENTORIES (Tables)", "shortName": "COLLABORATION INVENTORIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "58", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R59": { "role": "http://legendbiotech.com/role/TRADERECEIVABLESTables", "longName": "9954485 - Disclosure - TRADE RECEIVABLES (Tables)", "shortName": "TRADE RECEIVABLES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationOfTradeReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationOfTradeReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R60": { "role": "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables", "longName": "9954486 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Tables)", "shortName": "PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R61": { "role": "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSTables", "longName": "9954487 - Disclosure - CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS (Tables)", "shortName": "CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R62": { "role": "http://legendbiotech.com/role/TRADEPAYABLESTables", "longName": "9954488 - Disclosure - TRADE PAYABLES (Tables)", "shortName": "TRADE PAYABLES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfTradeAndOtherPayablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfTradeAndOtherPayablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R63": { "role": "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSTables", "longName": "9954489 - Disclosure - OTHER PAYABLES AND ACCRUALS (Tables)", "shortName": "OTHER PAYABLES AND ACCRUALS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R64": { "role": "http://legendbiotech.com/role/DEFERREDTAXTables", "longName": "9954490 - Disclosure - DEFERRED TAX (Tables)", "shortName": "DEFERRED TAX (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R65": { "role": "http://legendbiotech.com/role/WARRANTLIABILITYTables", "longName": "9954491 - Disclosure - WARRANT LIABILITY (Tables)", "shortName": "WARRANT LIABILITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "65", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R66": { "role": "http://legendbiotech.com/role/GOVERNMENTGRANTSTables", "longName": "9954492 - Disclosure - GOVERNMENT GRANTS (Tables)", "shortName": "GOVERNMENT GRANTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "66", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDeferredGovernmentGrantsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDeferredGovernmentGrantsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R67": { "role": "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGTables", "longName": "9954493 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING (Tables)", "shortName": "COLLABORATION INTEREST-BEARING ADVANCED FUNDING (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "67", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R68": { "role": "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMTables", "longName": "9954494 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM (Tables)", "shortName": "SHARE CAPITAL AND SHARE PREMIUM (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "68", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R69": { "role": "http://legendbiotech.com/role/SHAREOPTIONSCHEMETables", "longName": "9954495 - Disclosure - SHARE OPTION SCHEME (Tables)", "shortName": "SHARE OPTION SCHEME (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "69", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R70": { "role": "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSTables", "longName": "9954496 - Disclosure - RESTRICTED SHARE UNITS (Tables)", "shortName": "RESTRICTED SHARE UNITS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "70", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R71": { "role": "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSTables", "longName": "9954497 - Disclosure - NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS (Tables)", "shortName": "NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "71", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R72": { "role": "http://legendbiotech.com/role/COMMITMENTSANDCONTINGENCIESTables", "longName": "9954498 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "72", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfCapitalCommitmentsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfCapitalCommitmentsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R73": { "role": "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSTables", "longName": "9954499 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)", "shortName": "RELATED PARTY TRANSACTIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "73", "firstAnchor": { "contextRef": "c-1", "name": "legn:SummaryOfNatureOfRelatedPartyRelationshipTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:SummaryOfNatureOfRelatedPartyRelationshipTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R74": { "role": "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYTables", "longName": "9954500 - Disclosure - FINANCIAL INSTRUMENTS BY CATEGORY (Tables)", "shortName": "FINANCIAL INSTRUMENTS BY CATEGORY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "74", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R75": { "role": "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSTables", "longName": "9954501 - Disclosure - FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Tables)", "shortName": "FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "75", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R76": { "role": "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESTables", "longName": "9954502 - Disclosure - FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (Tables)", "shortName": "FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "76", "firstAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationAboutSensitivityToReasonablyPossibleChangeInExchangeRatesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:DisclosureOfDetailedInformationAboutSensitivityToReasonablyPossibleChangeInExchangeRatesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R77": { "role": "http://legendbiotech.com/role/CORPORATEINFORMATIONInformationAboutSubsidiariesDetails", "longName": "9954504 - Disclosure - CORPORATE INFORMATION - Information About Subsidiaries (Details)", "shortName": "CORPORATE INFORMATION - Information About Subsidiaries (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:IssuedCapital", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-59", "name": "ifrs-full:NameOfSubsidiary", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R78": { "role": "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails", "longName": "9954505 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R79": { "role": "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyPlantandEquipmentDetails", "longName": "9954506 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of Property, Plant and Equipment (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-77", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-77", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R80": { "role": "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsAmortizedonStraightLineBasisoverUsefulEconomicLivesDetails", "longName": "9954507 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets Amortized on Straight-Line Basis over Useful Economic Lives (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets Amortized on Straight-Line Basis over Useful Economic Lives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-78", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "legn:DisclosureOfIntangibleAssetsAmortizationExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-78", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "legn:DisclosureOfIntangibleAssetsAmortizationExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R81": { "role": "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRightofuseAssetsDepreciatedonStraightlineBasisoverLeaseTermsandEstimatedUsefulLivesDetails", "longName": "9954508 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Right-of-use Assets Depreciated on Straight-line Basis over Lease Terms and Estimated Useful Lives (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Right-of-use Assets Depreciated on Straight-line Basis over Lease Terms and Estimated Useful Lives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-80", "name": "legn:LeaseTermsAndEstimatedUsefulLivesOfRightOfUseAssets", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-80", "name": "legn:LeaseTermsAndEstimatedUsefulLivesOfRightOfUseAssets", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R82": { "role": "http://legendbiotech.com/role/SIGNIFICANTACCOUNTINGJUDGEMENTSANDESTIMATESDetails", "longName": "9954509 - Disclosure - SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES (Details)", "shortName": "SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:WarrantLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": null }, "R83": { "role": "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofRevenueDetails", "longName": "9954510 - Disclosure - OPERATING SEGMENT INFORMATION - Summary of Revenue (Details)", "shortName": "OPERATING SEGMENT INFORMATION - Summary of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R84": { "role": "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofNoncurrentAssetsDetails", "longName": "9954511 - Disclosure - OPERATING SEGMENT INFORMATION - Summary of Non-current Assets (Details)", "shortName": "OPERATING SEGMENT INFORMATION - Summary of Non-current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R85": { "role": "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONAdditionalInformationDetails", "longName": "9954512 - Disclosure - OPERATING SEGMENT INFORMATION - Additional Information (Details)", "shortName": "OPERATING SEGMENT INFORMATION - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-1", "name": "legn:RevenueFromLicensingOfIntellectualProperty", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-109", "name": "legn:RevenueFromLicensingOfIntellectualProperty", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R86": { "role": "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofAnalysisofRevenueDetails", "longName": "9954513 - Disclosure - REVENUE, OTHER INCOME AND GAINS - Summary of Analysis of Revenue (Details)", "shortName": "REVENUE, OTHER INCOME AND GAINS - Summary of Analysis of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-1", "name": "legn:RevenueFromLicensingOfIntellectualProperty", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": null }, "R87": { "role": "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSAdditionalInformationDetails", "longName": "9954514 - Disclosure - REVENUE, OTHER INCOME AND GAINS - Additional Information (Details)", "shortName": "REVENUE, OTHER INCOME AND GAINS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:CurrentTradeReceivables", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-135", "name": "legn:PerformanceObligationSatisfactionPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R88": { "role": "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofDeferredRevenueDetails", "longName": "9954515 - Disclosure - REVENUE, OTHER INCOME AND GAINS - Summary of Deferred Revenue (Details)", "shortName": "REVENUE, OTHER INCOME AND GAINS - Summary of Deferred Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:CurrentContractLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:ContractLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R89": { "role": "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceCompositionDetails", "longName": "9954516 - Disclosure - REVENUE, OTHER INCOME AND GAINS - Summary of Transaction Price Composition (Details)", "shortName": "REVENUE, OTHER INCOME AND GAINS - Summary of Transaction Price Composition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-99", "name": "legn:TransactionPrice", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": null }, "R90": { "role": "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceAllocationtoPerformanceObligationsDetails", "longName": "9954517 - Disclosure - REVENUE, OTHER INCOME AND GAINS - Summary of Transaction Price Allocation to Performance Obligations (Details)", "shortName": "REVENUE, OTHER INCOME AND GAINS - Summary of Transaction Price Allocation to Performance Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-99", "name": "legn:TransactionPrice", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": null }, "R91": { "role": "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTransactionPriceAmountsAllocatedtoRemainingPerformanceObligationsDetails", "longName": "9954518 - Disclosure - REVENUE, OTHER INCOME AND GAINS - Transaction Price Amounts Allocated to Remaining Performance Obligations (Details)", "shortName": "REVENUE, OTHER INCOME AND GAINS - Transaction Price Amounts Allocated to Remaining Performance Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-143", "name": "ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-145", "name": "ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R92": { "role": "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSOtherIncomeandGainsDetails", "longName": "9954519 - Disclosure - REVENUE, OTHER INCOME AND GAINS - Other Income and Gains (Details)", "shortName": "REVENUE, OTHER INCOME AND GAINS - Other Income and Gains (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:FinanceIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:FinanceIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R93": { "role": "http://legendbiotech.com/role/LOSSBEFORETAXDetails", "longName": "9954520 - Disclosure - LOSS BEFORE TAX (Details)", "shortName": "LOSS BEFORE TAX (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-163", "name": "ifrs-full:WagesAndSalaries", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "legn:DisclosureOfProfitLossBeforeTaxArrivedAfterChargingTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R94": { "role": "http://legendbiotech.com/role/FINANCECOSTSDetails", "longName": "9954521 - Disclosure - FINANCE COSTS (Details)", "shortName": "FINANCE COSTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:InterestExpenseOnLeaseLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfFinanceCostExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:InterestExpenseOnBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfFinanceCostExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R95": { "role": "http://legendbiotech.com/role/INCOMETAXAdditionalInformationDetails", "longName": "9954522 - Disclosure - INCOME TAX - Additional Information (Details)", "shortName": "INCOME TAX - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-166", "name": "ifrs-full:AccountingProfit", "unitRef": "hkd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-166", "name": "ifrs-full:AccountingProfit", "unitRef": "hkd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R96": { "role": "http://legendbiotech.com/role/INCOMETAXSummaryofTaxChargesDetails", "longName": "9954523 - Disclosure - INCOME TAX - Summary of Tax Charges (Details)", "shortName": "INCOME TAX - Summary of Tax Charges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DetailedDisclosureOfTaxChargesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DetailedDisclosureOfTaxChargesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R97": { "role": "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails", "longName": "9954524 - Disclosure - INCOME TAX - Summary of Reconciliation of Tax Expense Applicable to Loss Before Tax at the Statutory Rates (Details)", "shortName": "INCOME TAX - Summary of Reconciliation of Tax Expense Applicable to Loss Before Tax at the Statutory Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:TaxExpenseIncomeAtStatutoryBlendedIncomeTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "legn:DetailedDisclosureOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRateTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R98": { "role": "http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTAdditionalInformationDetails", "longName": "9954525 - Disclosure - LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT - Additional Information (Details)", "shortName": "LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:WeightedAverageShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": null }, "R99": { "role": "http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTSummaryofCalculationsofBasicandDilutedLossperShareDetails", "longName": "9954526 - Disclosure - LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT - Summary of Calculations of Basic and Diluted Loss per Share (Details)", "shortName": "LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT - Summary of Calculations of Basic and Diluted Loss per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:EarningsPerShareExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": null }, "R100": { "role": "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails", "longName": "9954527 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details)", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-28", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R101": { "role": "http://legendbiotech.com/role/INTANGIBLEASSETSDetails", "longName": "9954528 - Disclosure - INTANGIBLE ASSETS (Details)", "shortName": "INTANGIBLE ASSETS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-276", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R102": { "role": "http://legendbiotech.com/role/OTHERNONCURRENTASSETSDetails", "longName": "9954529 - Disclosure - OTHER NON-CURRENT ASSETS (Details)", "shortName": "OTHER NON-CURRENT ASSETS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:Prepayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "legn:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:OtherNoncurrentAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "legn:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R103": { "role": "http://legendbiotech.com/role/LEASESAdditionalInformationDetails", "longName": "9954530 - Disclosure - LEASES - Additional Information (Details)", "shortName": "LEASES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "c-278", "name": "legn:LesseeLeasingArrangementsLeasesTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-278", "name": "legn:LesseeLeasingArrangementsLeasesTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R104": { "role": "http://legendbiotech.com/role/LEASESRightofuseAssetsDetails", "longName": "9954531 - Disclosure - LEASES - Right-of-use Assets (Details)", "shortName": "LEASES - Right-of-use Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:RightofuseAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-280", "name": "ifrs-full:RightofuseAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R105": { "role": "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails", "longName": "9954532 - Disclosure - LEASES - Summary of Carrying Amounts of The Right-of-use Assets and Movements (Details)", "shortName": "LEASES - Summary of Carrying Amounts of The Right-of-use Assets and Movements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:RightofuseAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AdditionsToRightofuseAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R106": { "role": "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails", "longName": "9954533 - Disclosure - LEASES - Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term (Details)", "shortName": "LEASES - Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:CashOutflowForLeases", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfTotalCashOutflowForLeasesIncludedInStatementOfCashFlowsExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-309", "name": "legn:IncreaseInLeaseLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:LesseeLeaseLiabilitiesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R107": { "role": "http://legendbiotech.com/role/LEASESSummaryofLeaseExpenseDetails", "longName": "9954534 - Disclosure - LEASES - Summary of Lease Expense (Details)", "shortName": "LEASES - Summary of Lease Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:InterestExpenseOnLeaseLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfFinanceCostExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R108": { "role": "http://legendbiotech.com/role/LEASESSummaryofUndiscountedMinimumLeasePaymentsReceivablesinFuturePeriodsunderNoncancellableOperatingLeasesDetails", "longName": "9954535 - Disclosure - LEASES - Summary of Undiscounted Minimum Lease Payments Receivables in Future Periods under Non-cancellable Operating Leases (Details)", "shortName": "LEASES - Summary of Undiscounted Minimum Lease Payments Receivables in Future Periods under Non-cancellable Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:UndiscountedFinanceLeasePaymentsToBeReceived", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:UndiscountedFinanceLeasePaymentsToBeReceived", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R109": { "role": "http://legendbiotech.com/role/COLLABORATIONINVENTORIESSummaryofInventoriesDetails", "longName": "9954536 - Disclosure - COLLABORATION INVENTORIES - Summary of Inventories (Details)", "shortName": "COLLABORATION INVENTORIES - Summary of Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:RawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:RawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R110": { "role": "http://legendbiotech.com/role/COLLABORATIONINVENTORIESAdditionalInformationDetails", "longName": "9954537 - Disclosure - COLLABORATION INVENTORIES - Additional Information (Details)", "shortName": "COLLABORATION INVENTORIES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "c-3", "name": "legn:InventoryReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "legn:InventoryReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R111": { "role": "http://legendbiotech.com/role/TRADERECEIVABLESSummaryofTradeReceivablesDetails", "longName": "9954538 - Disclosure - TRADE RECEIVABLES - Summary of Trade Receivables (Details)", "shortName": "TRADE RECEIVABLES - Summary of Trade Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:CurrentTradeReceivables", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-229", "name": "ifrs-full:CurrentTradeReceivables", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationOfTradeReceivablesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R112": { "role": "http://legendbiotech.com/role/TRADERECEIVABLESAdditionalInformationDetails", "longName": "9954539 - Disclosure - TRADE RECEIVABLES - Additional Information (Details)", "shortName": "TRADE RECEIVABLES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "112", "firstAnchor": { "contextRef": "c-312", "name": "ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-312", "name": "ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R113": { "role": "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSSummaryofPrepaymentsOtherReceivablesandOtherAssetsDetails", "longName": "9954540 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS - Summary of Prepayments, Other Receivables and Other Assets (Details)", "shortName": "PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS - Summary of Prepayments, Other Receivables and Other Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "113", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:FinanceLeaseReceivables", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "legn:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-313", "name": "legn:OtherCollaborationReceivables", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R114": { "role": "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSAdditionalInformationDetails", "longName": "9954541 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS - Additional Information (Details)", "shortName": "PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "114", "firstAnchor": { "contextRef": "c-517", "name": "ifrs-full:AmountsReceivableRelatedPartyTransactions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfOutstandingBalancesWithRelatedPartiesExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-315", "name": "ifrs-full:AmountsReceivableRelatedPartyTransactions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R115": { "role": "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails", "longName": "9954542 - Disclosure - CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS - Summary of Cash and Cash Equivalents, Time Deposits and Pledged Deposits (Details)", "shortName": "CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS - Summary of Cash and Cash Equivalents, Time Deposits and Pledged Deposits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "115", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:CashAndBankBalancesAtCentralBanks", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:CashAndBankBalancesAtCentralBanks", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R116": { "role": "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails", "longName": "9954543 - Disclosure - CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS - Additional Information (Details)", "shortName": "CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "116", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": null }, "R117": { "role": "http://legendbiotech.com/role/TRADEPAYABLESSummaryofTradeandNotesPayablesDetails", "longName": "9954544 - Disclosure - TRADE PAYABLES - Summary of Trade and Notes Payables (Details)", "shortName": "TRADE PAYABLES - Summary of Trade and Notes Payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "117", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": null }, "R118": { "role": "http://legendbiotech.com/role/TRADEPAYABLESAdditionalInformationDetails", "longName": "9954545 - Disclosure - TRADE PAYABLES - Additional Information (Details)", "shortName": "TRADE PAYABLES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "118", "firstAnchor": { "contextRef": "c-1", "name": "legn:TradePayablesTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:TradePayablesTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R119": { "role": "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSSummaryofOtherPayablesandAccrualsDetails", "longName": "9954546 - Disclosure - OTHER PAYABLES AND ACCRUALS - Summary of Other Payables and Accruals (Details)", "shortName": "OTHER PAYABLES AND ACCRUALS - Summary of Other Payables and Accruals (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "119", "firstAnchor": { "contextRef": "c-3", "name": "legn:AccruedPayroll", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "legn:DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "legn:AccruedPayroll", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "legn:DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R120": { "role": "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSAdditionalInformationDetails", "longName": "9954547 - Disclosure - OTHER PAYABLES AND ACCRUALS - Additional Information (Details)", "shortName": "OTHER PAYABLES AND ACCRUALS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "120", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:TradeAndOtherPayablesToRelatedParties", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:TradeAndOtherPayablesToRelatedParties", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R121": { "role": "http://legendbiotech.com/role/DEFERREDTAXDisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryDetails", "longName": "9954548 - Disclosure - DEFERRED TAX - Disclosure Of Movements In Deferred Tax Assets And Liabilities Explanatory (Details)", "shortName": "DEFERRED TAX - Disclosure Of Movements In Deferred Tax Assets And Liabilities Explanatory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "121", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:DeferredTaxLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "legn:DisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-28", "name": "ifrs-full:DeferredTaxLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "legn:DisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R122": { "role": "http://legendbiotech.com/role/DEFERREDTAXAdditionalInformationDetails", "longName": "9954549 - Disclosure - DEFERRED TAX - Additional Information (Details)", "shortName": "DEFERRED TAX - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "122", "firstAnchor": { "contextRef": "c-372", "name": "ifrs-full:DeferredTaxExpenseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-372", "name": "ifrs-full:DeferredTaxExpenseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R123": { "role": "http://legendbiotech.com/role/DEFERREDTAXSummaryofItemswithRespecttoDeferredTaxAssetshavenotbeenRecognizedDetails", "longName": "9954550 - Disclosure - DEFERRED TAX - Summary of Items with Respect to, Deferred Tax Assets have not been Recognized (Details)", "shortName": "DEFERRED TAX - Summary of Items with Respect to, Deferred Tax Assets have not been Recognized (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "123", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutDeferredTaxAssetsExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutDeferredTaxAssetsExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R124": { "role": "http://legendbiotech.com/role/WARRANTLIABILITYAdditionalInformationDetails", "longName": "9954551 - Disclosure - WARRANT LIABILITY - Additional Information (Details)", "shortName": "WARRANT LIABILITY - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "124", "firstAnchor": { "contextRef": "c-380", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-380", "name": "legn:ExercisePricePerOrdinaryShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R125": { "role": "http://legendbiotech.com/role/WARRANTLIABILITYScheduleofMovementofWarrantLiabilityDetails", "longName": "9954552 - Disclosure - WARRANT LIABILITY - Schedule of Movement of Warrant Liability (Details)", "shortName": "WARRANT LIABILITY - Schedule of Movement of Warrant Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "125", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:WarrantLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:ExerciseOfTheWarrantLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R126": { "role": "http://legendbiotech.com/role/GOVERNMENTGRANTSDetails", "longName": "9954553 - Disclosure - GOVERNMENT GRANTS (Details)", "shortName": "GOVERNMENT GRANTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "126", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:GovernmentGrants", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "legn:DisclosureOfDeferredGovernmentGrantsExplanatoryTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:GovernmentGrants", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "legn:DisclosureOfDeferredGovernmentGrantsExplanatoryTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R127": { "role": "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails", "longName": "9954554 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Summary of Interest-Bearing Loans and Borrowings (Details)", "shortName": "COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Summary of Interest-Bearing Loans and Borrowings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "127", "firstAnchor": { "contextRef": "c-386", "name": "ifrs-full:BorrowingsInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-386", "name": "ifrs-full:BorrowingsInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R128": { "role": "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails", "longName": "9954555 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Additional Information (Details)", "shortName": "COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "128", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:Borrowings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:Borrowings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R129": { "role": "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails", "longName": "9954556 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM - Summary of Shares (Details)", "shortName": "SHARE CAPITAL AND SHARE PREMIUM - Summary of Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "129", "firstAnchor": { "contextRef": "c-380", "name": "ifrs-full:ParValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-396", "name": "ifrs-full:NumberOfSharesAuthorised", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ifrs-full:NumberOfSharesAuthorised", "span", "div", "td", "tr", "table", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R130": { "role": "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails", "longName": "9954557 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM - Summary of Movements in the Company's Share Capital and Share Premium (Details)", "shortName": "SHARE CAPITAL AND SHARE PREMIUM - Summary of Movements in the Company's Share Capital and Share Premium (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "130", "firstAnchor": { "contextRef": "c-6", "name": "legn:ShareCapitalAndSharePremium", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfMovementsInCompanySShareCapitalAndSharePremiumExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-28", "name": "legn:ShareCapitalAndSharePremium", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfMovementsInCompanySShareCapitalAndSharePremiumExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R131": { "role": "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails", "longName": "9954558 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM - Additional Information (Details)", "shortName": "SHARE CAPITAL AND SHARE PREMIUM - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "131", "firstAnchor": { "contextRef": "c-380", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-410", "name": "legn:AggregateExercisePriceOfWarrants", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R132": { "role": "http://legendbiotech.com/role/SHAREOPTIONSCHEMEAdditionalInformationDetails", "longName": "9954559 - Disclosure - SHARE OPTION SCHEME - Additional Information (Details)", "shortName": "SHARE OPTION SCHEME - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "132", "firstAnchor": { "contextRef": "c-412", "name": "legn:PeriodOfShareOptionSchemeRemainInForce", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-412", "name": "legn:PeriodOfShareOptionSchemeRemainInForce", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R133": { "role": "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofShareOptionsOutstandingUndertheSchemeDetails", "longName": "9954560 - Disclosure - SHARE OPTION SCHEME - Summary of Share Options Outstanding Under the Scheme (Details)", "shortName": "SHARE OPTION SCHEME - Summary of Share Options Outstanding Under the Scheme (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "133", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R134": { "role": "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails", "longName": "9954561 - Disclosure - SHARE OPTION SCHEME - Summary of Exercise Prices and Exercise Periods of Share Options Outstanding (Details)", "shortName": "SHARE OPTION SCHEME - Summary of Exercise Prices and Exercise Periods of Share Options Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "134", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-413", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R135": { "role": "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofFairValueofEquitySettledShareOptionsGrantedDetails", "longName": "9954562 - Disclosure - SHARE OPTION SCHEME - Summary of Fair Value of Equity Settled Share Options Granted (Details)", "shortName": "SHARE OPTION SCHEME - Summary of Fair Value of Equity Settled Share Options Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "135", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R136": { "role": "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSSummaryofMovementinNumberofRSUOutstandingDetails", "longName": "9954563 - Disclosure - RESTRICTED SHARE UNITS - Summary of Movement in Number of RSU Outstanding (Details)", "shortName": "RESTRICTED SHARE UNITS - Summary of Movement in Number of RSU Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "136", "firstAnchor": { "contextRef": "c-468", "name": "ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-470", "name": "ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R137": { "role": "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSAdditionalInformationDetails", "longName": "9954564 - Disclosure - RESTRICTED SHARE UNITS - Additional Information (Details)", "shortName": "RESTRICTED SHARE UNITS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "137", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-474", "name": "ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R138": { "role": "http://legendbiotech.com/role/RESERVESDetails", "longName": "9954565 - Disclosure - RESERVES (Details)", "shortName": "RESERVES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "138", "firstAnchor": { "contextRef": "c-3", "name": "legn:PaidInCapitalAndReserveFunds", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "legn:PaidInCapitalAndReserveFunds", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R139": { "role": "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSAdditionalInformationDetails", "longName": "9954566 - Disclosure - NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS - Additional Information (Details)", "shortName": "NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "139", "firstAnchor": { "contextRef": "c-1", "name": "legn:AdjustmentsToCollaborationInterestBearingAdvancedFundingIncreaseDecrease", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:AdjustmentsToCollaborationInterestBearingAdvancedFundingIncreaseDecrease", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R140": { "role": "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "longName": "9954567 - Disclosure - NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS - Summary of Changes in Liabilities Arising from Financing Activities (Details)", "shortName": "NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS - Summary of Changes in Liabilities Arising from Financing Activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "140", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-477", "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R141": { "role": "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofTotalCashOutflowforLeasesIncludedinStatementofCashFlowsDetails", "longName": "9954568 - Disclosure - NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS - Summary of Total Cash Outflow for Leases Included in Statement of Cash Flows (Details)", "shortName": "NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS - Summary of Total Cash Outflow for Leases Included in Statement of Cash Flows (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "141", "firstAnchor": { "contextRef": "c-1", "name": "legn:CashOutflowForLeasesWithinOperatingActivities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfTotalCashOutflowForLeasesIncludedInStatementOfCashFlowsExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:CashOutflowForLeasesWithinOperatingActivities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfTotalCashOutflowForLeasesIncludedInStatementOfCashFlowsExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R142": { "role": "http://legendbiotech.com/role/COMMITMENTSANDCONTINGENCIESSummaryofCapitalCommitmentsDetails", "longName": "9954569 - Disclosure - COMMITMENTS AND CONTINGENCIES - Summary of Capital Commitments (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES - Summary of Capital Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "142", "firstAnchor": { "contextRef": "c-3", "name": "legn:ConstructionPaymentPayableInFuture", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfCapitalCommitmentsExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "legn:ConstructionPaymentPayableInFuture", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfCapitalCommitmentsExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R143": { "role": "http://legendbiotech.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails", "longName": "9954570 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "143", "firstAnchor": { "contextRef": "c-479", "name": "legn:FormerEmployeeDamagesDemand", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-479", "name": "legn:FormerEmployeeDamagesDemand", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R144": { "role": "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofNatureofRelatedPartyRelationshipDetails", "longName": "9954571 - Disclosure - RELATED PARTY TRANSACTIONS - Summary of Nature of Related Party Relationship (Details)", "shortName": "RELATED PARTY TRANSACTIONS - Summary of Nature of Related Party Relationship (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "144", "firstAnchor": { "contextRef": "c-480", "name": "ifrs-full:DescriptionOfNatureOfRelatedPartyRelationship", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "legn:SummaryOfNatureOfRelatedPartyRelationshipTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-480", "name": "ifrs-full:DescriptionOfNatureOfRelatedPartyRelationship", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "legn:SummaryOfNatureOfRelatedPartyRelationshipTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R145": { "role": "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails", "longName": "9954572 - Disclosure - RELATED PARTY TRANSACTIONS - Summary of Transactions with Related Parties (Details)", "shortName": "RELATED PARTY TRANSACTIONS - Summary of Transactions with Related Parties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "145", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:PurchasesOfGoodsRelatedPartyTransactions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:PurchasesOfGoodsRelatedPartyTransactions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R146": { "role": "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSAdditionalInformationDetails", "longName": "9954573 - Disclosure - RELATED PARTY TRANSACTIONS - Additional Information (Details)", "shortName": "RELATED PARTY TRANSACTIONS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "146", "firstAnchor": { "contextRef": "c-380", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "legn:LeaseLiabilitiesRepaymentTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R147": { "role": "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails", "longName": "9954574 - Disclosure - RELATED PARTY TRANSACTIONS - Summary of Outstanding Balances with Related Parties (Details)", "shortName": "RELATED PARTY TRANSACTIONS - Summary of Outstanding Balances with Related Parties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "147", "firstAnchor": { "contextRef": "c-311", "name": "ifrs-full:AmountsPayableRelatedPartyTransactions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-311", "name": "ifrs-full:AmountsPayableRelatedPartyTransactions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R148": { "role": "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofCompensationofKeyManagementPersonnelDetails", "longName": "9954575 - Disclosure - RELATED PARTY TRANSACTIONS - Summary of Compensation of Key Management Personnel (Details)", "shortName": "RELATED PARTY TRANSACTIONS - Summary of Compensation of Key Management Personnel (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "148", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R149": { "role": "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialAssetsDetails", "longName": "9954576 - Disclosure - FINANCIAL INSTRUMENTS BY CATEGORY - Summary of Financial Assets (Details)", "shortName": "FINANCIAL INSTRUMENTS BY CATEGORY - Summary of Financial Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "149", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:FinancialAssetsAtAmortisedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:FinancialAssetsAtAmortisedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R150": { "role": "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialLiabilitiesDetails", "longName": "9954577 - Disclosure - FINANCIAL INSTRUMENTS BY CATEGORY - Summary of Financial Liabilities (Details)", "shortName": "FINANCIAL INSTRUMENTS BY CATEGORY - Summary of Financial Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "150", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:FinancialLiabilitiesAtAmortisedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:FinancialLiabilitiesAtAmortisedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R151": { "role": "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueMeasurementHierarchyofFinancialInstrumentsDetails", "longName": "9954578 - Disclosure - FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS - Summary of Fair Value Measurement Hierarchy of Financial Instruments (Details)", "shortName": "FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS - Summary of Fair Value Measurement Hierarchy of Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "151", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-574", "name": "ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R152": { "role": "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueValuationofWarrantLiabilityDetails", "longName": "9954579 - Disclosure - FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS - Summary of Fair Value Valuation of Warrant Liability (Details)", "shortName": "FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS - Summary of Fair Value Valuation of Warrant Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "152", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-583", "name": "ifrs-full:ExercisePriceShareOptionsGranted2019", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfInformationOfInputsUsedInFairValueValuationOfWarrantLiabilityExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R153": { "role": "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESAdditionalInformationDetails", "longName": "9954580 - Disclosure - FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES - Additional Information (Details)", "shortName": "FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "153", "firstAnchor": { "contextRef": "c-586", "name": "legn:PercentageOfForeignCurrencyForwardExchangeContract", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-586", "name": "legn:PercentageOfForeignCurrencyForwardExchangeContract", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R154": { "role": "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofSensitivitytoReasonablyPossibleChangeinExchangeRatesDetails", "longName": "9954581 - Disclosure - FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES - Summary of Sensitivity to Reasonably Possible Change in Exchange Rates (Details)", "shortName": "FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES - Summary of Sensitivity to Reasonably Possible Change in Exchange Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "154", "firstAnchor": { "contextRef": "c-589", "name": "legn:PercentageOfIncreaseDecreaseInRateOfForeignCurrency", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutSensitivityToReasonablyPossibleChangeInExchangeRatesExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-589", "name": "legn:PercentageOfIncreaseDecreaseInRateOfForeignCurrency", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutSensitivityToReasonablyPossibleChangeInExchangeRatesExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true, "unique": true } }, "R155": { "role": "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails", "longName": "9954582 - Disclosure - FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES - Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments (Details)", "shortName": "FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES - Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "155", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-603", "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfMaturityAnalysisForFinancialAssetsHeldForManagingLiquidityRiskExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } }, "R156": { "role": "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMonitoringCapitalUsingGearingRatioDetails", "longName": "9954583 - Disclosure - FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES - Summary of Monitoring Capital Using Gearing Ratio (Details)", "shortName": "FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES - Summary of Monitoring Capital Using Gearing Ratio (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "156", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:Liabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-609", "name": "ifrs-full:Liabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutMonitoringCapitalUsingGearingRatioExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "legn-20231231.htm", "unique": true } } }, "tag": { "legn_A110InterestBearingLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A110InterestBearingLoansMember", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Bearing Loans", "label": "11.0% Interest Bearing Loans [Member]", "documentation": "11.0% Interest Bearing Loans" } } }, "auth_ref": [] }, "legn_A2019070120280829Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2019070120280829Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019/07/01 \u2013 2028/08/29", "label": "2019/07/01 \u2013 2028/08/29 [Member]", "documentation": "2019/07/01 \u2013 2028/08/29" } } }, "auth_ref": [] }, "legn_A2019112920191209Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2019112920191209Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019/11/29 - 2019/12/09", "label": "2019/11/29 - 2019/12/09 [Member]", "documentation": "2019/11/29 - 2019/12/09" } } }, "auth_ref": [] }, "legn_A2019122520271225Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2019122520271225Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019/12/25 \u2013 2027/12/25", "label": "2019/12/25 \u2013 2027/12/25 [Member]", "documentation": "2019/12/25 \u2013 2027/12/25" } } }, "auth_ref": [] }, "legn_A2019123120281230Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2019123120281230Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019/12/31 \u2013 2028/12/30", "label": "2019/12/31 \u2013 2028/12/30 [Member]", "documentation": "2019/12/31 \u2013 2028/12/30" } } }, "auth_ref": [] }, "legn_A2020070220290701Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2020070220290701Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020/07/02 \u2013 2029/07/01", "label": "2020/07/02 \u2013 2029/07/01 [Member]", "documentation": "2020/07/02 \u2013 2029/07/01" } } }, "auth_ref": [] }, "legn_A2020112920291128Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2020112920291128Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020/11/29 \u2013 2029/11/28", "label": "2020/11/29 \u2013 2029/11/28 [Member]", "documentation": "2020/11/29 \u2013 2029/11/28" } } }, "auth_ref": [] }, "legn_A2021060520300604Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2021060520300604Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2021/06/05 \u2013 2030/06/04", "label": "2021/06/05 \u2013 2030/06/04 [Member]", "documentation": "2021/06/05 \u2013 2030/06/04" } } }, "auth_ref": [] }, "legn_A2021090120300831Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2021090120300831Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2021/09/01 \u2013 2030/08/31", "label": "2021/09/01 \u2013 2030/08/31 [Member]", "documentation": "2021/09/01 \u2013 2030/08/31" } } }, "auth_ref": [] }, "legn_A2021111920301118Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2021111920301118Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2021/11/19 \u2013 2030/11/18", "label": "2021/11/19 \u2013 2030/11/18 [Member]", "documentation": "2021/11/19 \u2013 2030/11/18" } } }, "auth_ref": [] }, "legn_A2022032920310328Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2022032920310328Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022/03/29 \u2013 2031/03/28", "label": "2022/03/29 \u2013 2031/03/28 [Member]", "documentation": "2022/03/29 \u2013 2031/03/28" } } }, "auth_ref": [] }, "legn_A2022082720310826Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2022082720310826Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022/08/27 \u2013 2031/08/26", "label": "2022/08/27 \u2013 2031/08/26 [Member]", "documentation": "2022/08/27 \u2013 2031/08/26" } } }, "auth_ref": [] }, "legn_A2023033120320330Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2023033120320330Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023/03/31 - 2032/03/30", "label": "2023/03/31 - 2032/03/30 [Member]", "documentation": "2023/03/31 - 2032/03/30" } } }, "auth_ref": [] }, "legn_A2023043020320429Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2023043020320429Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023/04/30 - 2032/04/29", "label": "2023/04/30 - 2032/04/29 [Member]", "documentation": "2023/04/30 - 2032/04/29" } } }, "auth_ref": [] }, "legn_A2023050220320501Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2023050220320501Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023/05/02 - 2032/05/01", "label": "2023/05/02 - 2032/05/01 [Member]", "documentation": "2023/05/02 - 2032/05/01" } } }, "auth_ref": [] }, "legn_A2023050520320504Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2023050520320504Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023/05/05 - 2032/05/04", "label": "2023/05/05 - 2032/05/04 [Member]", "documentation": "2023/05/05 - 2032/05/04" } } }, "auth_ref": [] }, "legn_A2023050820320507Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2023050820320507Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023/05/08 - 2032/05/07", "label": "2023/05/08 - 2032/05/07 [Member]", "documentation": "2023/05/08 - 2032/05/07" } } }, "auth_ref": [] }, "legn_A2023051020320509Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2023051020320509Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023/05/10 - 2032/05/09", "label": "2023/05/10 - 2032/05/09 [Member]", "documentation": "2023/05/10 - 2032/05/09" } } }, "auth_ref": [] }, "legn_A2023051320320512Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2023051320320512Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023/05/13 - 2032/05/12", "label": "2023/05/13 - 2032/05/12 [Member]", "documentation": "2023/05/13 - 2032/05/12" } } }, "auth_ref": [] }, "legn_A2023063020320629Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2023063020320629Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023/06/30 - 2032/06/29", "label": "2023/06/30 - 2032/06/29 [Member]", "documentation": "2023/06/30 - 2032/06/29" } } }, "auth_ref": [] }, "legn_A2023080220320801Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2023080220320801Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023/08/02 - 2032/08/01", "label": "2023/08/02 - 2032/08/01 [Member]", "documentation": "2023/08/02 - 2032/08/01" } } }, "auth_ref": [] }, "legn_A2024040320330402Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "A2024040320330402Member", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024/04/03 - 2033/04/02", "label": "2024/04/03 - 2033/04/02 [Member]", "documentation": "2024/04/03 - 2033/04/02" } } }, "auth_ref": [] }, "ifrs-full_AccountingProfit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccountingProfit", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/INCOMETAXAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Taxable income", "label": "Accounting profit" } }, "en": { "role": { "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r46", "r47" ] }, "legn_AccruedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AccruedExpense", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSSummaryofOtherPayablesandAccrualsDetails": { "parentTag": "legn_OtherPayablesAndAccrualsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSSummaryofOtherPayablesandAccrualsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expense", "label": "Accrued Expense", "documentation": "Accrued expense." } } }, "auth_ref": [] }, "legn_AccruedExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AccruedExpenseMember", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXDisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expense", "label": "Accrued Expense [Member]", "documentation": "Accrued Expense" } } }, "auth_ref": [] }, "legn_AccruedPayroll": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AccruedPayroll", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSSummaryofOtherPayablesandAccrualsDetails": { "parentTag": "legn_OtherPayablesAndAccrualsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSSummaryofOtherPayablesandAccrualsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll", "label": "Accrued Payroll", "documentation": "Accrued payroll." } } }, "auth_ref": [] }, "legn_AccumulatedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AccumulatedDepreciation", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated depreciation", "label": "Accumulated depreciation", "documentation": "Accumulated depreciation" } } }, "auth_ref": [] }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccumulatedDepreciationAndAmortisationMember", "presentation": [ "http://legendbiotech.com/role/INTANGIBLEASSETSDetails", "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated depreciation", "verboseLabel": "Accumulated amortization", "label": "Accumulated depreciation and amortisation [member]" } }, "en": { "role": { "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]" } } }, "auth_ref": [ "r62", "r309", "r314", "r315", "r316" ] }, "legn_AdditionInTimeDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AdditionInTimeDeposits", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Addition in time deposits", "label": "Addition In Time Deposits", "documentation": "Addition in time deposits." } } }, "auth_ref": [] }, "legn_AdditionalShareCapitalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AdditionalShareCapitalAmount", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMEAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional share capital amount", "label": "Additional Share Capital Amount", "documentation": "Additional share capital amount." } } }, "auth_ref": [] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/INTANGIBLEASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additions other than through business combinations, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r100" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additions other than through business combinations, property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]" } } }, "auth_ref": [ "r55" ] }, "ifrs-full_AdditionsToRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionsToRightofuseAssets", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additions to right-of-use assets" } }, "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r164" ] }, "ifrs-full_AddressOfRegisteredOfficeOfEntity": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AddressOfRegisteredOfficeOfEntity", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Address of entity's registered office", "label": "Address of entity's registered office" } }, "en": { "role": { "documentation": "The address at which the entity's office is registered." } } }, "auth_ref": [ "r7" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Address Type", "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "legn_AdjustmentForFairValueLossGainOfWarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AdjustmentForFairValueLossGainOfWarrantLiability", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value loss/(gain) of warrant liability", "verboseLabel": "Non-cash fair value loss (gain) of warrant liability", "label": "Adjustment For Fair Value Loss (Gain) Of Warrant Liability", "documentation": "Adjustment for fair value loss (gain) of warrant liability." } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForAmortisationExpense", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Adjustments for amortisation expense" } }, "en": { "role": { "documentation": "Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]" } } }, "auth_ref": [ "r322" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInInventories", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "(Increase)/decrease in collaboration inventories", "label": "Adjustments for decrease (increase) in inventories" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]" } } }, "auth_ref": [ "r319" ] }, "legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease/(increase) in other non-current assets", "label": "Adjustments for decrease (increase) in other non-current assets", "documentation": "Adjustments for decrease (increase) in other non-current assets" } } }, "auth_ref": [] }, "legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "(Increase)/decrease in prepayments, other receivables and other assets", "label": "Adjustments For Decrease Increase In Prepayments Other Receivable Other Assets", "documentation": "Adjustments for decrease increase in prepayments other receivable other assets." } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "(Increase)/decrease in trade receivables", "label": "Adjustments for decrease (increase) in trade accounts receivable" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r319" ] }, "ifrs-full_AdjustmentsForDepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDepreciationExpense", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation of property, plant and equipment", "label": "Adjustments for depreciation expense" } }, "en": { "role": { "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r322" ] }, "legn_AdjustmentsForDepreciationOfRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AdjustmentsForDepreciationOfRightOfUseAssets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation of right-of-use assets", "label": "Adjustments For Depreciation Of Right Of Use Assets", "documentation": "Adjustments for depreciation of right-of-use assets." } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForFairValueGainsLosses", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value gains on financial assets measured at fair value change through profit or loss", "label": "Adjustments for fair value losses (gains)" } }, "en": { "role": { "documentation": "Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r320" ] }, "ifrs-full_AdjustmentsForFinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForFinanceCosts", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Finance costs", "label": "Adjustments for finance costs" } }, "en": { "role": { "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]" } } }, "auth_ref": [ "r321" ] }, "ifrs-full_AdjustmentsForFinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForFinanceIncome", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Finance income", "label": "Adjustments for finance income" } }, "en": { "role": { "documentation": "Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]" } } }, "auth_ref": [ "r322" ] }, "legn_AdjustmentsForGovernmentGrantReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AdjustmentsForGovernmentGrantReceived", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Government grant received", "label": "Adjustments For Government Grant Received", "documentation": "Adjustments for government grant received." } } }, "auth_ref": [] }, "legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase/(decrease) in contract liabilities (current)", "label": "Adjustments For Increase (Decrease) In Contract Liabilities, Current", "documentation": "Adjustments For Increase (Decrease) In Contract Liabilities, Current" } } }, "auth_ref": [] }, "legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AdjustmentsForIncreaseDecreaseInContractLiabilitiesNonCurrent", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase/(decrease) in contract liabilities (non-current)", "label": "Adjustments For Increase (Decrease) In Contract Liabilities, Non-Current", "documentation": "Adjustments For Increase (Decrease) In Contract Liabilities, Non-Current" } } }, "auth_ref": [] }, "legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase/(decrease) in other non-current liabilities", "label": "Adjustments For Increase Decrease In Other Non Current Liabilities", "documentation": "Adjustments for increase (decrease) in other non current liabilities." } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInOtherOperatingPayables", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "(Decrease)/increase in other payables and accruals", "label": "Adjustments for increase (decrease) in other operating payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r319" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "(Decrease)/increase in trade payables", "label": "Adjustments for increase (decrease) in trade and other payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } } }, "auth_ref": [ "r322" ] }, "legn_AdjustmentsForInventoryReserveProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AdjustmentsForInventoryReserveProvision", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for inventory reserve", "label": "Adjustments For Inventory Reserve Provision", "documentation": "Adjustments For Inventory Reserve Provision" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments for:", "label": "Adjustments to reconcile profit (loss) [abstract]" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency exchange loss/(gain), net", "label": "Adjustments for unrealised foreign exchange losses (gains)" } }, "en": { "role": { "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r266", "r320" ] }, "legn_AdjustmentsToCollaborationInterestBearingAdvancedFundingIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AdjustmentsToCollaborationInterestBearingAdvancedFundingIncreaseDecrease", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash additions to collaboration interest-bearing advanced funding", "label": "Adjustments to Collaboration Interest-Bearing Advanced Funding, Increase (Decrease)", "documentation": "Adjustments to Collaboration Interest-Bearing Advanced Funding, Increase (Decrease)" } } }, "auth_ref": [] }, "ifrs-full_AdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdministrativeExpense", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "negatedLabel": "Administrative expenses", "label": "Administrative expenses" } }, "en": { "role": { "documentation": "The amount of expenses that the entity classifies as being administrative." } } }, "auth_ref": [ "r42", "r82", "r240" ] }, "legn_AdvancePaymentsForPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AdvancePaymentsForPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Advance payments for property, plant and equipment", "label": "Advance Payments For Property Plant And Equipment", "documentation": "Advance payments for property, plant and equipment." } } }, "auth_ref": [] }, "legn_AggregateExercisePriceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AggregateExercisePriceOfWarrants", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails", "http://legendbiotech.com/role/WARRANTLIABILITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate exercise price of warrant", "label": "Aggregate Exercise Price Of Warrants", "documentation": "Aggregate Exercise Price Of Warrants" } } }, "auth_ref": [] }, "ifrs-full_AggregatedMeasurementMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AggregatedMeasurementMember", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregated measurement [member]", "label": "Aggregated measurement [member]" } }, "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } } }, "auth_ref": [ "r108", "r112", "r145" ] }, "ifrs-full_AggregatedTimeBandsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AggregatedTimeBandsMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTransactionPriceAmountsAllocatedtoRemainingPerformanceObligationsDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregated time bands [member]", "label": "Aggregated time bands [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r21", "r156", "r167", "r168", "r171", "r172", "r173", "r179", "r199", "r252", "r279", "r280" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "AllCurrenciesDomain", "presentation": [ "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails", "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Currencies", "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ifrs-full_AllLevelsOfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AllLevelsOfFairValueHierarchyMember", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueMeasurementHierarchyofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All levels of fair value hierarchy [member]", "label": "All levels of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r64", "r146" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AmortisationIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://legendbiotech.com/role/INTANGIBLEASSETSDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amortization provided during the year", "label": "Amortisation, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r102" ] }, "ifrs-full_AmountsPayableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AmountsPayableRelatedPartyTransactions", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due to related parties", "label": "Amounts payable, related party transactions" } }, "en": { "role": { "documentation": "The amounts payable resulting from related party transactions. [Refer: Related parties [member]]" } } }, "auth_ref": [ "r75", "r79" ] }, "ifrs-full_AmountsReceivableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AmountsReceivableRelatedPartyTransactions", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSAdditionalInformationDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables due from related parties", "verboseLabel": "Due from related parties", "label": "Amounts receivable, related party transactions" } }, "en": { "role": { "documentation": "The amounts receivable resulting from related party transactions. [Refer: Related parties [member]]" } } }, "auth_ref": [ "r75", "r79" ] }, "ifrs-full_ApplicableTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ApplicableTaxRate", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXAdditionalInformationDetails", "http://legendbiotech.com/role/INCOMETAXAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax rate", "label": "Applicable tax rate" } }, "en": { "role": { "documentation": "The applicable income tax rate." } } }, "auth_ref": [ "r47" ] }, "legn_ApplicableTaxRateOnRemainingAssessableProfits": { "xbrltype": "percentItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ApplicableTaxRateOnRemainingAssessableProfits", "presentation": [ "http://legendbiotech.com/role/INCOMETAXAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax rate on remaining assessable profits", "label": "Applicable Tax Rate On Remaining Assessable Profits", "documentation": "Applicable tax rate on remaining assessable profits." } } }, "auth_ref": [] }, "legn_ApplicationAcceptanceMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ApplicationAcceptanceMember", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Application Acceptance", "label": "Application Acceptance [Member]", "documentation": "Application Acceptance" } } }, "auth_ref": [] }, "legn_AreaOfManufacturingFacilityExpectedToBeLeased": { "xbrltype": "areaItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AreaOfManufacturingFacilityExpectedToBeLeased", "presentation": [ "http://legendbiotech.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Area of manufacturing facility expected to be leased (in square feet)", "label": "Area of Manufacturing Facility Expected to be Leased", "documentation": "Area of Manufacturing Facility Expected to be Leased" } } }, "auth_ref": [] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMonitoringCapitalUsingGearingRatioDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "terseLabel": "Total assets", "label": "Assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r17", "r145", "r146", "r147", "r226", "r229" ] }, "legn_AssetsLeasedFromCollaborationPartner": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AssetsLeasedFromCollaborationPartner", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash additions to collaboration prepaid leases from collaboration partner", "label": "Assets Leased From Collaboration Partner", "documentation": "Assets Leased From Collaboration Partner" } } }, "auth_ref": [] }, "legn_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://legendbiotech.com/role/AUDITINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r290", "r291", "r292" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://legendbiotech.com/role/AUDITINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r290", "r291", "r292" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://legendbiotech.com/role/AUDITINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r290", "r291", "r292" ] }, "legn_AuthorisedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AuthorisedAbstract", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized:", "label": "Authorised [Abstract]", "documentation": "Authorised." } } }, "auth_ref": [] }, "legn_AuthorizedShareCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "AuthorizedShareCapital", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2,000,000,000 shares of $0.0001 each", "label": "Authorized Share Capital", "documentation": "Authorized share capital." } } }, "auth_ref": [] }, "ifrs-full_AverageEffectiveTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AverageEffectiveTaxRate", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Tax charge/(benefit) at the Company\u2019s effective rate", "label": "Average effective tax rate" } }, "en": { "role": { "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]" } } }, "auth_ref": [ "r47" ] }, "country_BE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "BE", "presentation": [ "http://legendbiotech.com/role/INCOMETAXAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Belgium", "label": "BELGIUM" } } }, "auth_ref": [] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "label": "Basic earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r90", "r91" ] }, "ifrs-full_BasicEarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BasicEarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Basic earnings per share [abstract]" } } }, "auth_ref": [] }, "legn_BasisOfPreparationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "BasisOfPreparationAbstract", "lang": { "en-us": { "role": { "label": "Basis Of Preparation [Abstract]", "documentation": "Basis of Preparation." } } }, "auth_ref": [] }, "legn_BinomialModelMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "BinomialModelMember", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMEAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Binomial Model", "label": "Binomial Model [Member]", "documentation": "Binomial model." } } }, "auth_ref": [] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Borrowings", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Funding advances from collaborator principal amount", "label": "Borrowings" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r303" ] }, "ifrs-full_BorrowingsAdjustmentToInterestRateBasis": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsAdjustmentToInterestRateBasis", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate margin percentage", "label": "Borrowings, adjustment to interest rate basis" } }, "en": { "role": { "documentation": "The adjustment to the basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r327" ] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings by name [axis]", "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r327" ] }, "ifrs-full_BorrowingsByNameMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsByNameMember", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings by name [member]", "label": "Borrowings by name [member]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r327" ] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Borrowings, interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r327" ] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueValuationofWarrantLiabilityDetails", "http://legendbiotech.com/role/LEASESAdditionalInformationDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSAdditionalInformationDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofFairValueofEquitySettledShareOptionsGrantedDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyPlantandEquipmentDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRightofuseAssetsDepreciatedonStraightlineBasisoverLeaseTermsandEstimatedUsefulLivesDetails", "http://legendbiotech.com/role/TRADERECEIVABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bottom of Range", "label": "Bottom of range [member]" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r149", "r173", "r190", "r269", "r270", "r327" ] }, "ifrs-full_BuildingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BuildingsMember", "presentation": [ "http://legendbiotech.com/role/LEASESRightofuseAssetsDetails", "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails", "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyPlantandEquipmentDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRightofuseAssetsDepreciatedonStraightlineBasisoverLeaseTermsandEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Building", "netLabel": "Buildings", "terseLabel": "Lease buildings", "label": "Buildings [member]" } }, "en": { "role": { "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r308" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "BusinessContactMember", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Business Contact", "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r291", "r292" ] }, "legn_CARTITUDE1ClinicalTrialMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CARTITUDE1ClinicalTrialMember", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CARTITUDE-1 Clinical Trial", "label": "CARTITUDE-1 Clinical Trial [Member]", "documentation": "CARTITUDE-1 clinical trial." } } }, "auth_ref": [] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "CN", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXAdditionalInformationDetails", "http://legendbiotech.com/role/INCOMETAXAdditionalInformationDetails", "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofNoncurrentAssetsDetails", "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofRevenueDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "China", "label": "CHINA" } } }, "auth_ref": [] }, "currency_CNY": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "CNY", "presentation": [ "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails", "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominated in RMB", "label": "China, Yuan Renminbi" } } }, "auth_ref": [] }, "ifrs-full_CapitalCommitmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CapitalCommitmentsAbstract", "lang": { "en-us": { "role": { "label": "Capital commitments [abstract]" } } }, "auth_ref": [] }, "legn_CapitalGearingRatio": { "xbrltype": "percentItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CapitalGearingRatio", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMonitoringCapitalUsingGearingRatioDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gearing ratio", "label": "Capital Gearing Ratio", "documentation": "Gearing ratio." } } }, "auth_ref": [] }, "ifrs-full_CapitalRequirementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CapitalRequirementsAxis", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSAdditionalInformationDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital requirements [axis]", "label": "Capital requirements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r6" ] }, "ifrs-full_CapitalRequirementsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CapitalRequirementsMember", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSAdditionalInformationDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital requirements [member]", "label": "Capital requirements [member]" } }, "en": { "role": { "documentation": "This member stands for capital requirements that the entity is subject to. It also represents the standard value for the 'Capital requirements' axis if no other member is used." } } }, "auth_ref": [ "r6" ] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://legendbiotech.com/role/INTANGIBLEASSETSDetails", "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails", "http://legendbiotech.com/role/TRADERECEIVABLESSummaryofTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]", "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r54", "r59", "r99", "r104", "r109", "r110", "r111", "r112", "r113", "r195", "r205", "r206" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://legendbiotech.com/role/INTANGIBLEASSETSDetails", "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails", "http://legendbiotech.com/role/TRADERECEIVABLESSummaryofTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount [member]", "label": "Carrying amount [member]" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r59", "r104", "r109", "r111", "r112", "r195", "r205", "r206" ] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Cash", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and bank balances", "label": "Cash" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r325" ] }, "ifrs-full_CashAndBankBalancesAtCentralBanks": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashAndBankBalancesAtCentralBanks", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and bank balances", "label": "Cash and bank balances at central banks" } }, "en": { "role": { "documentation": "The amount of cash and bank balances held at central banks." } } }, "auth_ref": [ "r303" ] }, "legn_CashAndCashEquivalentMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CashAndCashEquivalentMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash And Cash Equivalent [Member]", "documentation": "Cash and cash equivalents." } } }, "auth_ref": [] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 7.0 }, "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails", "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails", "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "periodStartLabel": "Cash and cash equivalents at beginning of year", "periodEndLabel": "CASH AND CASH EQUIVALENTS AT END OF YEAR", "totalLabel": "Cash and cash equivalents", "label": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r13", "r122", "r142" ] }, "ifrs-full_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashAndCashEquivalentsAbstract", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS", "label": "Cash and cash equivalents [abstract]" } } }, "auth_ref": [] }, "legn_CashAndCashEquivalentsAsStatedInStatementOfCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CashAndCashEquivalentsAsStatedInStatementOfCashFlows", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents as stated in the statement of cash flows", "label": "Cash And Cash Equivalents As Stated In Statement Of Cash Flows", "documentation": "Cash and cash equivalents as stated in statement of cash flows." } } }, "auth_ref": [] }, "legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents as stated in the statement of financial position", "label": "Cash And Cash Equivalents As Stated In Statement Of Financial Position", "documentation": "Cash and cash equivalents as stated in statement of financial position." } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Cash flows from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } } }, "auth_ref": [ "r114", "r124" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES", "label": "Cash flows from (used in) financing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by/(used in) investing activities", "label": "Cash flows from (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } } }, "auth_ref": [ "r114", "r124" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES", "label": "Cash flows from (used in) investing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Cash flows from (used in) operating activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } } }, "auth_ref": [ "r114", "r124" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES", "label": "Cash flows from (used in) operating activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperations", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Cash used in operations", "label": "Cash flows from (used in) operations" } }, "en": { "role": { "documentation": "The cash from (used in) the entity's operations." } } }, "auth_ref": [ "r262", "r266" ] }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Cash flows from (used in) operations before changes in working capital", "label": "Cash flows from (used in) operations before changes in working capital" } }, "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } } }, "auth_ref": [ "r266", "r322" ] }, "ifrs-full_CashOutflowForLeases": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashOutflowForLeases", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofTotalCashOutflowforLeasesIncludedinStatementofCashFlowsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails", "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofTotalCashOutflowforLeasesIncludedinStatementofCashFlowsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments", "totalLabel": "Total", "label": "Cash outflow for leases" } }, "en": { "role": { "documentation": "The cash outflow for leases." } } }, "auth_ref": [ "r163" ] }, "legn_CashOutflowForLeasesWithinFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CashOutflowForLeasesWithinFinancingActivities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofTotalCashOutflowforLeasesIncludedinStatementofCashFlowsDetails": { "parentTag": "ifrs-full_CashOutflowForLeases", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofTotalCashOutflowforLeasesIncludedinStatementofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Within financing activities", "label": "Cash Outflow For Leases Within Financing Activities", "documentation": "Cash outflow for leases within financing activities." } } }, "auth_ref": [] }, "legn_CashOutflowForLeasesWithinOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CashOutflowForLeasesWithinOperatingActivities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofTotalCashOutflowforLeasesIncludedinStatementofCashFlowsDetails": { "parentTag": "ifrs-full_CashOutflowForLeases", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofTotalCashOutflowforLeasesIncludedinStatementofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Within operating activities", "label": "Cash Outflow For Leases Within Operating Activities", "documentation": "Cash outflow for leases within operating activities." } } }, "auth_ref": [] }, "legn_CashOutflowForShortTermLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CashOutflowForShortTermLeases", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofTotalCashOutflowforLeasesIncludedinStatementofCashFlowsDetails": { "parentTag": "ifrs-full_CashOutflowForLeases", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofTotalCashOutflowforLeasesIncludedinStatementofCashFlowsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term leases", "label": "Cash Outflow For Short Term Leases", "documentation": "Cash outflow for short term leases." } } }, "auth_ref": [] }, "legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash receipts of investment income", "label": "Cash Receipts Of Investment Income Classified As Investing Activities", "documentation": "Cash receipts of investment income classified as investing activities." } } }, "auth_ref": [] }, "legn_CashReceivedFromWithdrawalOfFinancialAssetsAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CashReceivedFromWithdrawalOfFinancialAssetsAtFairValueThroughProfitOrLoss", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash received from withdrawal of financial assets measured at fair value through profit or loss", "label": "Cash Received From Withdrawal Of Financial Assets At Fair Value Through Profit Or Loss", "documentation": "Cash received from withdrawal of financial assets at fair value through profit or loss." } } }, "auth_ref": [] }, "legn_CashReceivedFromWithdrawalOfFinancialAssetsMeasuredAtAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CashReceivedFromWithdrawalOfFinancialAssetsMeasuredAtAmortizedCost", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash received from withdrawal of financial assets measured at amortized cost", "label": "Cash received from withdrawal of financial assets measured at amortized cost", "documentation": "Cash received from withdrawal of financial assets measured at amortized cost" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfCurrentFinancialAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfCurrentFinancialAssetsAbstract", "lang": { "en-us": { "role": { "label": "Categories of current financial assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSAdditionalInformationDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSAdditionalInformationDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofNatureofRelatedPartyRelationshipDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails", "http://legendbiotech.com/role/TRADEPAYABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of related parties [axis]", "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r78" ] }, "legn_CiltaCelClinicalDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CiltaCelClinicalDevelopmentMember", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cilta-cel", "label": "Cilta-Cel Clinical Development [Member]", "documentation": "Cilta-Cel Clinical Development" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfAssetsAxis", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRightofuseAssetsDepreciatedonStraightlineBasisoverLeaseTermsandEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of assets [axis]", "label": "Classes of assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r95", "r97", "r148", "r166" ] }, "ifrs-full_ClassesOfAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfAssetsMember", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRightofuseAssetsDepreciatedonStraightlineBasisoverLeaseTermsandEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets [member]", "label": "Assets [member]" } }, "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } } }, "auth_ref": [ "r95", "r148", "r166" ] }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfFinancialAssetsAxis", "presentation": [ "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial assets [axis]", "label": "Classes of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r180", "r212", "r213", "r236", "r237" ] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSAdditionalInformationDetails", "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSSummaryofPrepaymentsOtherReceivablesandOtherAssetsDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial instruments [axis]", "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r205", "r207", "r209", "r210" ] }, "ifrs-full_ClassesOfFinancialInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfFinancialInstrumentsMember", "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSAdditionalInformationDetails", "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSSummaryofPrepaymentsOtherReceivablesandOtherAssetsDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments, class [member]", "label": "Financial instruments, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r205", "r207", "r209", "r210" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://legendbiotech.com/role/INTANGIBLEASSETSDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsAmortizedonStraightLineBasisoverUsefulEconomicLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of intangible assets other than goodwill [axis]", "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r105" ] }, "ifrs-full_ClassesOfInventoriesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfInventoriesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Classes of current inventories [abstract]", "label": "Classes of current inventories [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails", "http://legendbiotech.com/role/LEASESRightofuseAssetsDetails", "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails", "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of property, plant and equipment [axis]", "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r60" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMEAdditionalInformationDetails", "http://legendbiotech.com/role/WARRANTLIABILITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of share capital [axis]", "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r29" ] }, "ifrs-full_ClassesOfShareCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfShareCapitalMember", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMEAdditionalInformationDetails", "http://legendbiotech.com/role/WARRANTLIABILITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital [member]", "label": "Share capital [member]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r29" ] }, "legn_CollaborationAgreementNumberOfCustomers": { "xbrltype": "integerItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CollaborationAgreementNumberOfCustomers", "presentation": [ "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONAdditionalInformationDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration agreement, number of customers", "label": "Collaboration Agreement, Number of Customers", "documentation": "Collaboration Agreement, Number of Customers" } } }, "auth_ref": [] }, "legn_CollaborationAgreementNumberOfPerformanceObligations": { "xbrltype": "integerItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CollaborationAgreementNumberOfPerformanceObligations", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration agreement, number of performance obligations", "label": "Collaboration Agreement, Number of Performance Obligations", "documentation": "Collaboration Agreement, Number of Performance Obligations" } } }, "auth_ref": [] }, "legn_CollaborationAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CollaborationAssetsMember", "presentation": [ "http://legendbiotech.com/role/LEASESRightofuseAssetsDetails", "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration assets", "verboseLabel": "Collaboration Assets Leased", "label": "Collaboration Assets [Member]", "documentation": "Collaboration Assets" } } }, "auth_ref": [] }, "legn_CollaborationInterestBearingAdvancedFunding": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CollaborationInterestBearingAdvancedFunding", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration interest-bearing advanced funding", "label": "Collaboration Interest-Bearing Advanced Funding", "documentation": "Collaboration Interest-Bearing Advanced Funding" } } }, "auth_ref": [] }, "legn_CollaborationInterestBearingAdvancedFundingMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CollaborationInterestBearingAdvancedFundingMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration interest-bearing advanced funding", "label": "Collaboration interest-bearing advanced funding [Member]", "documentation": "Collaboration interest-bearing advanced funding" } } }, "auth_ref": [] }, "legn_CollaborationPrepaidLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CollaborationPrepaidLeases", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration prepaid leases", "label": "Collaboration prepaid leases", "documentation": "Collaboration prepaid leases" } } }, "auth_ref": [] }, "legn_CollaborationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CollaborationRevenue", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofRevenueDetails": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 1.0 }, "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME", "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofRevenueDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofAnalysisofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration revenue", "verboseLabel": "Total collaboration revenue", "label": "Collaboration Revenue", "documentation": "Collaboration Revenue" } } }, "auth_ref": [] }, "legn_CollaborationRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CollaborationRevenueMember", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXDisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration revenue", "label": "Collaboration Revenue [Member]", "documentation": "Collaboration Revenue" } } }, "auth_ref": [] }, "legn_CompensationFeeForTerminationOfServiceAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CompensationFeeForTerminationOfServiceAgreement", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation fee for termination of service agreement", "label": "Compensation Fee For Termination Of Service Agreement", "documentation": "Compensation fee for termination of service agreement." } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails", "http://legendbiotech.com/role/WARRANTLIABILITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Components of equity [axis]", "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r5" ] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent", "weight": 1.0, "order": 1.0 }, "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL COMPREHENSIVE LOSS FOR THE YEAR", "label": "Comprehensive income" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r1", "r34", "r129", "r131", "r139", "r268" ] }, "ifrs-full_ComprehensiveIncomeAttributableToAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncomeAttributableToAbstract", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Attributable to:", "label": "Comprehensive income attributable to [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Ordinary equity holders of the parent", "label": "Comprehensive income, attributable to owners of parent" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } } }, "auth_ref": [ "r1", "r36" ] }, "legn_ComputerAndOfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ComputerAndOfficeEquipmentMember", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails", "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer and office equipment", "label": "Computer And Office Equipment [Member]", "documentation": "Computer and office equipment." } } }, "auth_ref": [] }, "ifrs-full_ComputerSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComputerSoftwareMember", "presentation": [ "http://legendbiotech.com/role/INTANGIBLEASSETSDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsAmortizedonStraightLineBasisoverUsefulEconomicLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Software", "label": "Computer software [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r257" ] }, "ifrs-full_ConcentrationsOfRiskAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ConcentrationsOfRiskAxis", "presentation": [ "http://legendbiotech.com/role/TRADERECEIVABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentrations of risk [axis]", "label": "Concentrations of risk [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r176" ] }, "ifrs-full_ConcentrationsOfRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ConcentrationsOfRiskMember", "presentation": [ "http://legendbiotech.com/role/TRADERECEIVABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentrations of risk [member]", "label": "Concentrations of risk [member]" } }, "en": { "role": { "documentation": "This member stands for the concentrations of risk. It also represents the standard value for the 'Concentrations of risk' axis if no other member is used." } } }, "auth_ref": [ "r176" ] }, "ifrs-full_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ConstructionInProgressMember", "presentation": [ "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in progress [member]" } }, "en": { "role": { "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r308" ] }, "legn_ConstructionPaymentPayableInFuture": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ConstructionPaymentPayableInFuture", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/COMMITMENTSANDCONTINGENCIESSummaryofCapitalCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction Payment Payable In Future", "documentation": "Construction payment payable in future." } } }, "auth_ref": [] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelName", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Contact Personnel Name", "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "ifrs-full_ContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ContractLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofDeferredRevenueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Contract liabilities" } }, "en": { "role": { "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer." } } }, "auth_ref": [ "r150", "r153" ] }, "ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsAmortizedonStraightLineBasisoverUsefulEconomicLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents", "label": "Copyrights, patents and other industrial property rights, service and operating rights [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing copyrights, patents and other industrial property rights, service and operating rights. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r258" ] }, "ifrs-full_CostOfSales": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CostOfSales", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Collaboration cost of revenue", "label": "Cost of sales" } }, "en": { "role": { "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories." } } }, "auth_ref": [ "r0", "r42" ] }, "legn_CostRecoveryOfResearchedAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CostRecoveryOfResearchedAndDevelopmentExpenseMember", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXDisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost recovery of R&D expense", "label": "Cost Recovery of Researched and Development Expense [Member]", "documentation": "Cost Recovery of Researched and Development Expense" } } }, "auth_ref": [] }, "legn_CostSharingAndProfitLossSplit": { "xbrltype": "percentItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CostSharingAndProfitLossSplit", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Profit/loss split percentage", "label": "Cost-Sharing and Profit (Loss) Split", "documentation": "Cost-Sharing and Profit (Loss) Split" } } }, "auth_ref": [] }, "ifrs-full_CounterpartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CounterpartiesAxis", "presentation": [ "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONAdditionalInformationDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSAdditionalInformationDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceAllocationtoPerformanceObligationsDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceCompositionDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTransactionPriceAmountsAllocatedtoRemainingPerformanceObligationsDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparties [axis]", "label": "Counterparties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r220" ] }, "ifrs-full_CounterpartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CounterpartiesMember", "presentation": [ "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONAdditionalInformationDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSAdditionalInformationDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceAllocationtoPerformanceObligationsDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceCompositionDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTransactionPriceAmountsAllocatedtoRemainingPerformanceObligationsDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparties [member]", "label": "Counterparties [member]" } }, "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "auth_ref": [ "r220" ] }, "ifrs-full_CountryOfIncorporation": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CountryOfIncorporation", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Country of incorporation", "label": "Country of incorporation" } }, "en": { "role": { "documentation": "The country in which the entity is incorporated." } } }, "auth_ref": [ "r7" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "legn_CreditPeriodOfTradeReceivables": { "xbrltype": "durationItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "CreditPeriodOfTradeReceivables", "presentation": [ "http://legendbiotech.com/role/TRADERECEIVABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit period of trade receivables", "label": "Credit Period Of Trade Receivables", "documentation": "Credit period of trade receivables." } } }, "auth_ref": [] }, "ifrs-full_CreditRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CreditRiskMember", "presentation": [ "http://legendbiotech.com/role/TRADERECEIVABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit risk", "label": "Credit risk [member]" } }, "en": { "role": { "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r174", "r175", "r176", "r275" ] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CurrencyAxis", "presentation": [ "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails", "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency", "label": "Currency [Axis]" } } }, "auth_ref": [] }, "ifrs-full_CurrencyRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrencyRiskMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESAdditionalInformationDetails", "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofSensitivitytoReasonablyPossibleChangeinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Risk", "label": "Currency risk [member]" } }, "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r174", "r175", "r176", "r177", "r222" ] }, "ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofTaxChargesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofTaxChargesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total tax charge/(credit) for the year", "label": "Current and deferred tax relating to items credited (charged) directly to equity" } }, "en": { "role": { "documentation": "The aggregate current and deferred tax relating to particular items that are charged or credited directly to equity, for example: (a) an adjustment to the opening balance of retained earnings resulting from either a change in accounting policy that is applied retrospectively or the correction of an error; and (b) amounts arising on initial recognition of the equity component of a compound financial instrument. [Refer: Deferred tax relating to items credited (charged) directly to equity; Retained earnings; Financial instruments, class [member]]" } } }, "auth_ref": [ "r45" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r22", "r135", "r268" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "CURRENT ASSETS", "label": "Current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentContractLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofDeferredRevenueDetails": { "parentTag": "ifrs-full_ContractLiabilities", "weight": 1.0, "order": 2.0 }, "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "verboseLabel": "Contract liabilities (Current)", "label": "Current contract liabilities" } }, "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r150" ] }, "ifrs-full_CurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant liability", "label": "Current derivative financial liabilities" } }, "en": { "role": { "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r303" ] }, "ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentFinancialAssetsAtFairValueThroughProfitOrLoss", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueMeasurementHierarchyofFinancialInstrumentsDetails", "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets at fair value through profit or loss", "verboseLabel": "Financial\u00a0assets\u00a0at value through profit or loss", "label": "Current financial assets at fair value through profit or loss" } }, "en": { "role": { "documentation": "The amount of current financial assets measured at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]" } } }, "auth_ref": [ "r215" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentGovernmentGrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentGovernmentGrants", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/GOVERNMENTGRANTSDetails": { "parentTag": "ifrs-full_GovernmentGrants", "weight": 1.0, "order": 1.0 }, "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://legendbiotech.com/role/GOVERNMENTGRANTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government grants", "verboseLabel": "Current", "label": "Current government grants" } }, "en": { "role": { "documentation": "The amount of current government grants recognised in the statement of financial position as deferred income. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r303" ] }, "ifrs-full_CurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails": { "parentTag": "ifrs-full_LeaseLiabilities", "weight": 1.0, "order": 2.0 }, "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "verboseLabel": "Current portion", "label": "Current lease liabilities" } }, "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r159" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r23", "r137", "r268" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "CURRENT LIABILITIES", "label": "Current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentPrepaymentsAndOtherCurrentAssets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayments, other receivables and other assets", "label": "Current prepayments and other current assets" } }, "en": { "role": { "documentation": "The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]" } } }, "auth_ref": [ "r303" ] }, "ifrs-full_CurrentTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentTaxLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Tax payable", "label": "Current tax liabilities" } }, "en": { "role": { "documentation": "The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period." } } }, "auth_ref": [ "r14" ] }, "ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofTaxChargesDetails": { "parentTag": "ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofTaxChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Current tax relating to items credited (charged) directly to equity" } }, "en": { "role": { "documentation": "The amount of current tax relating to particular items that are charged or credited directly to equity, for example: (a) an adjustment to the opening balance of retained earnings resulting from either a change in accounting policy that is applied retrospectively or the correction of an error; and (b) amounts arising on initial recognition of the equity component of a compound financial instrument. [Refer: Retained earnings; Financial instruments, class [member]]" } } }, "auth_ref": [ "r45" ] }, "ifrs-full_CurrentTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentTradeReceivables", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSAdditionalInformationDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails", "http://legendbiotech.com/role/TRADERECEIVABLESSummaryofTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables", "verboseLabel": "Upfront fee receivable", "label": "Current trade receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r242", "r243" ] }, "legn_DateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DateOfIncorporation", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATIONAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Date of incorporation", "label": "Date Of Incorporation", "documentation": "Date of incorporation." } } }, "auth_ref": [] }, "legn_DecreaseInPledgedDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DecreaseInPledgedDeposits", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in pledged deposits", "label": "Decrease In Pledged Deposits", "documentation": "Decrease in pledged deposits." } } }, "auth_ref": [] }, "legn_DecreaseInTimeDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DecreaseInTimeDeposits", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in time deposits", "label": "Decrease In Time Deposits", "documentation": "Decrease in time deposits." } } }, "auth_ref": [] }, "ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised", "calculation": { "http://legendbiotech.com/role/DEFERREDTAXSummaryofItemswithRespecttoDeferredTaxAssetshavenotbeenRecognizedDetails": { "parentTag": "legn_DeferredTaxAssetNotYetRecognized", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXSummaryofItemswithRespecttoDeferredTaxAssetshavenotbeenRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deductible temporary differences", "label": "Deductible temporary differences for which no deferred tax asset is recognised" } }, "en": { "role": { "documentation": "The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]" } } }, "auth_ref": [ "r48" ] }, "legn_DeferredGovernmentGrant": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DeferredGovernmentGrant", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred government grant", "label": "Deferred Government Grant", "documentation": "Deferred government grant." } } }, "auth_ref": [] }, "legn_DeferredTaxAssetMaximumPercentageOfFutureTaxableProfitsForIndefiniteOffsetting": { "xbrltype": "percentItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DeferredTaxAssetMaximumPercentageOfFutureTaxableProfitsForIndefiniteOffsetting", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum percent of future taxable profits that can be indefinitely offset", "label": "Deferred Tax Asset, Maximum Percentage of Future Taxable Profits For Indefinite Offsetting", "documentation": "Deferred Tax Asset, Maximum Percentage of Future Taxable Profits For Indefinite Offsetting" } } }, "auth_ref": [] }, "legn_DeferredTaxAssetNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DeferredTaxAssetNotYetRecognized", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/DEFERREDTAXSummaryofItemswithRespecttoDeferredTaxAssetshavenotbeenRecognizedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXSummaryofItemswithRespecttoDeferredTaxAssetshavenotbeenRecognizedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Deferred Tax Asset Not Yet Recognized", "documentation": "Deferred tax asset not yet recognized." } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXDisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Deferred tax assets, beginning balance", "periodEndLabel": "Deferred tax assets, ending balance", "label": "Deferred tax assets" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r15", "r18", "r49" ] }, "ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxAssetsAndLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Deferred tax assets and liabilities [abstract]" } } }, "auth_ref": [] }, "legn_DeferredTaxAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DeferredTaxAssetsRollForward", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXDisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets [Roll Forward]", "label": "Deferred Tax Assets [Roll Forward]", "documentation": "Deferred Tax Assets" } } }, "auth_ref": [] }, "legn_DeferredTaxCarryBackPeriod": { "xbrltype": "durationItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DeferredTaxCarryBackPeriod", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax carry back period", "label": "Deferred Tax Carry Back Period", "documentation": "Deferred tax carry back period." } } }, "auth_ref": [] }, "legn_DeferredTaxCarryForwardPeriod": { "xbrltype": "durationItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DeferredTaxCarryForwardPeriod", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax carry forward period", "label": "Deferred Tax Carry Forward Period", "documentation": "Deferred tax carry forward period." } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxExpenseIncome", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax losses", "label": "Deferred tax expense (income)" } }, "en": { "role": { "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]" } } }, "auth_ref": [ "r50" ] }, "legn_DeferredTaxExpenseIncomeRecognisedInProfitOrLossRelatedToDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLossRelatedToDeferredTaxAssets", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXDisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax charged to the statement of profit or loss during the year", "label": "Deferred tax expense (income) recognised in profit or loss related to deferred tax assets", "documentation": "Deferred tax expense (income) recognised in profit or loss related to deferred tax assets" } } }, "auth_ref": [] }, "legn_DeferredTaxExpenseIncomeRecognisedInProfitOrLossRelatedToDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLossRelatedToDeferredTaxLiabilities", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXDisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax charged/(credited) to the statement of profit or loss during the year", "label": "Deferred tax expense (income) recognised in profit or loss related to deferred tax liabilities", "documentation": "Deferred tax expense (income) recognised in profit or loss related to deferred tax liabilities" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxLiabilities", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXDisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryDetails" ], "lang": { "en-us": { "role": { "negatedPeriodStartLabel": "Deferred tax liabilities, beginning balance", "negatedPeriodEndLabel": "Deferred tax liabilities, ending balance", "label": "Deferred tax liabilities" } }, "en": { "role": { "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]" } } }, "auth_ref": [ "r15", "r18", "r49" ] }, "legn_DeferredTaxLiabilitiesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DeferredTaxLiabilitiesRollForward", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXDisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Liabilities [Roll Forward]", "label": "Deferred Tax Liabilities [Roll Forward]", "documentation": "Deferred Tax Liabilities" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofTaxChargesDetails": { "parentTag": "ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofTaxChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred (note 20)", "label": "Deferred tax relating to items credited (charged) directly to equity" } }, "en": { "role": { "documentation": "The amount of deferred tax related to items credited (charged) directly to equity. [Refer: Deferred tax expense (income)]" } } }, "auth_ref": [ "r45" ] }, "legn_DepositsFromBank": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DepositsFromBank", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Time deposits", "label": "Deposits From Bank", "documentation": "Deposits from bank." } } }, "auth_ref": [] }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DepreciationPropertyPlantAndEquipment", "presentation": [ "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Depreciation provided during the year", "label": "Depreciation, property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]" } } }, "auth_ref": [ "r57", "r61" ] }, "ifrs-full_DepreciationRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DepreciationRightofuseAssets", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails", "http://legendbiotech.com/role/LEASESSummaryofLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Depreciation of right-of-use assets", "terseLabel": "Depreciation charge of right-of-use assets", "label": "Depreciation, right-of-use assets" } }, "en": { "role": { "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]" } } }, "auth_ref": [ "r160" ] }, "legn_DescriptionOfAccountingPolicyForCollaborationArrangementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DescriptionOfAccountingPolicyForCollaborationArrangementsTextBlock", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration Arrangements", "label": "Description of accounting policy for collaboration arrangements [Text Block]", "documentation": "Description of accounting policy for collaboration arrangements" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Other employee benefits", "label": "Description of accounting policy for employee benefits [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r302" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value measurement", "label": "Description of accounting policy for fair value measurement [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r302" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets at fair value through profit or loss", "label": "Description of accounting policy for financial instruments at fair value through profit or loss [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial instruments at fair value through profit or loss. [Refer: At fair value [member]; Financial instruments, class [member]]" } } }, "auth_ref": [ "r302" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities", "label": "Description of accounting policy for financial liabilities [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r302" ] }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Transactions and Foreign Currency Translation", "label": "Description of accounting policy for foreign currency translation [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for foreign currency translation." } } }, "auth_ref": [ "r302" ] }, "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForGovernmentGrants", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Government grants", "label": "Description of accounting policy for government grants [text block]" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r68" ] }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of financial assets", "label": "Description of accounting policy for impairment of financial assets [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for the impairment of financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r302" ] }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of non-financial assets", "label": "Description of accounting policy for impairment of non-financial assets [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r302" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax", "label": "Description of accounting policy for income tax [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for income tax." } } }, "auth_ref": [ "r302" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Description of accounting policy for intangible assets other than goodwill [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r302" ] }, "legn_DescriptionOfAccountingPolicyForInvestmentsAndOtherFinancialAssetsExplanatoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DescriptionOfAccountingPolicyForInvestmentsAndOtherFinancialAssetsExplanatoryPolicyTextBlock", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Investments and other financial assets", "label": "Description Of Accounting Policy For Investments And Other Financial Assets Explanatory [Policy Text Block]", "documentation": "Description of accounting policy for investments and other financial assets." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Description of accounting policy for leases [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } } }, "auth_ref": [ "r302" ] }, "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForMeasuringInventories", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration inventories", "label": "Description of accounting policy for measuring inventories [text block]" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r65" ] }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, and depreciation", "label": "Description of accounting policy for property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r302" ] }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognition", "label": "Description of accounting policy for recognition of revenue [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]" } } }, "auth_ref": [ "r302" ] }, "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development costs", "label": "Description of accounting policy for research and development expense [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]" } } }, "auth_ref": [ "r302" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments", "label": "Description of accounting policy for share-based payment transactions [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]" } } }, "auth_ref": [ "r302" ] }, "ifrs-full_DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Related parties", "label": "Description of accounting policy for transactions with related parties [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for transactions with related parties. [Refer: Related parties [member]]" } } }, "auth_ref": [ "r302" ] }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r123" ] }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "presentation": [ "http://legendbiotech.com/role/ISSUEDBUTNOTYETEFFECTIVEINTERNATIONALFINANCIALREPORTINGSTANDARDS" ], "lang": { "en-us": { "role": { "terseLabel": "ISSUED BUT NOT YET EFFECTIVE INTERNATIONAL FINANCIAL REPORTING STANDARDS", "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]" } }, "en": { "role": { "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have." } } }, "auth_ref": [ "r127" ] }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of expected impact of initial application of new standards or interpretations [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyPlantandEquipmentDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsAmortizedonStraightLineBasisoverUsefulEconomicLivesDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRightofuseAssetsDepreciatedonStraightlineBasisoverLeaseTermsandEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]", "label": "Disclosure of expected impact of initial application of new standards or interpretations [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyPlantandEquipmentDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsAmortizedonStraightLineBasisoverUsefulEconomicLivesDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRightofuseAssetsDepreciatedonStraightlineBasisoverLeaseTermsandEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Table]", "label": "Disclosure of expected impact of initial application of new standards or interpretations [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the expected impact of the initial application of new standards or interpretations." } } }, "auth_ref": [ "r127" ] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueValuationofWarrantLiabilityDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofFairValueofEquitySettledShareOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility (%)", "verboseLabel": "Volatility", "label": "Expected volatility, share options granted" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r192" ] }, "ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATIONInformationAboutSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal activities", "label": "Description of nature of entity's operations and principal activities" } }, "en": { "role": { "documentation": "The description of the nature of the entity's operations and principal activities." } } }, "auth_ref": [ "r8" ] }, "ifrs-full_DescriptionOfNatureOfRelatedPartyRelationship": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfNatureOfRelatedPartyRelationship", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofNatureofRelatedPartyRelationshipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Relationship", "label": "Description of nature of related party relationship" } }, "en": { "role": { "documentation": "The description of the nature of the related party relationships. [Refer: Related parties [member]]" } } }, "auth_ref": [ "r76" ] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueValuationofWarrantLiabilityDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofFairValueofEquitySettledShareOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate (%)", "verboseLabel": "Risk free rate", "label": "Risk free interest rate, share options granted" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r192" ] }, "legn_DescriptionOfUseOfEstimatesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DescriptionOfUseOfEstimatesPolicyPolicyTextBlock", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Description Of Use Of Estimates Policy [Policy Text Block]", "documentation": "Description Of Use Of Estimates Policy" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfVoluntaryChangeInAccountingPolicy": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfVoluntaryChangeInAccountingPolicy", "presentation": [ "http://legendbiotech.com/role/CHANGESINACCOUNTINGPOLICIESANDDISCLOSURES" ], "lang": { "en-us": { "role": { "terseLabel": "CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES", "label": "Disclosure of voluntary change in accounting policy [text block]" } }, "en": { "role": { "documentation": "The disclosure of a voluntary change in accounting policy." } } }, "auth_ref": [ "r126" ] }, "legn_DetailedDisclosureOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DetailedDisclosureOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRateTableTextBlock", "presentation": [ "http://legendbiotech.com/role/INCOMETAXTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Reconciliation of Tax Expense Applicable to Loss Before Tax at the Statutory Rates", "label": "Detailed Disclosure Of Reconciliation Of Tax Expense Applicable To Loss Before Tax At Statutory Rate [Table Text Block]", "documentation": "Detailed disclosure of reconciliation of tax expense applicable to loss before tax at the statutory rate." } } }, "auth_ref": [] }, "legn_DetailedDisclosureOfTaxChargesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DetailedDisclosureOfTaxChargesTableTextBlock", "presentation": [ "http://legendbiotech.com/role/INCOMETAXTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Tax Charges", "label": "Detailed Disclosure Of Tax Charges [Table Text Block]", "documentation": "Detailed disclosure of tax charges." } } }, "auth_ref": [] }, "legn_DifferenceAllowanceInExcessOfRelatedDepreciationMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DifferenceAllowanceInExcessOfRelatedDepreciationMember", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXDisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Difference allowance in excess of related depreciation", "label": "Difference Allowance In Excess Of Related Depreciation [Member]", "documentation": "Difference Allowance In Excess Of Related Depreciation" } } }, "auth_ref": [] }, "legn_DifferenceInIntangibleAssetsAmortizationMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DifferenceInIntangibleAssetsAmortizationMember", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXDisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Difference in intangible assets amortization", "label": "Difference In Intangible Assets Amortization [Member]", "documentation": "Difference In Intangible Assets Amortization" } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "label": "Diluted earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r90", "r91" ] }, "legn_DisclosureFairValueMeasurementHierarchyOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureFairValueMeasurementHierarchyOfFinancialInstrumentsLineItems", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueMeasurementHierarchyofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Fair Value Measurement Hierarchy Of Financial Instruments [Line Items]", "label": "Disclosure Fair Value Measurement Hierarchy Of Financial Instruments [Line Items]", "documentation": "Disclosure fair value measurement hierarchy of financial instruments." } } }, "auth_ref": [] }, "legn_DisclosureFairValueMeasurementHierarchyOfFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureFairValueMeasurementHierarchyOfFinancialInstrumentsTable", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueMeasurementHierarchyofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Fair Value Measurement Hierarchy Of Financial Instruments [Table]", "label": "Disclosure Fair Value Measurement Hierarchy Of Financial Instruments [Table]", "documentation": "Disclosure fair value measurement hierarchy of financial instruments." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "presentation": [ "http://legendbiotech.com/role/SIGNIFICANTACCOUNTINGJUDGEMENTSANDESTIMATES" ], "lang": { "en-us": { "role": { "terseLabel": "SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES", "label": "Disclosure of accounting judgements and estimates [text block]" } }, "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r297" ] }, "legn_DisclosureOfAmountsIncurredForCompensationOfKeyManagementPersonnelExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfAmountsIncurredForCompensationOfKeyManagementPersonnelExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Compensation of Key Management Personnel", "label": "Disclosure Of Amounts Incurred For Compensation Of Key Management Personnel Explanatory [Table Text Block]", "documentation": "Disclosure of amounts incurred for compensation of key management personnel." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfAuthorisationOfFinancialStatementsExplanatory", "presentation": [ "http://legendbiotech.com/role/APPROVALOFTHECONSOLIDATEDFINANCIALSTATEMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "APPROVAL OF THE CONSOLIDATED FINANCIAL STATEMENTS", "label": "Disclosure of authorisation of financial statements [text block]" } }, "en": { "role": { "documentation": "The disclosure of the authorisation of financial statements for issue." } } }, "auth_ref": [ "r297" ] }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "presentation": [ "http://legendbiotech.com/role/BASISOFPREPARATION" ], "lang": { "en-us": { "role": { "terseLabel": "BASIS OF PREPARATION", "label": "Disclosure of basis of preparation of financial statements [text block]" } }, "en": { "role": { "documentation": "The disclosure of the basis used for the preparation of the financial statements." } } }, "auth_ref": [ "r297" ] }, "ifrs-full_DisclosureOfBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfBorrowingsExplanatory", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDING" ], "lang": { "en-us": { "role": { "terseLabel": "COLLABORATION INTEREST-BEARING ADVANCED FUNDING", "label": "Disclosure of borrowings [text block]" } }, "en": { "role": { "documentation": "The disclosure of borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r297" ] }, "legn_DisclosureOfCapitalCommitmentsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfCapitalCommitmentsExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/COMMITMENTSANDCONTINGENCIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Capital Commitments", "label": "Disclosure Of Capital Commitments Explanatory [Table Text Block]", "documentation": "Disclosure of capital commitments." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "presentation": [ "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITS" ], "lang": { "en-us": { "role": { "terseLabel": "CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS", "label": "Disclosure of cash and cash equivalents [text block]" } }, "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r297" ] }, "legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Abstract]", "documentation": "Disclosure of cash and cash equivalents, time deposits and pledged deposits." } } }, "auth_ref": [] }, "legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems", "presentation": [ "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails", "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]", "label": "Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]", "documentation": "Disclosure of cash and cash equivalents, time deposits and pledged deposits." } } }, "auth_ref": [] }, "legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable", "presentation": [ "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails", "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Table]", "label": "Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Table]", "documentation": "Disclosure of cash and cash equivalents, time deposits and pledged deposits." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCashFlowStatementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfCashFlowStatementExplanatory", "presentation": [ "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS", "label": "Disclosure of cash flow statement [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for a statement of cash flows." } } }, "auth_ref": [ "r125" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUM" ], "lang": { "en-us": { "role": { "terseLabel": "SHARE CAPITAL AND SHARE PREMIUM", "label": "Disclosure of classes of share capital [text block]" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]" } } }, "auth_ref": [ "r29" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Classes Of Share Capital [Line Items]", "label": "Disclosure of classes of share capital [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Classes Of Share Capital [Table]", "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r29" ] }, "ifrs-full_DisclosureOfCommitmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfCommitmentsExplanatory", "presentation": [ "http://legendbiotech.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Disclosure of commitments [text block]" } }, "en": { "role": { "documentation": "The disclosure of commitments." } } }, "auth_ref": [ "r297" ] }, "legn_DisclosureOfDeferredGovernmentGrantsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfDeferredGovernmentGrantsExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/GOVERNMENTGRANTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Deferred Government Grants", "label": "Disclosure Of Deferred Government Grants Explanatory [Table Text Block]", "documentation": "Disclosure of deferred government grants." } } }, "auth_ref": [] }, "legn_DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTextBlock", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Deferred Revenue from Contract Liabilities", "label": "Disclosure Of Deferred Revenue From Customer Contract Liabilities [Text Block]", "documentation": "Disclosure Of Deferred Revenue From Customer Contract Liabilities" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDeferredTaxesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDeferredTaxesExplanatory", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAX" ], "lang": { "en-us": { "role": { "terseLabel": "DEFERRED TAX", "label": "Disclosure of deferred taxes [text block]" } }, "en": { "role": { "documentation": "The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]" } } }, "auth_ref": [ "r297" ] }, "ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDepreciationAndAmortisationExpenseExplanatory", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Depreciation Calculated on Straight-line Basis Over Estimated Useful Lives of Assets", "label": "Disclosure of depreciation and amortisation expense [text block]" } }, "en": { "role": { "documentation": "The disclosure of depreciation and amortisation expense. [Refer: Depreciation and amortisation expense]" } } }, "auth_ref": [ "r297" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Interest-Bearing Loans and Borrowings", "label": "Disclosure of detailed information about borrowings [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r327" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Borrowings [Line Items]", "label": "Disclosure of detailed information about borrowings [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Borrowings [Table]", "label": "Disclosure of detailed information about borrowings [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } } }, "auth_ref": [ "r327" ] }, "legn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Cash and Cash Equivalents, Time Deposits and Pledged Deposits", "label": "Disclosure Of Detailed Information About Cash And Cash Equivalents Time Deposits And Pledged Deposits Explanatory [Table Text Block]", "documentation": "Disclosure of detailed information about cash and cash equivalents, time deposits and pledged deposits." } } }, "auth_ref": [] }, "legn_DisclosureOfDetailedInformationAboutDeferredTaxAssetsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfDetailedInformationAboutDeferredTaxAssetsExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Items with Respect to, Deferred Tax Assets have not been Recognized", "label": "Disclosure Of Detailed Information About Deferred Tax Assets Explanatory [Table Text Block]", "documentation": "Disclosure of detailed information about deferred tax assets." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "presentation": [ "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORY" ], "lang": { "en-us": { "role": { "terseLabel": "FINANCIAL INSTRUMENTS BY CATEGORY", "label": "Disclosure of detailed information about financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r201", "r207", "r214" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "presentation": [ "http://legendbiotech.com/role/INTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Intangible Assets", "label": "Disclosure of detailed information about intangible assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r105" ] }, "legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINVENTORIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Inventories", "label": "Disclosure Of Detailed Information About Inventories Explanatory [Table Text Block]", "documentation": "The disclosure of detailed information about inventories." } } }, "auth_ref": [] }, "legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Lease Liabilities [Line Items]", "label": "Disclosure Of Detailed Information About Lease Liabilities [Line Items]", "documentation": "Disclosure of detailed information about lease liabilities." } } }, "auth_ref": [] }, "legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Lease Liabilities [Table]", "label": "Disclosure Of Detailed Information About Lease Liabilities [Table]", "documentation": "Disclosure of detailed information about lease liabilities." } } }, "auth_ref": [] }, "legn_DisclosureOfDetailedInformationAboutMonitoringCapitalUsingGearingRatioExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfDetailedInformationAboutMonitoringCapitalUsingGearingRatioExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Monitoring Capital Using Gearing Ratio", "label": "Disclosure Of Detailed Information About Monitoring Capital Using Gearing Ratio Explanatory [Table Text Block]", "documentation": "Disclosure of detailed information about monitoring capital using gearing ratio." } } }, "auth_ref": [] }, "legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Other Payables and Accruals", "label": "Disclosure Of Detailed Information About Other Payables And Accruals Explanatory [Table Text Block]", "documentation": "Disclosure of detailed information about other payables and accruals." } } }, "auth_ref": [] }, "legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Prepayments, Other Receivables and Other Assets", "label": "Disclosure Of Detailed Information About Prepayments Other Receivables And Other Assets Explanatory [Table Text Block]", "documentation": "Disclosure of detailed information about prepayments, other receivables and other assets." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant and Equipment", "label": "Disclosure of detailed information about property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r60" ] }, "legn_DisclosureOfDetailedInformationAboutSensitivityToReasonablyPossibleChangeInExchangeRatesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfDetailedInformationAboutSensitivityToReasonablyPossibleChangeInExchangeRatesExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Sensitivity to Reasonably Possible Change in Exchange Rates", "label": "Disclosure Of Detailed Information About Sensitivity To Reasonably Possible Change In Exchange Rates Explanatory [Table Text Block]", "documentation": "Disclosure of detailed information about the sensitivity to reasonably possible change in exchange rates." } } }, "auth_ref": [] }, "legn_DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/WARRANTLIABILITYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Movement of Warrant Liability", "label": "Disclosure Of Detailed Information About Warrant Liability Explanatory [Table Text Block]", "documentation": "Disclosure of detailed information about warrant liability explanatory." } } }, "auth_ref": [] }, "legn_DisclosureOfDetailedInformationOfTradeReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfDetailedInformationOfTradeReceivablesTableTextBlock", "presentation": [ "http://legendbiotech.com/role/TRADERECEIVABLESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Trade Receivables", "label": "Disclosure Of Detailed Information Of Trade Receivables Table [Text Block]", "documentation": "Disclosure of detailed information of trade receivables." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Analysis of Revenue", "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]" } }, "en": { "role": { "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]" } } }, "auth_ref": [ "r152" ] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]", "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Table]", "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } } }, "auth_ref": [ "r152" ] }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEarningsPerShareExplanatory", "presentation": [ "http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENT" ], "lang": { "en-us": { "role": { "terseLabel": "LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT", "label": "Disclosure of earnings per share [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r93" ] }, "legn_DisclosureOfEstimatedUsefulLivesOfRightOfUseAssetsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfEstimatedUsefulLivesOfRightOfUseAssetsExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Estimated Useful Lives of Right-of-Use Assets", "label": "Disclosure Of Estimated Useful Lives Of Right Of Use Assets Explanatory [Table Text Block]", "documentation": "Disclosure of estimated useful lives of right-of-use assets." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "presentation": [ "http://legendbiotech.com/role/SUBSEQUENTEVENT" ], "lang": { "en-us": { "role": { "terseLabel": "SUBSEQUENT EVENT", "label": "Disclosure of events after reporting period [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } } }, "auth_ref": [ "r43" ] }, "legn_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Fair Value Measurement Of Assets And Liabilities [Abstract]", "documentation": "Disclosure of fair value measurement of assets and liabilities." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfAssetsExplanatory", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Assets Measured at Fair Value", "label": "Disclosure of fair value measurement of assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of the fair value measurement of assets." } } }, "auth_ref": [ "r148" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Liabilities Measured at Fair Value", "label": "Disclosure of fair value measurement of liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of the fair value measurement of liabilities." } } }, "auth_ref": [ "r148" ] }, "legn_DisclosureOfFairValueOfFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfFairValueOfFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Fair Value Of Financial Instruments [Abstract]", "documentation": "Disclosure of fair value of financial instruments." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS", "label": "Disclosure of fair value of financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]" } } }, "auth_ref": [ "r297" ] }, "legn_DisclosureOfFairValueValuationOfWarrantLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfFairValueValuationOfWarrantLiabilityAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Fair Value Valuation Of Warrant Liability [Abstract]", "documentation": "Disclosure of fair value valuation of warrant liability." } } }, "auth_ref": [] }, "legn_DisclosureOfFairValueValuationOfWarrantLiabilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfFairValueValuationOfWarrantLiabilityLineItems", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueValuationofWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Fair Value Valuation Of Warrant Liability [Line Items]", "label": "Disclosure Of Fair Value Valuation Of Warrant Liability [Line Items]", "documentation": "Disclosure of fair value valuation of warrant liability." } } }, "auth_ref": [] }, "legn_DisclosureOfFairValueValuationOfWarrantLiabilityTable": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfFairValueValuationOfWarrantLiabilityTable", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueValuationofWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Fair Value Valuation Of Warrant Liability [Table]", "label": "Disclosure Of Fair Value Valuation Of Warrant Liability [Table]", "documentation": "Disclosure of fair value valuation of warrant liability." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinanceCostExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinanceCostExplanatory", "presentation": [ "http://legendbiotech.com/role/FINANCECOSTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Finance Costs", "label": "Disclosure of finance cost [text block]" } }, "en": { "role": { "documentation": "The disclosure of finance cost. [Refer: Finance costs]" } } }, "auth_ref": [ "r297" ] }, "ifrs-full_DisclosureOfFinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialAssetsExplanatory", "presentation": [ "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Financial Assets", "label": "Disclosure of financial assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r214" ] }, "ifrs-full_DisclosureOfFinancialAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialAssetsLineItems", "presentation": [ "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialAssetsDetails", "http://legendbiotech.com/role/TRADERECEIVABLESAdditionalInformationDetails", "http://legendbiotech.com/role/TRADERECEIVABLESSummaryofTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Financial Assets [Line Items]", "label": "Disclosure of financial assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialAssetsTable", "presentation": [ "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialAssetsDetails", "http://legendbiotech.com/role/TRADERECEIVABLESAdditionalInformationDetails", "http://legendbiotech.com/role/TRADERECEIVABLESSummaryofTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Financial Assets [Table]", "label": "Disclosure of financial assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial assets." } } }, "auth_ref": [ "r214" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsExplanatory", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES", "label": "Disclosure of financial instruments [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for financial instruments." } } }, "auth_ref": [ "r223" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsLineItems", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESAdditionalInformationDetails", "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMonitoringCapitalUsingGearingRatioDetails", "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofSensitivitytoReasonablyPossibleChangeinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Financial Instruments [Line Items]", "label": "Disclosure of detailed information about financial instruments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsTable", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESAdditionalInformationDetails", "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMonitoringCapitalUsingGearingRatioDetails", "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofSensitivitytoReasonablyPossibleChangeinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Financial Instruments [Table]", "label": "Disclosure of detailed information about financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } } }, "auth_ref": [ "r201", "r207", "r214" ] }, "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesExplanatory", "presentation": [ "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Financial Liabilities", "label": "Disclosure of financial liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r214" ] }, "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesLineItems", "presentation": [ "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Financial Liabilities [Line Items]", "label": "Disclosure of financial liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesTable", "presentation": [ "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Financial Liabilities [Table]", "label": "Disclosure of financial liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial liabilities." } } }, "auth_ref": [ "r214" ] }, "ifrs-full_DisclosureOfGeographicalAreasExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfGeographicalAreasExplanatory", "presentation": [ "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Revenue", "label": "Disclosure of geographical areas [text block]" } }, "en": { "role": { "documentation": "The disclosure of geographical information." } } }, "auth_ref": [ "r234" ] }, "ifrs-full_DisclosureOfGovernmentGrantsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfGovernmentGrantsExplanatory", "presentation": [ "http://legendbiotech.com/role/GOVERNMENTGRANTS" ], "lang": { "en-us": { "role": { "terseLabel": "GOVERNMENT GRANTS", "label": "Disclosure of government grants [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for government grants." } } }, "auth_ref": [ "r69" ] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://legendbiotech.com/role/INCOMETAX" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAX", "label": "Disclosure of income tax [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r52" ] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMETables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Fair Value of Equity Settled Share Options Granted", "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } } }, "auth_ref": [ "r193" ] }, "legn_DisclosureOfInformationOfInputsUsedInFairValueValuationOfWarrantLiabilityExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfInformationOfInputsUsedInFairValueValuationOfWarrantLiabilityExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Fair Value Valuation of Warrant Liability", "label": "Disclosure Of Information Of Inputs Used In Fair Value Valuation Of Warrant Liability Explanatory [Table Text Block]", "documentation": "Disclosure of information of inputs used in fair value valuation of warrant liability." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [abstract]" } } }, "auth_ref": [] }, "legn_DisclosureOfIntangibleAssetsAmortizationExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfIntangibleAssetsAmortizationExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Intangible Assets Amortized", "label": "Disclosure Of Intangible Assets Amortization Explanatory [Table Text Block]", "documentation": "Disclosure of intangible assets amortization." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsExplanatory", "presentation": [ "http://legendbiotech.com/role/INTANGIBLEASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "INTANGIBLE ASSETS", "label": "Disclosure of intangible assets [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for intangible assets." } } }, "auth_ref": [ "r107" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://legendbiotech.com/role/INTANGIBLEASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Intangible Assets [Line Items]", "label": "Disclosure of detailed information about intangible assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://legendbiotech.com/role/INTANGIBLEASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Intangible Assets [Table]", "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r105" ] }, "ifrs-full_DisclosureOfInventoriesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInventoriesExplanatory", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINVENTORIES" ], "lang": { "en-us": { "role": { "terseLabel": "COLLABORATION INVENTORIES", "label": "Disclosure of inventories [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for inventories." } } }, "auth_ref": [ "r67" ] }, "ifrs-full_DisclosureOfLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfLeasesExplanatory", "presentation": [ "http://legendbiotech.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Disclosure of leases [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for leases." } } }, "auth_ref": [ "r169", "r170" ] }, "ifrs-full_DisclosureOfMaturityAnalysisForFinancialAssetsHeldForManagingLiquidityRiskExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfMaturityAnalysisForFinancialAssetsHeldForManagingLiquidityRiskExplanatory", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments", "label": "Disclosure of maturity analysis for financial assets held for managing liquidity risk [text block]" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis for financial assets held for managing liquidity risk. [Refer: Financial assets; Liquidity risk [member]]" } } }, "auth_ref": [ "r219" ] }, "ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableExplanatory", "presentation": [ "http://legendbiotech.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Undiscounted Minimum Lease Payments Receivables for Leases", "label": "Disclosure of maturity analysis of finance lease payments receivable [text block]" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis of finance lease payments receivable. Finance lease is a lease that transfers substantially all the risks and rewards incidental to ownership of an underlying asset." } } }, "auth_ref": [ "r167" ] }, "legn_DisclosureOfMovementsInCompanySShareCapitalAndSharePremiumExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfMovementsInCompanySShareCapitalAndSharePremiumExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Movements in the Company's Share Capital and Share Premium", "label": "Disclosure Of Movements In Company S Share Capital And Share Premium Explanatory [Table Text Block]", "documentation": "Disclosure of movements in the company's share capital and share premium explanatory." } } }, "auth_ref": [] }, "legn_DisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryTextBlock", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Movements In Deferred Tax Assets And Liabilities", "label": "Disclosure Of Movements In Deferred Tax Assets And Liabilities Explanatory [Text Block]", "documentation": "Disclosure Of Movements In Deferred Tax Assets And Liabilities Explanatory" } } }, "auth_ref": [] }, "legn_DisclosureOfNonCurrentAssetInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfNonCurrentAssetInformationTextBlock", "presentation": [ "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Non-current Assets", "label": "Disclosure Of Non Current Asset Information [Text Block]", "documentation": "Disclosure of non-current asset Information." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [abstract]" } } }, "auth_ref": [] }, "legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "CORPORATE INFORMATION", "label": "Disclosure of notes and other explanatory information [text block]", "documentation": "The disclosure of notes and other explanatory information as part of a complete set of financial statements." } } }, "auth_ref": [] }, "legn_DisclosureOfNotesToConsolidatedStatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfNotesToConsolidatedStatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Notes To Consolidated Statement Of Cash Flows [Abstract]", "documentation": "Disclosure of notes to the consolidated statement of cash flows." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Movement in Number of RSU Outstanding", "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r326" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMETables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Share Options Outstanding Under the Scheme", "label": "Disclosure of number and weighted average exercise prices of share options [text block]" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r188" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofFairValueofEquitySettledShareOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]", "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofFairValueofEquitySettledShareOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Table]", "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the number and weighted average remaining contractual life of outstanding share options." } } }, "auth_ref": [ "r190" ] }, "ifrs-full_DisclosureOfOperatingSegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOperatingSegmentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of operating segments [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOperatingSegmentsExplanatory", "presentation": [ "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "OPERATING SEGMENT INFORMATION", "label": "Disclosure of operating segments [text block]" } }, "en": { "role": { "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]" } } }, "auth_ref": [ "r226" ] }, "ifrs-full_DisclosureOfOperatingSegmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOperatingSegmentsLineItems", "presentation": [ "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONAdditionalInformationDetails", "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofNoncurrentAssetsDetails", "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Operating Segments [Line Items]", "label": "Disclosure of operating segments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOperatingSegmentsTable", "presentation": [ "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONAdditionalInformationDetails", "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofNoncurrentAssetsDetails", "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Operating Segments [Table]", "label": "Disclosure of operating segments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to operating segments." } } }, "auth_ref": [ "r226" ] }, "ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherNoncurrentAssetsExplanatory", "presentation": [ "http://legendbiotech.com/role/OTHERNONCURRENTASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER NON-CURRENT ASSETS", "label": "Disclosure of other non-current assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of other non-current assets. [Refer: Other non-current assets]" } } }, "auth_ref": [ "r297" ] }, "legn_DisclosureOfOtherNoncurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfOtherNoncurrentAssetsTableTextBlock", "presentation": [ "http://legendbiotech.com/role/OTHERNONCURRENTASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Other Non-Current Assets", "label": "Disclosure Of Other Noncurrent Assets Table [Text Block]", "documentation": "Disclosure of other noncurrent assets table text block." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherOperatingIncomeExplanatory", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Other Income and Gains", "label": "Disclosure of other operating income [text block]" } }, "en": { "role": { "documentation": "The disclosure of other operating income. [Refer: Other operating income (expense)]" } } }, "auth_ref": [ "r297" ] }, "legn_DisclosureOfOtherPayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfOtherPayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Other Payables And Accruals [Abstract]", "documentation": "Disclosure of other payables and accruals." } } }, "auth_ref": [] }, "legn_DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock", "presentation": [ "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALS" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER PAYABLES AND ACCRUALS", "label": "Disclosure Of Other Payables And Accruals Explanatory [Text Block]", "documentation": "Disclosure of other payables and accruals." } } }, "auth_ref": [] }, "legn_DisclosureOfOutstandingBalancesWithRelatedPartiesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfOutstandingBalancesWithRelatedPartiesExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Outstanding Balances with Related Parties Explanatory", "label": "Disclosure Of Outstanding Balances With Related Parties Explanatory [Table Text Block]", "documentation": "Disclosure of outstanding balances with related parties." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPerformanceObligationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPerformanceObligationsExplanatory", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Transaction Price and Performance Obligations", "label": "Disclosure of performance obligations [text block]" } }, "en": { "role": { "documentation": "The disclosure of performance obligations in contracts with customers. [Refer: Performance obligations [member]]" } } }, "auth_ref": [ "r154" ] }, "ifrs-full_DisclosureOfPerformanceObligationsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPerformanceObligationsLineItems", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceAllocationtoPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of performance obligations [line items]", "label": "Disclosure of performance obligations [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPerformanceObligationsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPerformanceObligationsTable", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceAllocationtoPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of performance obligations [table]", "label": "Disclosure of performance obligations [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to performance obligations in contracts with customers." } } }, "auth_ref": [ "r154" ] }, "legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Prepayments Other Receivables And Other Assets [Abstract]", "documentation": "Disclosure of prepayments, other receivables and other assets." } } }, "auth_ref": [] }, "legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock", "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS", "label": "Disclosure Of Prepayments Other Receivables And Other Assets Explanatory [Text Block]", "documentation": "Disclosure of prepayments, other receivables and other assets." } } }, "auth_ref": [] }, "legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems", "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSAdditionalInformationDetails", "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSSummaryofPrepaymentsOtherReceivablesandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]", "label": "Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]", "documentation": "Disclosure of prepayments, other receivables and other assets." } } }, "auth_ref": [] }, "legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable", "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSAdditionalInformationDetails", "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSSummaryofPrepaymentsOtherReceivablesandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Prepayments Other Receivables And Other Assets [Table]", "label": "Disclosure Of Prepayments Other Receivables And Other Assets [Table]", "documentation": "Disclosure of prepayments, other receivables and other assets." } } }, "auth_ref": [] }, "legn_DisclosureOfProfitLossBeforeTaxArrivedAfterChargingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfProfitLossBeforeTaxArrivedAfterChargingTableTextBlock", "presentation": [ "http://legendbiotech.com/role/LOSSBEFORETAXTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Profit (Loss) Before Tax Arrived After Charging", "label": "Disclosure Of Profit Loss Before Tax Arrived After Charging [Table Text Block]", "documentation": "The disclosure of profit loss before tax arrived after charging and crediting." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "presentation": [ "http://legendbiotech.com/role/LOSSBEFORETAX" ], "lang": { "en-us": { "role": { "terseLabel": "LOSS BEFORE TAX", "label": "Disclosure of profit (loss) from operating activities [text block]" } }, "en": { "role": { "documentation": "The disclosure of profit (loss) from operating activities. [Refer: Profit (loss) from operating activities]" } } }, "auth_ref": [ "r297" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENT" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY, PLANT AND EQUIPMENT", "label": "Disclosure of property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } } }, "auth_ref": [ "r63" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Property Plant And Equipment [Line Items]", "label": "Disclosure of detailed information about property, plant and equipment [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Property Plant And Equipment [Table]", "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r60" ] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "presentation": [ "http://legendbiotech.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Carrying Amounts of The Right-of-use Assets and Movements", "label": "Disclosure of quantitative information about right-of-use assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r166" ] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems", "presentation": [ "http://legendbiotech.com/role/LEASESRightofuseAssetsDetails", "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]", "label": "Disclosure of quantitative information about right-of-use assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable", "presentation": [ "http://legendbiotech.com/role/LEASESRightofuseAssetsDetails", "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Quantitative Information About Rightofuse Assets [Table]", "label": "Disclosure of quantitative information about right-of-use assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to right-of-use assets." } } }, "auth_ref": [ "r166" ] }, "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMETables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Exercise Prices and Exercise Periods of Share Options Outstanding", "label": "Disclosure of range of exercise prices of outstanding share options [text block]" } }, "en": { "role": { "documentation": "The disclosure of the range of exercise prices for outstanding share options." } } }, "auth_ref": [ "r190" ] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "presentation": [ "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Changes in Liabilities Arising from Financing Activities", "label": "Disclosure of reconciliation of liabilities arising from financing activities [text block]" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r265" ] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems", "presentation": [ "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]", "label": "Disclosure of reconciliation of liabilities arising from financing activities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable", "presentation": [ "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Table]", "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities." } } }, "auth_ref": [ "r265" ] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONS" ], "lang": { "en-us": { "role": { "terseLabel": "RELATED PARTY TRANSACTIONS", "label": "Disclosure of related party [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r80" ] }, "ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://legendbiotech.com/role/RESERVES" ], "lang": { "en-us": { "role": { "terseLabel": "RESERVES", "label": "Disclosure of reserves within equity [text block]" } }, "en": { "role": { "documentation": "The disclosure of reserves within equity. [Refer: Other reserves [member]]" } } }, "auth_ref": [ "r30" ] }, "ifrs-full_DisclosureOfReservesWithinEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReservesWithinEquityAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of reserves within equity [abstract]" } } }, "auth_ref": [] }, "legn_DisclosureOfRevenueOtherIncomeAndGainsExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfRevenueOtherIncomeAndGainsExplanatoryTextBlock", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINS" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUE, OTHER INCOME AND GAINS", "label": "Disclosure Of Revenue Other Income And Gains Explanatory [Text Block]", "documentation": "Disclosure of revenue, other income and gains." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Shares", "label": "Disclosure of share capital, reserves and other equity interest [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r31" ] }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEME" ], "lang": { "en-us": { "role": { "terseLabel": "SHARE OPTION SCHEME", "label": "Disclosure of share-based payment arrangements [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } } }, "auth_ref": [ "r181" ] }, "legn_DisclosureOfSignificantAccountingJudgementsAndEstimatesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfSignificantAccountingJudgementsAndEstimatesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Significant Accounting Judgements And Estimates [Abstract]", "documentation": "Disclosure of significant accounting judgements and estimates." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of subsidiaries [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Information About Subsidiaries", "label": "Disclosure of subsidiaries [text block]" } }, "en": { "role": { "documentation": "The disclosure of subsidiaries. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r86", "r89", "r144" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATIONInformationAboutSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Significant Investments In Subsidiaries [Line Items]", "label": "Disclosure of subsidiaries [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATIONInformationAboutSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Significant Investments In Subsidiaries [Table]", "label": "Disclosure of subsidiaries [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to subsidiaries." } } }, "auth_ref": [ "r86", "r89", "r144" ] }, "legn_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Disclosure of significant accounting policies [text block]", "documentation": "The entire disclosure for significant accounting policies applied by the entity." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMEAdditionalInformationDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]", "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMEAdditionalInformationDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Table]", "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r191" ] }, "legn_DisclosureOfTotalCashOutflowForLeasesIncludedInStatementOfCashFlowsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfTotalCashOutflowForLeasesIncludedInStatementOfCashFlowsExplanatoryTableTextBlock", "presentation": [ "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Total Cash Outflow for Leases Included in Statement of Cash Flows", "label": "Disclosure Of Total Cash Outflow For Leases Included In Statement Of Cash Flows Explanatory [Table Text Block]", "documentation": "Disclosure of total cash outflow for leases included in statement of cash flows explanatory." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://legendbiotech.com/role/TRADEPAYABLES" ], "lang": { "en-us": { "role": { "terseLabel": "TRADE PAYABLES", "label": "Disclosure of trade and other payables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r297" ] }, "legn_DisclosureOfTradeAndOtherPayablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfTradeAndOtherPayablesTableTextBlock", "presentation": [ "http://legendbiotech.com/role/TRADEPAYABLESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Trade and Notes Payables", "label": "Disclosure Of Trade And Other Payables Table [Text Block]", "documentation": "Disclosure of trade and other payables table text block." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory", "presentation": [ "http://legendbiotech.com/role/TRADERECEIVABLES" ], "lang": { "en-us": { "role": { "terseLabel": "TRADE RECEIVABLES", "label": "Disclosure of trade and other receivables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]" } } }, "auth_ref": [ "r297" ] }, "ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction Price Amounts Allocated to Remaining Performance Obligations", "label": "Disclosure of transaction price allocated to remaining performance obligations [text block]" } }, "en": { "role": { "documentation": "The disclosure of the transaction price allocated to the remaining performance obligations in contracts with customers." } } }, "auth_ref": [ "r156" ] }, "ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceCompositionDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTransactionPriceAmountsAllocatedtoRemainingPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Transaction Price Allocated To Remaining Performance Obligations [Line Items]", "label": "Disclosure of transaction price allocated to remaining performance obligations [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceCompositionDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTransactionPriceAmountsAllocatedtoRemainingPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Transaction Price Allocated To Remaining Performance Obligations [Table]", "label": "Disclosure of transaction price allocated to remaining performance obligations [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the transaction price allocated to the remaining performance obligations in contracts with customers." } } }, "auth_ref": [ "r156" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Transactions with Related Parties", "label": "Disclosure of transactions between related parties [text block]" } }, "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]" } } }, "auth_ref": [ "r76" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSAdditionalInformationDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofNatureofRelatedPartyRelationshipDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Transactions Between Related Parties [Line Items]", "label": "Disclosure of transactions between related parties [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSAdditionalInformationDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofNatureofRelatedPartyRelationshipDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Transactions Between Related Parties [Table]", "label": "Disclosure of transactions between related parties [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } } }, "auth_ref": [ "r78" ] }, "ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfVoluntaryChangeInAccountingPolicyAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of voluntary change in accounting policy [abstract]" } } }, "auth_ref": [] }, "legn_DisclosureOfWarrantLiabilityExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "DisclosureOfWarrantLiabilityExplanatoryTextBlock", "presentation": [ "http://legendbiotech.com/role/WARRANTLIABILITY" ], "lang": { "en-us": { "role": { "terseLabel": "WARRANT LIABILITY", "label": "Disclosure Of Warrant Liability Explanatory [Text Block]", "documentation": "Disclosure of warrant liability explanatory." } } }, "auth_ref": [] }, "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisposalsIntangibleAssetsOtherThanGoodwill", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/INTANGIBLEASSETSDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Disposals", "label": "Disposals, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r101" ] }, "ifrs-full_DisposalsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisposalsPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Disposals", "label": "Disposals, property, plant and equipment" } }, "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r56" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Accounting Standard", "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r291" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r290", "r291", "r292" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r290", "r291", "r292", "r294" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Registration Statement", "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r286" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Shell Company Report", "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r291" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r293" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "EUR", "presentation": [ "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominated in EUR", "label": "Euro Member Countries, Euro" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareAbstract", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT", "label": "Earnings per share [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Calculations of Basic and Diluted Loss per Share", "label": "Earnings per share [text block]" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r90" ] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign exchange rate changes, net", "label": "Effect of exchange rate changes on cash and cash equivalents" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r116", "r117" ] }, "legn_EmployeeBenefitExpenseExcludingDirectorsRemunerationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "EmployeeBenefitExpenseExcludingDirectorsRemunerationAbstract", "presentation": [ "http://legendbiotech.com/role/LOSSBEFORETAXDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefit expense (including directors\u2019 remuneration):", "label": "Employee Benefit Expense Excluding Directors Remuneration [Abstract]", "documentation": "Employee Benefit Expense Excluding Directors Remuneration [Abstract]" } } }, "auth_ref": [] }, "legn_EntireDisclosureOfFinanceCostsExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "EntireDisclosureOfFinanceCostsExplanatoryTextBlock", "presentation": [ "http://legendbiotech.com/role/FINANCECOSTS" ], "lang": { "en-us": { "role": { "terseLabel": "FINANCE COSTS", "label": "Entire Disclosure Of Finance Costs Explanatory [Text Block]", "documentation": "The entire disclosure of finance costs." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses, Address Type", "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r288" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r288" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r288" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r295" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r288" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r288" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r296" ] }, "ifrs-full_EntitysTotalForProbabilityOfDefaultMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForProbabilityOfDefaultMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofSensitivitytoReasonablyPossibleChangeinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity's total for probability of default [member]", "label": "Entity's total for probability of default [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Probability of default' axis if no other member is used." } } }, "auth_ref": [ "r276", "r281" ] }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForRelatedPartiesMember", "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSAdditionalInformationDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSAdditionalInformationDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofNatureofRelatedPartyRelationshipDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails", "http://legendbiotech.com/role/TRADEPAYABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity's total for related parties [member]", "label": "Entity's total for related parties [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r78" ] }, "ifrs-full_EntitysTotalForSubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForSubsidiariesMember", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATIONInformationAboutSubsidiariesDetails", "http://legendbiotech.com/role/DEFERREDTAXAdditionalInformationDetails", "http://legendbiotech.com/role/INCOMETAXAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity's total for subsidiaries [member]", "label": "Entity's total for subsidiaries [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } } }, "auth_ref": [ "r86", "r89", "r144" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r17", "r25", "r128", "r130", "r145", "r146", "r147" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "EQUITY", "label": "Equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r17" ] }, "ifrs-full_EquityAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total ordinary shareholders\u2019 equity", "label": "Equity attributable to owners of parent" } }, "en": { "role": { "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest." } } }, "auth_ref": [ "r16" ] }, "ifrs-full_EquityMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityMember", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails", "http://legendbiotech.com/role/WARRANTLIABILITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity [member]", "label": "Equity [member]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r5" ] }, "ifrs-full_EquityPriceRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityPriceRiskMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMonitoringCapitalUsingGearingRatioDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Management", "label": "Equity price risk [member]" } }, "en": { "role": { "documentation": "This member stands for a component of other price risk that represents the type of risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in equity prices. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r278", "r283" ] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EuropeMember", "presentation": [ "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofNoncurrentAssetsDetails", "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Europe", "label": "Europe [Member]" } } }, "auth_ref": [] }, "ifrs-full_ExchangeDifferencesOnTranslationAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExchangeDifferencesOnTranslationAbstract", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER COMPREHENSIVE INCOME", "label": "Exchange differences on translation [abstract]" } } }, "auth_ref": [] }, "legn_ExerciseOfShareOption": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ExerciseOfShareOption", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of share options", "label": "Exercise Of Share Option", "documentation": "Exercise of share option." } } }, "auth_ref": [] }, "legn_ExerciseOfShareOptionNumberOfSharesInIssue": { "xbrltype": "sharesItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ExerciseOfShareOptionNumberOfSharesInIssue", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of share options (in shares)", "label": "Exercise Of Share Option Number Of Shares In Issue", "documentation": "Exercise of share option number of shares in issue." } } }, "auth_ref": [] }, "legn_ExerciseOfTheWarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ExerciseOfTheWarrantLiability", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/WARRANTLIABILITYScheduleofMovementofWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Exercise of the warrant liability", "label": "Exercise Of The Warrant Liability", "documentation": "Exercise Of The Warrant Liability" } } }, "auth_ref": [] }, "legn_ExerciseOfWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ExerciseOfWarrantMember", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of Warrant", "label": "Exercise Of Warrant [Member]", "documentation": "Exercise Of Warrant" } } }, "auth_ref": [] }, "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExercisePriceOfOutstandingShareOptions2019", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price per share (in dollars per share)", "label": "Exercise price of outstanding share options" } }, "en": { "role": { "documentation": "The exercise price of outstanding share options." } } }, "auth_ref": [ "r190" ] }, "legn_ExercisePricePerOrdinaryShare": { "xbrltype": "perShareItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ExercisePricePerOrdinaryShare", "presentation": [ "http://legendbiotech.com/role/WARRANTLIABILITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private placement purchase price per share (in dollars per share)", "label": "Exercise Price Per Ordinary Share", "documentation": "Exercise price per ordinary share." } } }, "auth_ref": [] }, "ifrs-full_ExercisePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExercisePriceShareOptionsGranted2019", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueValuationofWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying stock price (in dollars per share)", "label": "Exercise price, share options granted" } }, "en": { "role": { "documentation": "The exercise price of share options granted." } } }, "auth_ref": [ "r192" ] }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueValuationofWarrantLiabilityDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofFairValueofEquitySettledShareOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield (%)", "verboseLabel": "Dividend", "label": "Expected dividend as percentage, share options granted" } }, "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } } }, "auth_ref": [ "r192" ] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://legendbiotech.com/role/LOSSBEFORETAXDetails", "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSAdditionalInformationDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-settled share-based compensation expense", "verboseLabel": "Equity-settled share-based compensation expense", "label": "Expense from share-based payment transactions with employees" } }, "en": { "role": { "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]" } } }, "auth_ref": [ "r301" ] }, "ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense relating to short-term leases", "label": "Expense relating to short-term leases for which recognition exemption has been used" } }, "en": { "role": { "documentation": "The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease." } } }, "auth_ref": [ "r162" ] }, "legn_ExpensesRecognizedForShareOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ExpensesRecognizedForShareOptions", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMEAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share option expense", "label": "Expenses Recognized For Share Options", "documentation": "Expenses recognized for share options." } } }, "auth_ref": [] }, "legn_FairValueLossOfWarrantsLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "FairValueLossOfWarrantsLiabilities", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "negatedLabel": "Fair value (loss)/gain of warrant liability", "label": "Fair Value Loss Of Warrants Liabilities", "documentation": "Fair value loss of warrant liabilities." } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 9.0 }, "http://legendbiotech.com/role/FINANCECOSTSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME", "http://legendbiotech.com/role/FINANCECOSTSDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Finance costs", "totalLabel": "Total", "label": "Finance costs" } }, "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } } }, "auth_ref": [ "r38" ] }, "legn_FinanceCostsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "FinanceCostsAbstract", "lang": { "en-us": { "role": { "label": "Finance Costs [Abstract]", "documentation": "Finance costs." } } }, "auth_ref": [] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSOtherIncomeandGainsDetails": { "parentTag": "ifrs-full_OtherIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSOtherIncomeandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance income", "label": "Finance income" } }, "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r307" ] }, "ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinanceIncomeReceivedClassifiedAsOperatingActivities", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income received", "label": "Finance income received, classified as operating activities" } }, "en": { "role": { "documentation": "The cash inflow from finance income received, classified as operating activities. [Refer: Finance income]" } } }, "auth_ref": [ "r323" ] }, "ifrs-full_FinanceLeaseReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinanceLeaseReceivables", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/OTHERNONCURRENTASSETSDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0, "order": 2.0 }, "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSSummaryofPrepaymentsOtherReceivablesandOtherAssetsDetails": { "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/OTHERNONCURRENTASSETSDetails", "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSSummaryofPrepaymentsOtherReceivablesandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Lease receivables", "terseLabel": "Lease receivables", "label": "Finance lease receivables" } }, "en": { "role": { "documentation": "The amount of receivables related to finance leases." } } }, "auth_ref": [ "r303" ] }, "ifrs-full_FinancialAssetsAtAmortisedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsAtAmortisedCost", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Financial\u00a0assets\u00a0at amortized\u00a0cost", "label": "Financial assets at amortised cost" } }, "en": { "role": { "documentation": "The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]" } } }, "auth_ref": [ "r217" ] }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets measured at fair value through profit and loss", "label": "Financial assets at fair value through profit or loss, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]" } } }, "auth_ref": [ "r215" ] }, "legn_FinancialAssetsIncludedInPrepaymentsOtherReceivablesAndOtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "FinancialAssetsIncludedInPrepaymentsOtherReceivablesAndOtherAssetsMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets included in prepayments, other receivables and other assets (note 16)", "label": "Financial Assets Included In Prepayments Other Receivables And Other Assets [Member]", "documentation": "Financial assets included in prepayments, other receivables and other assets." } } }, "auth_ref": [] }, "ifrs-full_FinancialAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets, class [member]", "label": "Financial assets, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r180", "r212", "r213", "r236", "r237" ] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r200" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCost", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial\u00a0liabilities at\u00a0amortized\u00a0cost", "label": "Financial liabilities at amortised cost" } }, "en": { "role": { "documentation": "The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r218" ] }, "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLoss", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueMeasurementHierarchyofFinancialInstrumentsDetails", "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities at fair value", "verboseLabel": "Financial liabilities at fair value through profit or loss", "label": "Financial liabilities at fair value through profit or loss" } }, "en": { "role": { "documentation": "The amount of financial liabilities that meet either of the following conditions: (a) they meet the definition of held for trading; or (b) upon initial recognition they are designated by the entity as at fair value through profit or loss. An entity may use this designation only when permitted by paragraph 4.3.5 of IFRS 9 (embedded derivatives) or when doing so results in more relevant information, because either: (a) it eliminates or significantly reduces a measurement or recognition inconsistency (sometimes referred to as \u2018an accounting mismatch\u2019) that would otherwise arise from measuring assets or liabilities or recognising the gains and losses on them on different bases; or (b) a group of financial liabilities or financial assets and financial liabilities is managed and its performance is evaluated on a fair value basis, in accordance with a documented risk management or investment strategy, and information about the group is provided internally on that basis to the entity\u2019s key management personnel (as defined in IAS 24). [Refer: At fair value [member]; Key management personnel of entity or parent [member]; Derivatives [member]; Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r216" ] }, "legn_FinancialLiabilitiesIncludedInOtherPayablesAndAccrualsMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "FinancialLiabilitiesIncludedInOtherPayablesAndAccrualsMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities included in other payables and accruals (note 19)", "label": "Financial Liabilities Included In Other Payables And Accruals [Member]", "documentation": "Financial liabilities included in other payables and accruals." } } }, "auth_ref": [] }, "legn_FinancingFromFollowOnPublicOfferingNetOfIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "FinancingFromFollowOnPublicOfferingNetOfIssuanceCost", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing from follow-on public offering, net of issuance cost", "label": "Financing From Follow On Public Offering Net Of Issuance Cost", "documentation": "Financing from follow-on public offering, net of issuance cost." } } }, "auth_ref": [] }, "ifrs-full_FinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinishedGoods", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/COLLABORATIONINVENTORIESSummaryofInventoriesDetails": { "parentTag": "ifrs-full_Inventories", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINVENTORIESSummaryofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Current finished goods" } }, "en": { "role": { "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]" } } }, "auth_ref": [ "r244", "r313" ] }, "legn_FollowOnPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "FollowOnPublicOfferingMember", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSAdditionalInformationDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Follow-On Public Offering", "label": "Follow On Public Offering [Member]", "documentation": "Follow-on public offering." } } }, "auth_ref": [] }, "legn_FormerEmployeeDamagesDemand": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "FormerEmployeeDamagesDemand", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Former employee damages demanded", "label": "Former Employee Damages Demand", "documentation": "Former employee damages demand." } } }, "auth_ref": [] }, "legn_FutureEstimatedMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "FutureEstimatedMilestonePayments", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSAdditionalInformationDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future estimated milestone payments", "verboseLabel": "Future estimated milestone payments (up to)", "label": "Future Estimated Milestone Payments", "documentation": "Estimated milestone payments to be received" } } }, "auth_ref": [] }, "ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainsLossesOnDisposalsOfPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposal of property, plant and equipment", "label": "Gains (losses) on disposals of property, plant and equipment" } }, "en": { "role": { "documentation": "The gains (losses) on disposals of property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r41" ] }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofSensitivitytoReasonablyPossibleChangeinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Decrease/ (increase) in loss before\u00a0tax", "label": "Foreign exchange gain (loss)" } }, "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]" } } }, "auth_ref": [ "r9", "r70" ] }, "ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSOtherIncomeandGainsDetails": { "parentTag": "ifrs-full_OtherGainsLosses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSOtherIncomeandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value gains on financial assets measured at fair value change through profit or loss", "label": "Gains (losses) on financial assets at fair value through profit or loss" } }, "en": { "role": { "documentation": "The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]" } } }, "auth_ref": [ "r197" ] }, "ifrs-full_GainsLossesOnFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainsLossesOnFinancialInstrumentsAbstract", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSOtherIncomeandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gains:", "label": "Gains (losses) on financial instruments [abstract]" } } }, "auth_ref": [] }, "legn_GenscriptBiotechCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "GenscriptBiotechCorporationMember", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSAdditionalInformationDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofNatureofRelatedPartyRelationshipDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Genscript Biotech Corporation", "label": "Genscript Biotech Corporation [Member]", "documentation": "Genscript Biotech Corporation (\"Genscript\")" } } }, "auth_ref": [] }, "legn_GenscriptGroupMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "GenscriptGroupMember", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Genscript Group", "label": "Genscript Group [Member]", "documentation": "Genscript Group." } } }, "auth_ref": [] }, "legn_GenscriptNetherlandsMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "GenscriptNetherlandsMember", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofNatureofRelatedPartyRelationshipDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Genscript Netherlands", "label": "Genscript Netherlands [Member]", "documentation": "Genscript Netherlands." } } }, "auth_ref": [] }, "legn_GenscriptProbioUSAIncMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "GenscriptProbioUSAIncMember", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofNatureofRelatedPartyRelationshipDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Genscript Probio USA Inc", "label": "Genscript Probio U S A Inc [Member]", "documentation": "Genscript Probio U S A Inc" } } }, "auth_ref": [] }, "legn_GenscriptUSAHoldingsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "GenscriptUSAHoldingsIncMember", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofNatureofRelatedPartyRelationshipDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Genscript USA Holdings Inc", "label": "Genscript U S A Holdings Inc [Member]", "documentation": "Genscript USA Holdings Inc." } } }, "auth_ref": [] }, "legn_GenscriptUSAIncorporatedMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "GenscriptUSAIncorporatedMember", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofNatureofRelatedPartyRelationshipDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Genscript USA Incorporated", "label": "Genscript U S A Incorporated [Member]", "documentation": "Genscript USA Incorporated." } } }, "auth_ref": [] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://legendbiotech.com/role/INCOMETAXAdditionalInformationDetails", "http://legendbiotech.com/role/INCOMETAXSummaryofTaxChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical areas [axis]", "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r234", "r251", "r271", "r274" ] }, "ifrs-full_GeographicalAreasMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GeographicalAreasMember", "presentation": [ "http://legendbiotech.com/role/INCOMETAXAdditionalInformationDetails", "http://legendbiotech.com/role/INCOMETAXSummaryofTaxChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical areas [member]", "label": "Geographical areas [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r234", "r251", "r271", "r274" ] }, "legn_GlobalEconomicConditionsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "GlobalEconomicConditionsTextBlock", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Global Economic Conditions", "label": "Global Economic Conditions [Text Block]", "documentation": "Global Economic Conditions" } } }, "auth_ref": [] }, "legn_GovernmentGrantAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "GovernmentGrantAbstract", "lang": { "en-us": { "role": { "label": "Government Grant [Abstract]", "documentation": "Government grant." } } }, "auth_ref": [] }, "ifrs-full_GovernmentGrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GovernmentGrants", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/GOVERNMENTGRANTSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/GOVERNMENTGRANTSDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred government grants", "label": "Government grants" } }, "en": { "role": { "documentation": "The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]" } } }, "auth_ref": [ "r303" ] }, "legn_GovernmentGrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "GovernmentGrantsAbstract", "lang": { "en-us": { "role": { "label": "Government Grants [Abstract]", "documentation": "Government grants." } } }, "auth_ref": [] }, "legn_GovernmentGrantsReceivedFromLocalGovernmentAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "GovernmentGrantsReceivedFromLocalGovernmentAuthorities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSOtherIncomeandGainsDetails": { "parentTag": "ifrs-full_OtherIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSOtherIncomeandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government grants", "label": "Government Grants Received From Local Government Authorities", "documentation": "Government grants received from local government authorities." } } }, "auth_ref": [] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://legendbiotech.com/role/INTANGIBLEASSETSDetails", "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails", "http://legendbiotech.com/role/TRADERECEIVABLESSummaryofTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost", "verboseLabel": "Gross Carrying Amount", "label": "Gross carrying amount [member]" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r54", "r99", "r110", "r113", "r195", "r206", "r209", "r277" ] }, "country_HK": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "HK", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXAdditionalInformationDetails", "http://legendbiotech.com/role/INCOMETAXAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hong Kong", "label": "HONG KONG" } } }, "auth_ref": [] }, "legn_HainanChuanjiBiotechnologyCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "HainanChuanjiBiotechnologyCoLtdMember", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATIONInformationAboutSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hainan Chuanji Biotechnology Co., Ltd. (\u201cHainan Chuanji\u201d)", "label": "Hainan Chuanji Biotechnology Co Ltd [Member]", "documentation": "Hainan Chuanji Biotechnology Co., Ltd." } } }, "auth_ref": [] }, "country_IE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "IE", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXAdditionalInformationDetails", "http://legendbiotech.com/role/INCOMETAXAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ireland", "label": "IRELAND" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r290", "r291", "r292" ] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLoss", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment loss of non-financial assets", "label": "Impairment loss recognised in profit or loss" } }, "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]" } } }, "auth_ref": [ "r94", "r96" ] }, "legn_IncomeOtherAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "IncomeOtherAbstract", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSOtherIncomeandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income:", "label": "Income, Other [Abstract]", "documentation": "Income, Other" } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 2.0 }, "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME", "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax benefit/(expense)", "totalLabel": "Tax charge/(benefit) at the Company\u2019s effective rate", "label": "Tax expense (income)" } }, "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } } }, "auth_ref": [ "r39", "r44", "r46", "r47", "r83", "r143", "r225" ] }, "ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxesPaidClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax paid", "label": "Income taxes paid, classified as operating activities" } }, "en": { "role": { "documentation": "The cash outflow for income taxes paid, classified as operating activities." } } }, "auth_ref": [ "r324" ] }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax received", "label": "Income taxes paid (refund), classified as operating activities" } }, "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } } }, "auth_ref": [ "r119", "r259" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "NET INCREASE IN CASH AND CASH EQUIVALENTS", "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r122" ] }, "legn_IncreaseDecreaseInPledgedDepositsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "IncreaseDecreaseInPledgedDepositsNet", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in pledged deposits, net", "label": "Increase Decrease In Pledged Deposits Net", "documentation": "Increase decrease in pledged deposits net." } } }, "auth_ref": [] }, "legn_IncreaseDecreaseThroughDisposalLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "IncreaseDecreaseThroughDisposalLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal", "label": "Increase Decrease Through Disposal Liabilities Arising From Financing Activities", "documentation": "Increase (decrease) through disposal, liabilities arising from financing activities." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails", "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange realignment", "verboseLabel": "Foreign exchange movement", "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r121" ] }, "legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange realignment", "label": "Increase (Decrease) Through Effect Of Exchange Realignment In Foreign Exchange Rate", "documentation": "Increase (decrease) through effect of exchange realignment in foreign exchange rate." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfOptions", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of share options", "label": "Increase (decrease) through exercise of options, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of options." } } }, "auth_ref": [ "r300" ] }, "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes from financing cash flows", "label": "Increase (decrease) through financing cash flows, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]" } } }, "auth_ref": [ "r120" ] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/INTANGIBLEASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange realignment", "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r103" ] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange realignment", "label": "Increase (decrease) through net exchange differences, property, plant and equipment" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r58" ] }, "legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of vested restricted share units", "label": "Increase (Decrease) Through Reclassification Of Vested Restricted Stock Equity", "documentation": "Increase (decrease) through reclassification of vested restricted stock, equity." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-settled share-based compensation expense", "label": "Increase (decrease) through share-based payment transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r4" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersFromToInvestmentPropertyPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersFromToInvestmentPropertyPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfers", "label": "Increase (decrease) through transfers from (to) investment property, property, plant and equipment" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers from (to) investment property. [Refer: Property, plant and equipment; Investment property]" } } }, "auth_ref": [ "r310" ] }, "legn_IncreaseInLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "IncreaseInLeaseLiabilities", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Increase In Lease Liabilities", "documentation": "Increase in lease liabilities." } } }, "auth_ref": [] }, "legn_IncreaseOfLeaseLiabilitiesBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "IncreaseOfLeaseLiabilitiesBalance", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accretion of interest recognized during the year", "label": "Increase Of Lease Liabilities Balance", "documentation": "Increase of lease liabilities balance." } } }, "auth_ref": [] }, "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSAdditionalInformationDetails", "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash additions to lease liabilities", "verboseLabel": "Additions of lease liabilities", "label": "Increase through new leases, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r263", "r266" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://legendbiotech.com/role/INTANGIBLEASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "periodStartLabel": "Net carrying amount, beginning balance", "periodEndLabel": "Net carrying amount, ending balance", "label": "Intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r11", "r104" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwillMember", "presentation": [ "http://legendbiotech.com/role/INTANGIBLEASSETSDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsAmortizedonStraightLineBasisoverUsefulEconomicLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets other than goodwill [member]", "label": "Intangible assets other than goodwill [member]" } }, "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r105", "r255", "r272" ] }, "legn_IntangibleAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "IntangibleAssetsRollForward", "presentation": [ "http://legendbiotech.com/role/INTANGIBLEASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets [Roll Forward]", "label": "Intangible Assets [Roll Forward]", "documentation": "Intangible Assets" } } }, "auth_ref": [] }, "legn_InterestBearingBorrowingsFundedInterestsAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "InterestBearingBorrowingsFundedInterestsAccrued", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest accrued on funding advances", "label": "Interest Bearing Borrowings Funded Interests Accrued", "documentation": "Interest bearing borrowings funded interests accrued." } } }, "auth_ref": [] }, "ifrs-full_InterestExpenseOnBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpenseOnBorrowings", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/FINANCECOSTSDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/FINANCECOSTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration interest-bearing advanced funding", "label": "Interest expense on borrowings" } }, "en": { "role": { "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]" } } }, "auth_ref": [ "r301" ] }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpenseOnLeaseLiabilities", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/FINANCECOSTSDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/FINANCECOSTSDetails", "http://legendbiotech.com/role/LEASESSummaryofLeaseExpenseDetails", "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest on lease liabilities", "terseLabel": "Interest expense", "label": "Interest expense on lease liabilities" } }, "en": { "role": { "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r161" ] }, "legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "InterestOnLeasePaymentsClassifiedAsOperatingActivities", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest on lease payments", "label": "Interest On Lease Payments Classified As Operating Activities", "documentation": "Interest on lease payments classified as operating activities." } } }, "auth_ref": [] }, "ifrs-full_InterestPaidClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestPaidClassifiedAsOperatingActivities", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest paid classified as operating cash flows", "label": "Interest paid, classified as operating activities" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as operating activities." } } }, "auth_ref": [ "r118" ] }, "ifrs-full_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestReceivable", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSSummaryofPrepaymentsOtherReceivablesandOtherAssetsDetails": { "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSSummaryofPrepaymentsOtherReceivablesandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest receivable", "label": "Interest receivable" } }, "en": { "role": { "documentation": "The amount of interest recognised as a receivable." } } }, "auth_ref": [ "r301" ] }, "ifrs-full_Inventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Inventories", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 }, "http://legendbiotech.com/role/COLLABORATIONINVENTORIESSummaryofInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINVENTORIESSummaryofInventoriesDetails", "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration inventories", "totalLabel": "Total collaboration inventories", "label": "Current inventories" } }, "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r12", "r66", "r242" ] }, "legn_InventoryReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "InventoryReserve", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINVENTORIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory reserve", "label": "Inventory reserve", "documentation": "Inventory reserve" } } }, "auth_ref": [] }, "legn_IssuanceOfOrdinaryShareRelatingToPrivatePlacementForInstitutionalInvestor": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "IssuanceOfOrdinaryShareRelatingToPrivatePlacementForInstitutionalInvestor", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of ordinary shares for private placements, net of issuance cost", "label": "Issuance Of Ordinary Share Relating To Private Placement For Institutional Investor", "documentation": "Issuance of ordinary shares relating to private placement for institutional investor." } } }, "auth_ref": [] }, "legn_IssuanceOfOrdinarySharesForExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "IssuanceOfOrdinarySharesForExerciseOfWarrants", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of ordinary shares for exercise of warrants", "label": "Issuance Of Ordinary Shares For Exercise Of Warrants", "documentation": "Issuance Of Ordinary Shares For Exercise Of Warrants" } } }, "auth_ref": [] }, "legn_IssuanceOfOrdinarySharesForExerciseOfWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "IssuanceOfOrdinarySharesForExerciseOfWarrantsShares", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of ordinary shares for exercise of warrants (in shares)", "label": "Issuance Of Ordinary Shares For Exercise Of Warrants, Shares", "documentation": "Issuance Of Ordinary Shares For Exercise Of Warrants, Shares" } } }, "auth_ref": [] }, "legn_IssuanceOfOrdinarySharesForFollowOnPublicOfferingNetOfIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "IssuanceOfOrdinarySharesForFollowOnPublicOfferingNetOfIssuanceCost", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of ordinary shares for follow-on public offering, net of issuance cost", "label": "Issuance Of Ordinary Shares For Follow On Public Offering Net Of Issuance Cost", "documentation": "Issuance Of Ordinary Shares For Follow On Public Offering Net Of Issuance Cost" } } }, "auth_ref": [] }, "legn_IssuanceOfOrdinarySharesForFollowOnPublicOfferingNetOfIssuanceCostNumberOfSharesInIssue": { "xbrltype": "sharesItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "IssuanceOfOrdinarySharesForFollowOnPublicOfferingNetOfIssuanceCostNumberOfSharesInIssue", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of ordinary shares for follow-on public offering, net of issuance cost (in shares)", "label": "Issuance Of Ordinary Shares For Follow On Public Offering Net Of Issuance Cost Number Of Shares In Issue", "documentation": "Issuance of ordinary shares for follow-on-public offering, net of issuance cost, number of shares in issue." } } }, "auth_ref": [] }, "legn_IssuanceOfOrdinarySharesForRegisteredDirectOfferingNetOfIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "IssuanceOfOrdinarySharesForRegisteredDirectOfferingNetOfIssuance", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of ordinary shares for registered direct offering, net of issuance cost", "label": "Issuance Of Ordinary Shares For Registered Direct Offering Net Of Issuance", "documentation": "Issuance Of Ordinary Shares For Registered Direct Offering Net Of Issuance" } } }, "auth_ref": [] }, "legn_IssuanceOfOrdinarySharesForRegisteredDirectOfferingNetOfIssuanceCostNumberOfSharesInIssue": { "xbrltype": "sharesItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "IssuanceOfOrdinarySharesForRegisteredDirectOfferingNetOfIssuanceCostNumberOfSharesInIssue", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of ordinary shares for registered direct offering, net of issuance cost (in shares)", "label": "Issuance Of Ordinary Shares For Registered Direct Offering Net Of Issuance Cost Number Of Shares In Issue", "documentation": "Issuance Of Ordinary Shares For Registered Direct Offering Net Of Issuance Cost Number Of Shares In Issue" } } }, "auth_ref": [] }, "legn_IssuanceOfOrdinarySharesRelatingToPrivatePlacementForInstitutionalInvestorNumberOfSharesIssue": { "xbrltype": "sharesItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "IssuanceOfOrdinarySharesRelatingToPrivatePlacementForInstitutionalInvestorNumberOfSharesIssue", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of ordinary shares for private placements, net of issuance cost (in shares)", "label": "Issuance Of Ordinary Shares Relating To Private Placement For Institutional Investor Number Of Shares Issue", "documentation": "Issuance of ordinary shares relating to private placement for institutional investor number of shares issue." } } }, "auth_ref": [] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of ordinary shares", "label": "Issue of equity" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r4" ] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://legendbiotech.com/role/CORPORATEINFORMATIONInformationAboutSubsidiariesDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "netLabel": "Issued ordinary shares/paid-up capital", "verboseLabel": "363,822,069 (2022: 330,134,480) ordinary shares of $0.0001 each", "label": "Issued capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r245" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "verboseLabel": "Number of shares in issue", "label": "Issued capital [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r5" ] }, "legn_JanssenMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "JanssenMember", "presentation": [ "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONAdditionalInformationDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Janssen", "label": "Janssen [Member]", "documentation": "Janssen" } } }, "auth_ref": [] }, "legn_JiangsuGenScriptBiotechCo.Ltd.Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "JiangsuGenScriptBiotechCo.Ltd.Member", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofNatureofRelatedPartyRelationshipDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Jiangsu GenScript Biotech Co., Ltd.", "label": "Jiangsu GenScript Biotech Co., Ltd. [Member]", "documentation": "Jiangsu GenScript Biotech Co., Ltd." } } }, "auth_ref": [] }, "legn_JiangsuGenScriptProbioBiotechCo.Ltd.Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "JiangsuGenScriptProbioBiotechCo.Ltd.Member", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofNatureofRelatedPartyRelationshipDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Jiangsu GenScript Probio Biotech Co., Ltd.", "label": "Jiangsu GenScript Probio Biotech Co., Ltd. [Member]", "documentation": "Jiangsu Genscript Probio Biotech Co., Ltd." } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofCompensationofKeyManagementPersonnelDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofCompensationofKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Key management personnel compensation" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r74" ] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofCompensationofKeyManagementPersonnelDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofCompensationofKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-settled share-based compensation expense", "label": "Key management personnel compensation, share-based payment" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r73" ] }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofCompensationofKeyManagementPersonnelDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofCompensationofKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term employee benefits", "label": "Key management personnel compensation, short-term employee benefits" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r72" ] }, "ifrs-full_LandMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LandMember", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails", "http://legendbiotech.com/role/LEASESRightofuseAssetsDetails", "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails", "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Freehold land", "verboseLabel": "Leasehold land", "label": "Land [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing land held by the entity for use in operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r248" ] }, "legn_LaterThanFourYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "LaterThanFourYearsMember", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTransactionPriceAmountsAllocatedtoRemainingPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "After 4 years", "label": "Later Than Four Years [Member]", "documentation": "Later Than Four Years" } } }, "auth_ref": [] }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTransactionPriceAmountsAllocatedtoRemainingPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1 - 2 years", "label": "Later than one year and not later than two years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } } }, "auth_ref": [ "r167", "r168", "r179", "r279", "r282", "r301" ] }, "ifrs-full_LaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanOneYearMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Over 1 years", "label": "Later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year." } } }, "auth_ref": [ "r20" ] }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTransactionPriceAmountsAllocatedtoRemainingPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3 - 4 years", "label": "Later than three years and not later than four years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than four years." } } }, "auth_ref": [ "r167", "r168", "r179", "r279", "r282", "r301" ] }, "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTransactionPriceAmountsAllocatedtoRemainingPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2 - 3 Years", "label": "Later than two years and not later than three years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than two years and not later than three years." } } }, "auth_ref": [ "r167", "r168", "r179", "r279", "r282", "r301" ] }, "legn_LeaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "LeaseAbstract", "lang": { "en-us": { "role": { "terseLabel": "Lease [Abstract]", "label": "Lease [Abstract]", "documentation": "Lease abstract." } } }, "auth_ref": [] }, "legn_LeaseExpenseAmountRecognizedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "LeaseExpenseAmountRecognizedInProfitOrLoss", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total amount recognized in profit or loss", "label": "Lease Expense Amount Recognized In Profit Or Loss", "documentation": "Lease expense amount recognized in profit or loss." } } }, "auth_ref": [] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 5.0 }, "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Carrying amount at January 1", "periodEndLabel": "Carrying amount at December 31", "totalLabel": "Total", "terseLabel": "Lease liabilities", "label": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r159" ] }, "ifrs-full_LeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LeaseLiabilitiesAbstract", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Analyzed into:", "label": "Lease liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_LeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LeaseLiabilitiesMember", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXDisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryDetails", "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialLiabilitiesDetails", "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails", "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "verboseLabel": "Lease liability", "label": "Lease liabilities [member]" } }, "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r264", "r267" ] }, "legn_LeaseLiabilitiesRepaymentTerm": { "xbrltype": "durationItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "LeaseLiabilitiesRepaymentTerm", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities, repayment term", "label": "Lease Liabilities Repayment Term", "documentation": "Lease liabilities, repayment term." } } }, "auth_ref": [] }, "legn_LeaseTermsAndEstimatedUsefulLivesOfRightOfUseAssets": { "xbrltype": "durationItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "LeaseTermsAndEstimatedUsefulLivesOfRightOfUseAssets", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRightofuseAssetsDepreciatedonStraightlineBasisoverLeaseTermsandEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease terms and estimated useful lives of right-of-use assets", "label": "Lease Terms And Estimated Useful Lives Of Right Of Use Assets", "documentation": "Lease terms and estimated useful lives of right of use assets." } } }, "auth_ref": [] }, "ifrs-full_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvement", "label": "Leasehold improvements [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement." } } }, "auth_ref": [ "r308" ] }, "legn_LeaseholdLandMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "LeaseholdLandMember", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRightofuseAssetsDepreciatedonStraightlineBasisoverLeaseTermsandEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold land", "label": "Leasehold Land [Member]", "documentation": "Leasehold land." } } }, "auth_ref": [] }, "legn_LeasesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "LeasesLineItems", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leases [Line Items]", "label": "Leases [Line Items]", "documentation": "Leases line items." } } }, "auth_ref": [] }, "legn_LeasesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "LeasesRollForward", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leases [Roll Forward]", "label": "Leases [Roll Forward]", "documentation": "Leases" } } }, "auth_ref": [] }, "legn_LeasesTable": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "LeasesTable", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leases [Table]", "label": "Leases [Table]", "documentation": "Leases table." } } }, "auth_ref": [] }, "legn_LegendBiotechBelgiumBVMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "LegendBiotechBelgiumBVMember", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATIONInformationAboutSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legend Biotech Belgium B.V. (\u201cLegend Belgium\u201d)", "label": "Legend Biotech Belgium B V [Member]", "documentation": "Legend Biotech Belgium B.V." } } }, "auth_ref": [] }, "legn_LegendBiotechHKLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "LegendBiotechHKLimitedMember", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATIONInformationAboutSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legend Biotech HK Limited (\u201cLegend HK\u201d)", "label": "Legend Biotech H K Limited [Member]", "documentation": "Legend Biotech HK Limited." } } }, "auth_ref": [] }, "legn_LegendBiotechIrelandLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "LegendBiotechIrelandLimitedMember", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATIONInformationAboutSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legend Biotech Ireland Limited (\u201cLegend Ireland\u201d)", "label": "Legend Biotech Ireland Limited [Member]", "documentation": "Legend Biotech Ireland Limited." } } }, "auth_ref": [] }, "legn_LegendBiotechLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "LegendBiotechLimitedMember", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATIONInformationAboutSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legend Biotech Limited (\u201cLegend BVI\u201d)", "label": "Legend Biotech Limited [Member]", "documentation": "Legend Biotech Limited." } } }, "auth_ref": [] }, "legn_LegendBiotechMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "LegendBiotechMember", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legend Biotech", "label": "Legend Biotech [Member]", "documentation": "Legend Biotech" } } }, "auth_ref": [] }, "legn_LegendBiotechUSAIncorporatedMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "LegendBiotechUSAIncorporatedMember", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATIONInformationAboutSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legend Biotech USA Incorporated (\u201cLegend USA\u201d)", "label": "Legend Biotech U S A Incorporated [Member]", "documentation": "Legend Biotech USA Incorporated." } } }, "auth_ref": [] }, "legn_LesseeLeaseExpensesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "LesseeLeaseExpensesTextBlock", "presentation": [ "http://legendbiotech.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Lease Expense", "label": "Lessee Lease Expenses [Text Block]", "documentation": "Lessee lease expenses text block." } } }, "auth_ref": [] }, "legn_LesseeLeaseLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "LesseeLeaseLiabilitiesTextBlock", "presentation": [ "http://legendbiotech.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term", "label": "Lessee Lease Liabilities [Text Block]", "documentation": "Lessee lease liabilities text block." } } }, "auth_ref": [] }, "legn_LesseeLeasingArrangementsLeasesTerm": { "xbrltype": "durationItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "LesseeLeasingArrangementsLeasesTerm", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, lease terms", "label": "Lessee Leasing Arrangements Leases Term", "documentation": "Lessee leasing arrangements leases term." } } }, "auth_ref": [] }, "legn_LesseesIncrementalBorrowingRateAppliedToLeaseLiabilities": { "xbrltype": "percentItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "LesseesIncrementalBorrowingRateAppliedToLeaseLiabilities", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee's incremental borrowing rate applied to lease liabilities (in percent)", "label": "Lessees Incremental Borrowing Rate Applied To Lease Liabilities", "documentation": "Lessees incremental borrowing rate applied to lease liabilities." } } }, "auth_ref": [] }, "ifrs-full_Level1OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Level1OfFairValueHierarchyMember", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueMeasurementHierarchyofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted prices in active markets (Level 1)", "label": "Level 1 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } } }, "auth_ref": [ "r64", "r146" ] }, "ifrs-full_Level2OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Level2OfFairValueHierarchyMember", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueMeasurementHierarchyofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant observable inputs (Level 2)", "label": "Level 2 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } } }, "auth_ref": [ "r146" ] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueMeasurementHierarchyofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant unobservable inputs (Level 3)", "label": "Level 3 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r146" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueMeasurementHierarchyofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Levels of fair value hierarchy [axis]", "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r64", "r146" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMonitoringCapitalUsingGearingRatioDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "terseLabel": "Total liabilities", "label": "Liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r17", "r145", "r146", "r147", "r226", "r230" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]" } } }, "auth_ref": [ "r265" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesAxis", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueMeasurementHierarchyofFinancialInstrumentsDetails", "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueValuationofWarrantLiabilityDetails", "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialLiabilitiesDetails", "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails", "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities arising from financing activities [axis]", "label": "Liabilities arising from financing activities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r265" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesMember", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueMeasurementHierarchyofFinancialInstrumentsDetails", "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueValuationofWarrantLiabilityDetails", "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialLiabilitiesDetails", "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails", "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofChangesinLiabilitiesArisingfromFinancingActivitiesDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities arising from financing activities [member]", "label": "Liabilities arising from financing activities [member]" } }, "en": { "role": { "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r265" ] }, "legn_LiabilitiesFromFinancingActivitiesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "LiabilitiesFromFinancingActivitiesRollForward", "presentation": [ "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSSummaryofChangesinLiabilitiesArisingfromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities from Financing Activities [Roll Forward]", "label": "Liabilities from Financing Activities [Roll Forward]", "documentation": "Liabilities from Financing Activities" } } }, "auth_ref": [] }, "ifrs-full_LiquidityRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiquidityRiskMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidity Risk", "label": "Liquidity risk [member]" } }, "en": { "role": { "documentation": "This member stands for the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r174", "r175", "r176", "r275" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ifrs-full_LongtermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LongtermBorrowings", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration interest-bearing advanced funding", "label": "Non-current portion of non-current borrowings" } }, "en": { "role": { "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r303" ] }, "ifrs-full_MachineryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MachineryMember", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails", "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyPlantandEquipmentDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRightofuseAssetsDepreciatedonStraightlineBasisoverLeaseTermsandEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Machinery and equipment", "terseLabel": "Machinery and equipment", "label": "Machinery [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing long-lived, depreciable machinery used in operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r249" ] }, "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MajorComponentsOfTaxExpenseIncomeAbstract", "lang": { "en-us": { "role": { "label": "Major components of tax expense (income) [abstract]" } } }, "auth_ref": [] }, "legn_MajorComponentsOfTaxExpenseIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "MajorComponentsOfTaxExpenseIncomeLineItems", "presentation": [ "http://legendbiotech.com/role/INCOMETAXAdditionalInformationDetails", "http://legendbiotech.com/role/INCOMETAXSummaryofTaxChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Major Components Of Tax Expense Income [Line Items]", "label": "Major Components Of Tax Expense Income [Line Items]", "documentation": "Major components of tax expense income." } } }, "auth_ref": [] }, "legn_MajorComponentsOfTaxExpenseIncomeTable": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "MajorComponentsOfTaxExpenseIncomeTable", "presentation": [ "http://legendbiotech.com/role/INCOMETAXAdditionalInformationDetails", "http://legendbiotech.com/role/INCOMETAXSummaryofTaxChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Major Components Of Tax Expense Income [Table]", "label": "Major Components Of Tax Expense Income [Table]", "documentation": "Major components of tax expense income." } } }, "auth_ref": [] }, "ifrs-full_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MajorCustomersAxis", "presentation": [ "http://legendbiotech.com/role/TRADERECEIVABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Major customers [axis]", "label": "Major customers [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r235" ] }, "ifrs-full_MajorCustomersMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MajorCustomersMember", "presentation": [ "http://legendbiotech.com/role/TRADERECEIVABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customers [member]", "label": "Customers [member]" } }, "en": { "role": { "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used." } } }, "auth_ref": [ "r235" ] }, "legn_MarketingAuthorizationSubmissionCARTITUDE5ClinicalTrialAndDrugApprovalApplicationMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "MarketingAuthorizationSubmissionCARTITUDE5ClinicalTrialAndDrugApprovalApplicationMember", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CARTITUDE-5 Clinical Trial", "label": "Marketing Authorization Submission, CARTITUDE-5 Clinical Trial, And Drug Approval Application [Member]", "documentation": "Marketing Authorization Submission, CARTITUDE-5 Clinical Trial, And Drug Approval Application" } } }, "auth_ref": [] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTransactionPriceAmountsAllocatedtoRemainingPerformanceObligationsDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity [axis]", "verboseLabel": "Less than 1 years", "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r21", "r156", "r167", "r168", "r171", "r172", "r173", "r179", "r199", "r211", "r252", "r279" ] }, "legn_MaximumAdditionalTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "MaximumAdditionalTransactionPrice", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction price, total aggregate reimbursable development costs (up to)", "label": "Maximum Additional Transaction Price", "documentation": "Maximum Additional Transaction Price" } } }, "auth_ref": [] }, "ifrs-full_MeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MeasurementAxis", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement [axis]", "label": "Measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r108", "r112", "r145" ] }, "legn_MilestonePaymentNotEligibleToReceiveBasedOnSubsequentChangeInDevelopmentPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "MilestonePaymentNotEligibleToReceiveBasedOnSubsequentChangeInDevelopmentPlan", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment not eligible to receive based on subsequent change in development plan", "label": "Milestone Payment Not Eligible To Receive Based On Subsequent Change In Development Plan", "documentation": "Milestone payment not eligible to receive based on subsequent change in development plan." } } }, "auth_ref": [] }, "legn_NDASubmissionMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "NDASubmissionMember", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Submission of NDA", "label": "NDA Submission [Member]", "documentation": "NDA Submission" } } }, "auth_ref": [] }, "stpr_NJ": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "NJ", "presentation": [ "http://legendbiotech.com/role/INCOMETAXAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Jersey", "label": "NEW JERSEY" } } }, "auth_ref": [] }, "ifrs-full_NameOfSubsidiary": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NameOfSubsidiary", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATIONInformationAboutSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company", "label": "Name of subsidiary" } }, "en": { "role": { "documentation": "The name of a subsidiary. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r84", "r87", "r132", "r133" ] }, "legn_NanjingGenScriptBiotechCo.Ltd.Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "NanjingGenScriptBiotechCo.Ltd.Member", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSAdditionalInformationDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofNatureofRelatedPartyRelationshipDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nanjing GenScript Biotech Co., Ltd.", "label": "Nanjing GenScript Biotech Co., Ltd. [Member]", "documentation": "Nanjing GenScript Biotech Co., Ltd. (formerly named as Nanjing Jinsirui Biotechnology Co., Ltd.)" } } }, "auth_ref": [] }, "legn_NanjingLegendBiotechnologyCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "NanjingLegendBiotechnologyCoLtdMember", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATIONInformationAboutSubsidiariesDetails", "http://legendbiotech.com/role/INCOMETAXAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nanjing Legend Biotechnology Co., Ltd. (\u201cLegend Nanjing\u201d)", "verboseLabel": "Legend Nanjing", "label": "Nanjing Legend Biotechnology Co Ltd [Member]", "documentation": "Nanjing Legend Biotechnology Co Ltd." } } }, "auth_ref": [] }, "legn_NanjingProbioBiotechCo.Ltd.Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "NanjingProbioBiotechCo.Ltd.Member", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofNatureofRelatedPartyRelationshipDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nanjing Probio Biotech Co., Ltd.", "label": "Nanjing Probio Biotech Co., Ltd. [Member]", "documentation": "Nanjing Probio Biotech Co Ltd." } } }, "auth_ref": [] }, "legn_NonCashAdditionsToPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "NonCashAdditionsToPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash additions to property, plant and equipment", "label": "Non Cash Additions To Property Plant And Equipment", "documentation": "Non-cash additions to property, plant and equipment." } } }, "auth_ref": [] }, "legn_NonCashAdditionsToRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "NonCashAdditionsToRightOfUseAssets", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/NOTESTOTHECONSOLIDATEDSTATEMENTOFCASHFLOWSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash additions to right-of-use assets", "label": "Non Cash Additions To Right Of Use Assets", "documentation": "Non-cash additions to right-of-use assets." } } }, "auth_ref": [] }, "legn_NonTradingIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "NonTradingIncomeTaxRate", "presentation": [ "http://legendbiotech.com/role/INCOMETAXAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-trading income tax rate", "label": "Non Trading Income Tax Rate", "documentation": "Non trading income tax rate." } } }, "auth_ref": [] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current assets", "label": "Non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r22", "r136", "r268" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "NON-CURRENT ASSETS", "label": "Non-current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofNoncurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts" } }, "en": { "role": { "documentation": "The amount of non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets and rights arising under insurance contracts. [Refer: Deferred tax assets; Financial instruments, class [member]; Non-current assets]" } } }, "auth_ref": [ "r233" ] }, "ifrs-full_NoncurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentContractLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofDeferredRevenueDetails": { "parentTag": "ifrs-full_ContractLiabilities", "weight": 1.0, "order": 1.0 }, "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "verboseLabel": "Contract liabilities (Non Current)", "label": "Non-current contract liabilities" } }, "en": { "role": { "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r150" ] }, "ifrs-full_NoncurrentGovernmentGrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentGovernmentGrants", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/GOVERNMENTGRANTSDetails": { "parentTag": "ifrs-full_GovernmentGrants", "weight": 1.0, "order": 2.0 }, "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://legendbiotech.com/role/GOVERNMENTGRANTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government grants", "verboseLabel": "Non-current", "label": "Non-current government grants" } }, "en": { "role": { "documentation": "The amount of non-current government grants recognised on the statement of financial position as deferred income. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r303" ] }, "ifrs-full_NoncurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails": { "parentTag": "ifrs-full_LeaseLiabilities", "weight": 1.0, "order": 1.0 }, "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities long term", "verboseLabel": "Non-current portion", "label": "Non-current lease liabilities" } }, "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r159" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current liabilities", "label": "Non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r23", "r138", "r268" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "NON-CURRENT LIABILITIES", "label": "Non-current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentPortionOfNoncurrentLoansReceived", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans from a collaborator", "label": "Non-current portion of non-current loans received" } }, "en": { "role": { "documentation": "The non-current portion of non-current loans received. [Refer: Loans received]" } } }, "auth_ref": [ "r301" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTransactionPriceAmountsAllocatedtoRemainingPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Within 1 year", "verboseLabel": "Less than 1 years", "label": "Not later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r19", "r167", "r168", "r179", "r279", "r282" ] }, "legn_NovartisMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "NovartisMember", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSAdditionalInformationDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceAllocationtoPerformanceObligationsDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceCompositionDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTransactionPriceAmountsAllocatedtoRemainingPerformanceObligationsDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Novartis", "label": "Novartis [Member]", "documentation": "Novartis" } } }, "auth_ref": [] }, "legn_NumberOfBorrowingBatches": { "xbrltype": "integerItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "NumberOfBorrowingBatches", "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of batches of funding advances", "label": "Number Of Borrowing Batches", "documentation": "Number Of Borrowing Batches" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSSummaryofMovementinNumberofRSUOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted during the year (in shares)", "label": "Number of other equity instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r194", "r326" ] }, "legn_NumberOfMilestonePayments": { "xbrltype": "integerItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "NumberOfMilestonePayments", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of milestone payments", "label": "Number Of Milestone Payments", "documentation": "Number of milestone payments." } } }, "auth_ref": [] }, "legn_NumberOfOptionsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "NumberOfOptionsRollForward", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSSummaryofMovementinNumberofRSUOutstandingDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofShareOptionsOutstandingUndertheSchemeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of options", "verboseLabel": "Number of RSU", "label": "Number of Options [Roll Forward]", "documentation": "Number of Options" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSSummaryofMovementinNumberofRSUOutstandingDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested during the year (in shares)", "label": "Number of other equity instruments exercised or vested in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } } }, "auth_ref": [ "r326" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSSummaryofMovementinNumberofRSUOutstandingDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited during the year (in shares)", "label": "Number of other equity instruments forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r326" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSAdditionalInformationDetails", "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSSummaryofMovementinNumberofRSUOutstandingDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at January 1 (in shares)", "periodEndLabel": "Outstanding at December 31 (in shares)", "verboseLabel": "Number of RSU, outstanding (in shares)", "label": "Number of other equity instruments outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r326" ] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMEAdditionalInformationDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofExercisePricesandExercisePeriodsofShareOptionsOutstandingDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofShareOptionsOutstandingUndertheSchemeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of options (in shares)", "periodStartLabel": "At January 1 (in shares)", "periodEndLabel": "At December 31 (in shares)", "label": "Number of share options outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r182", "r186", "r190" ] }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofShareOptionsOutstandingUndertheSchemeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at December 31 (in shares)", "label": "Number of share options exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r187" ] }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofShareOptionsOutstandingUndertheSchemeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Exercised during the year (in shares)", "label": "Number of share options exercised in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } } }, "auth_ref": [ "r185" ] }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofShareOptionsOutstandingUndertheSchemeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited during the year (in shares)", "label": "Number of share options forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r184" ] }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofShareOptionsOutstandingUndertheSchemeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted during the year (in shares)", "label": "Number of share options granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } } }, "auth_ref": [ "r183" ] }, "ifrs-full_NumberOfSharesAuthorised": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesAuthorised", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized (in shares)", "label": "Number of shares authorised" } }, "en": { "role": { "documentation": "The number of shares authorised." } } }, "auth_ref": [ "r26" ] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSAdditionalInformationDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMEAdditionalInformationDetails", "http://legendbiotech.com/role/WARRANTLIABILITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued (in shares)", "verboseLabel": "Ordinary shares, purchased (in shares)", "label": "Number of shares issued" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r300" ] }, "ifrs-full_NumberOfSharesIssuedAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesIssuedAbstract", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued and fully paid:", "label": "Number of shares issued [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesIssuedAndFullyPaid": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesIssuedAndFullyPaid", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued and fully paid (in shares)", "label": "Number of shares issued and fully paid" } }, "en": { "role": { "documentation": "The number of shares issued by the entity, for which full payment has been received." } } }, "auth_ref": [ "r27" ] }, "ifrs-full_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OfficeEquipmentMember", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRightofuseAssetsDepreciatedonStraightlineBasisoverLeaseTermsandEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer and office equipment", "label": "Office equipment [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r250" ] }, "legn_OneCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "OneCustomerMember", "presentation": [ "http://legendbiotech.com/role/TRADERECEIVABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "One Customer", "label": "One Customer [Member]", "documentation": "One Customer" } } }, "auth_ref": [] }, "legn_OngoingLeasePaymentsUnderTheLandLease": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "OngoingLeasePaymentsUnderTheLandLease", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ongoing lease payments", "label": "Ongoing Lease Payments Under The Land Lease", "documentation": "Ongoing lease payments under the land lease." } } }, "auth_ref": [] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMEAdditionalInformationDetails", "http://legendbiotech.com/role/WARRANTLIABILITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary Shares", "verboseLabel": "Ordinary Shares", "label": "Ordinary shares [member]" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } } }, "auth_ref": [ "r90", "r306" ] }, "legn_OtherCollaborationReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "OtherCollaborationReceivables", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSSummaryofPrepaymentsOtherReceivablesandOtherAssetsDetails": { "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSSummaryofPrepaymentsOtherReceivablesandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Collaboration Receivables", "label": "Other Collaboration Receivables", "documentation": "Other Collaboration Receivables" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "OTHER COMPREHENSIVE INCOME FOR THE YEAR, NET OF TAX", "label": "Other comprehensive income" } }, "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } } }, "auth_ref": [ "r3", "r33", "r40", "r141" ] }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeAbstract", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "verboseLabel": "Other comprehensive loss:", "label": "Other comprehensive income [abstract]" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 }, "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange differences on translation of foreign operations", "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r24", "r40" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Net other comprehensive income that may be reclassified to profit or loss in subsequent periods", "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r246", "r247" ] }, "ifrs-full_OtherEmployeeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherEmployeeExpense", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/LOSSBEFORETAXDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other employee benefits", "label": "Other employee expense" } }, "en": { "role": { "documentation": "The amount of employee expenses that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r311" ] }, "ifrs-full_OtherExpenseByNature": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherExpenseByNature", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "negatedLabel": "Other expenses", "label": "Other expenses, by nature" } }, "en": { "role": { "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]" } } }, "auth_ref": [ "r42", "r239" ] }, "legn_OtherFinanceGains": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "OtherFinanceGains", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSOtherIncomeandGainsDetails": { "parentTag": "ifrs-full_OtherGainsLosses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSOtherIncomeandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Finance Gains", "documentation": "Other finance gains." } } }, "auth_ref": [] }, "ifrs-full_OtherFinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherFinanceIncome", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSOtherIncomeandGainsDetails": { "parentTag": "ifrs-full_OtherIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSOtherIncomeandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other finance income" } }, "en": { "role": { "documentation": "The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]" } } }, "auth_ref": [ "r301" ] }, "ifrs-full_OtherGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherGainsLosses", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSOtherIncomeandGainsDetails": { "parentTag": "legn_OtherIncomeAndGains", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSOtherIncomeandGainsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total gains", "label": "Other gains (losses)" } }, "en": { "role": { "documentation": "The gains (losses) that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r298", "r299" ] }, "ifrs-full_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSOtherIncomeandGainsDetails": { "parentTag": "legn_OtherIncomeAndGains", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSOtherIncomeandGainsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total income", "label": "Other income" } }, "en": { "role": { "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r81", "r239", "r240" ] }, "legn_OtherIncomeAndGains": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "OtherIncomeAndGains", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 3.0 }, "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSOtherIncomeandGainsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSOtherIncomeandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income and gains", "totalLabel": "Total other income and gains", "label": "Other Income And Gains", "documentation": "Other income and gains." } } }, "auth_ref": [] }, "legn_OtherIncomeAndGainsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "OtherIncomeAndGainsAbstract", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSOtherIncomeandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income and gains", "label": "Other Income And Gains [Abstract]", "documentation": "Other income and gains." } } }, "auth_ref": [] }, "ifrs-full_OtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/OTHERNONCURRENTASSETSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/OTHERNONCURRENTASSETSDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Other non-current assets" } }, "en": { "role": { "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]" } } }, "auth_ref": [ "r303" ] }, "ifrs-full_OtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherNoncurrentLiabilities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other non-current liabilities" } }, "en": { "role": { "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]" } } }, "auth_ref": [ "r303" ] }, "ifrs-full_OtherNoncurrentNonfinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherNoncurrentNonfinancialAssets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other non-current non-financial assets" } }, "en": { "role": { "documentation": "The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]" } } }, "auth_ref": [ "r303" ] }, "ifrs-full_OtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherPayables", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSSummaryofOtherPayablesandAccrualsDetails": { "parentTag": "legn_OtherPayablesAndAccrualsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSSummaryofOtherPayablesandAccrualsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other payables", "label": "Other payables" } }, "en": { "role": { "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r303" ] }, "legn_OtherPayablesAndAccrualsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "OtherPayablesAndAccrualsCurrent", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 }, "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 2.0 }, "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSSummaryofOtherPayablesandAccrualsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSSummaryofOtherPayablesandAccrualsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other payables and accruals", "totalLabel": "Other payables and accruals", "verboseLabel": "Other payables", "label": "Other Payables And Accruals Current", "documentation": "Other payables and accruals, current." } } }, "auth_ref": [] }, "legn_OtherPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "OtherPayablesMember", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other payables", "label": "Other Payables [Member]", "documentation": "Other payables." } } }, "auth_ref": [] }, "ifrs-full_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherReceivables", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSSummaryofPrepaymentsOtherReceivablesandOtherAssetsDetails": { "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSSummaryofPrepaymentsOtherReceivablesandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other receivables" } }, "en": { "role": { "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r243" ] }, "legn_OtherReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "OtherReceivablesMember", "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSAdditionalInformationDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other Receivables [Member]", "documentation": "Other receivables." } } }, "auth_ref": [] }, "ifrs-full_OtherReserves": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherReserves", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Reserves", "label": "Other reserves" } }, "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r245" ] }, "ifrs-full_OtherRevenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherRevenue", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofAnalysisofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other revenue", "verboseLabel": "Other revenue", "label": "Other revenue" } }, "en": { "role": { "documentation": "The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]" } } }, "auth_ref": [ "r301" ] }, "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Others", "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r46" ] }, "legn_OtherTaxPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "OtherTaxPayables", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSSummaryofOtherPayablesandAccrualsDetails": { "parentTag": "legn_OtherPayablesAndAccrualsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSSummaryofOtherPayablesandAccrualsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other tax payables", "label": "Other Tax Payables", "documentation": "Other tax payables," } } }, "auth_ref": [] }, "ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails": { "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Others", "label": "Other tax rate effects for reconciliation between accounting profit and tax expense (income)" } }, "en": { "role": { "documentation": "Tax rate effects, in aggregate, on the reconciliation between the average effective tax rate and the applicable tax rate that the entity does not separately disclose in the reconciliation. [Refer: Average effective tax rate; Applicable tax rate]" } } }, "auth_ref": [ "r47" ] }, "legn_OtherThanUSMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "OtherThanUSMember", "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofTaxChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Elsewhere", "label": "Other Than U S [Member]", "documentation": "Other than U.S." } } }, "auth_ref": [] }, "legn_OutstandingForeignCurrencyForwardExchangeContracts": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "OutstandingForeignCurrencyForwardExchangeContracts", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding foreign currency forward exchange contracts", "label": "Outstanding Foreign Currency Forward Exchange Contracts", "documentation": "Outstanding foreign currency forward exchange contracts." } } }, "auth_ref": [] }, "legn_PaidInCapitalAndReserveFunds": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PaidInCapitalAndReserveFunds", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/RESERVESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Paid in capital and reserve funds", "label": "Paid In Capital And Reserve Funds", "documentation": "Paid in capital and reserve funds." } } }, "auth_ref": [] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails", "http://legendbiotech.com/role/WARRANTLIABILITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Price per share (in dollars per share)", "netLabel": "Authorized, price per share (in dollars per share)", "verboseLabel": "Issued and fully paid, price per share (in dollars per share)", "label": "Par value per share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r28" ] }, "legn_PayableForCollaborationAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PayableForCollaborationAssets", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSSummaryofOtherPayablesandAccrualsDetails": { "parentTag": "legn_OtherPayablesAndAccrualsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSSummaryofOtherPayablesandAccrualsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payable for Collaboration Assets", "label": "Payable For Collaboration Assets", "documentation": "Payable For Collaboration Assets" } } }, "auth_ref": [] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Principal portion of lease payments", "label": "Payments of lease liabilities, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r261" ] }, "legn_PercentageOfForeignCurrencyForwardExchangeContract": { "xbrltype": "percentItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PercentageOfForeignCurrencyForwardExchangeContract", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of foreign currency forward exchange contract", "label": "Percentage Of Foreign Currency Forward Exchange Contract", "documentation": "Percentage of foreign currency forward exchange contract." } } }, "auth_ref": [] }, "legn_PercentageOfIncreaseDecreaseInRateOfForeignCurrency": { "xbrltype": "percentItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PercentageOfIncreaseDecreaseInRateOfForeignCurrency", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofSensitivitytoReasonablyPossibleChangeinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase/ (decrease) in the rate of foreign currency", "label": "Percentage Of Increase Decrease In Rate Of Foreign Currency", "documentation": "Percentage of increase (decrease) in the rate of foreign currency." } } }, "auth_ref": [] }, "legn_PercentageOfNumberOfNumberSharesIssued": { "xbrltype": "percentItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PercentageOfNumberOfNumberSharesIssued", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of number of shares issued", "label": "Percentage Of Number Of Number Shares Issued", "documentation": "Percentage of number of number shares issued." } } }, "auth_ref": [] }, "legn_PercentageOfOutstandingShareOptions": { "xbrltype": "percentItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PercentageOfOutstandingShareOptions", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMEAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of options outstanding", "label": "Percentage Of Outstanding Share Options", "documentation": "Percentage of outstanding share options." } } }, "auth_ref": [] }, "legn_PerformanceObligation1FirstTwelveMonthsOfExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PerformanceObligation1FirstTwelveMonthsOfExpensesMember", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PO1: First Twelve Months of Expenses", "label": "Performance Obligation 1, First Twelve Months Of Expenses [Member]", "documentation": "Performance Obligation 1, First Twelve Months Of Expenses" } } }, "auth_ref": [] }, "legn_PerformanceObligation1Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PerformanceObligation1Member", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSAdditionalInformationDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceAllocationtoPerformanceObligationsDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceCompositionDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTransactionPriceAmountsAllocatedtoRemainingPerformanceObligationsDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PO1: Licensing of intellectual property and completion of Legend Phase 1 trial", "label": "Performance Obligation 1 [Member]", "documentation": "Performance Obligation 1" } } }, "auth_ref": [] }, "legn_PerformanceObligation1UpFrontPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PerformanceObligation1UpFrontPaymentMember", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PO1: Up-Front Payment", "label": "Performance Obligation 1, Up-Front Payment [Member]", "documentation": "Performance Obligation 1, Up-Front Payment" } } }, "auth_ref": [] }, "legn_PerformanceObligation2Member": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PerformanceObligation2Member", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSAdditionalInformationDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceAllocationtoPerformanceObligationsDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceCompositionDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PO2: Supply of materials", "label": "Performance Obligation 2 [Member]", "documentation": "Performance Obligation 2" } } }, "auth_ref": [] }, "legn_PerformanceObligationSatisfactionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PerformanceObligationSatisfactionPeriod", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance obligation satisfaction period", "label": "Performance Obligation Satisfaction Period", "documentation": "Performance Obligation Satisfaction Period" } } }, "auth_ref": [] }, "ifrs-full_PerformanceObligationsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PerformanceObligationsAxis", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSAdditionalInformationDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceAllocationtoPerformanceObligationsDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceCompositionDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTransactionPriceAmountsAllocatedtoRemainingPerformanceObligationsDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance obligations [axis]", "label": "Performance obligations [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r154" ] }, "ifrs-full_PerformanceObligationsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PerformanceObligationsMember", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSAdditionalInformationDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceAllocationtoPerformanceObligationsDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceCompositionDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTransactionPriceAmountsAllocatedtoRemainingPerformanceObligationsDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance obligations [member]", "label": "Performance obligations [member]" } }, "en": { "role": { "documentation": "This member stands for all performance obligations. A performance obligation is a promise in a contract with a customer to transfer to the customer either: (a) a good or service (or a bundle of goods or services) that is distinct; or (b) a series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer. This member also represents the standard value for the 'Performance obligations' axis if no other member is used." } } }, "auth_ref": [ "r154" ] }, "legn_PeriodOfShareOptionSchemeRemainInForce": { "xbrltype": "durationItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PeriodOfShareOptionSchemeRemainInForce", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMEAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period that share option scheme remains in force", "label": "Period Of Share Option Scheme Remain In Force", "documentation": "Period of share option scheme remain in force." } } }, "auth_ref": [] }, "legn_PlaceAndDateOfIncorporationOfBusinessOfSubsidiary": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PlaceAndDateOfIncorporationOfBusinessOfSubsidiary", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATIONInformationAboutSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Place and date of incorporation", "label": "Place And Date Of Incorporation Of Business Of Subsidiary", "documentation": "Place and date of incorporation of business of subsidiary." } } }, "auth_ref": [] }, "legn_PledgedDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PledgedDeposits", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "verboseLabel": "Pledged deposits", "label": "Pledged Deposits", "documentation": "Pledged deposits." } } }, "auth_ref": [] }, "legn_PledgedDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PledgedDepositsMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pledged deposits", "label": "Pledged Deposits [Member]", "documentation": "Pledged deposits." } } }, "auth_ref": [] }, "legn_PledgedShortTermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PledgedShortTermDeposits", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Pledged deposits", "label": "Pledged Short Term Deposits", "documentation": "Pledged short-term deposits." } } }, "auth_ref": [] }, "legn_PrepaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PrepaymentMember", "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSAdditionalInformationDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayment", "label": "Prepayment [Member]", "documentation": "Prepayment." } } }, "auth_ref": [] }, "legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PrepaymentToCollaboratorForCollaborationRightOfUseAssets", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepayment to collaborator for collaboration assets", "label": "Prepayment To Collaborator For Collaboration Right Of Use Assets", "documentation": "Prepayment To Collaborator For Collaboration Right Of Use Assets" } } }, "auth_ref": [] }, "ifrs-full_Prepayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Prepayments", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/OTHERNONCURRENTASSETSDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0, "order": 1.0 }, "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSSummaryofPrepaymentsOtherReceivablesandOtherAssetsDetails": { "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://legendbiotech.com/role/OTHERNONCURRENTASSETSDetails", "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSSummaryofPrepaymentsOtherReceivablesandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "verboseLabel": "Prepayments", "label": "Prepayments" } }, "en": { "role": { "documentation": "Receivables that represent amounts paid for goods and services before they have been delivered." } } }, "auth_ref": [ "r243" ] }, "legn_PrepaymentsOtherReceivablesAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PrepaymentsOtherReceivablesAndOtherAssets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSSummaryofPrepaymentsOtherReceivablesandOtherAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSSummaryofPrepaymentsOtherReceivablesandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Prepayments Other Receivables And Other Assets", "documentation": "Prepayments, other receivables and other assets." } } }, "auth_ref": [] }, "legn_PrepaymentsOtherReceivablesAndOtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PrepaymentsOtherReceivablesAndOtherAssetsMember", "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSSummaryofPrepaymentsOtherReceivablesandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayments, Other Receivable and Other Assets", "label": "Prepayments Other Receivables And Other Assets [Member]", "documentation": "Prepayments other receivables and other assets.," } } }, "auth_ref": [] }, "legn_PrivatePlacementForInstitutionalInvestorMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PrivatePlacementForInstitutionalInvestorMember", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement for Institutional Investor", "label": "Private Placement For Institutional Investor [Member]", "documentation": "Private Placement For Institutional Investor" } } }, "auth_ref": [] }, "legn_PrivatePlacementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PrivatePlacementTransactionsMember", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement Transactions", "label": "Private Placement Transactions [Member]", "documentation": "Private Placement Transactions" } } }, "auth_ref": [] }, "ifrs-full_ProbabilityOfDefaultAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProbabilityOfDefaultAxis", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofSensitivitytoReasonablyPossibleChangeinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Probability of default [axis]", "label": "Probability of default [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r276", "r281" ] }, "ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from disposal of property, plant and equipment", "label": "Proceeds from disposals of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets" } }, "en": { "role": { "documentation": "The cash inflow from the disposal of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]" } } }, "auth_ref": [ "r317" ] }, "ifrs-full_ProceedsFromExerciseOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromExerciseOfOptions", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of share options", "label": "Proceeds from exercise of options" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of options." } } }, "auth_ref": [ "r318" ] }, "legn_ProceedsFromExerciseOfWarrantByWarrantHolderNetOfIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ProceedsFromExerciseOfWarrantByWarrantHolderNetOfIssuanceCost", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from exercise of warrant by warrant holder, net of issuance cost", "label": "Proceeds From Exercise Of Warrant By Warrant Holder, Net Of Issuance Cost", "documentation": "Proceeds From Exercise Of Warrant By Warrant Holder, Net Of Issuance Cost" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/WARRANTLIABILITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of warrants", "label": "Proceeds from exercise of warrants" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } } }, "auth_ref": [ "r318" ] }, "legn_ProceedsFromIssuanceOfOrdinarySharesAndWarrantRelatingToPrivatePlacementForAnInstitutionalInvestor": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ProceedsFromIssuanceOfOrdinarySharesAndWarrantRelatingToPrivatePlacementForAnInstitutionalInvestor", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of ordinary shares and warrant relating to private placement for an institutional investor", "label": "Proceeds From Issuance Of Ordinary Shares And Warrant Relating To Private Placement For An Institutional Investor", "documentation": "Proceeds from issuance of ordinary shares and warrant relating to private placement for an institutional investor." } } }, "auth_ref": [] }, "legn_ProceedsFromIssuanceOfOrdinarySharesForFollowOnPublicOfferingNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ProceedsFromIssuanceOfOrdinarySharesForFollowOnPublicOfferingNetOfIssuanceCosts", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of ordinary shares for follow on public offering, net of issuance costs", "label": "Proceeds From Issuance Of Ordinary Shares For Follow On Public Offering, Net Of Issuance Costs", "documentation": "Proceeds from issuance of ordinary shares for follow on public offering, net of issuance costs." } } }, "auth_ref": [] }, "legn_ProceedsFromIssuanceOfOrdinarySharesForInstitutionalInvestorsNetOfIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ProceedsFromIssuanceOfOrdinarySharesForInstitutionalInvestorsNetOfIssuanceCost", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of ordinary shares for institutional investors, net of issuance cost", "label": "Proceeds From Issuance Of Ordinary Shares For Institutional Investors, Net Of Issuance Cost", "documentation": "Proceeds From Issuance Of Ordinary Shares For Institutional Investors, Net Of Issuance Cost" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromIssueOfOrdinaryShares", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issue of ordinary shares", "label": "Proceeds from issue of ordinary shares" } }, "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r318" ] }, "legn_ProceedsFromMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ProceedsFromMilestonePayments", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payments recognized as revenue", "label": "Proceeds from Milestone Payments", "documentation": "Milestone payments." } } }, "auth_ref": [] }, "legn_ProceedsFromUpfrontFeesRecognizedAsRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ProceedsFromUpfrontFeesRecognizedAsRevenue", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from upfront fees recognized as revenue", "label": "Proceeds From Upfront Fees Recognized As Revenue", "documentation": "Proceeds From Upfront Fees Recognized As Revenue" } } }, "auth_ref": [] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "LOSS FOR THE YEAR", "terseLabel": "Loss for the year", "label": "Profit (loss)" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r2", "r32", "r115", "r129", "r131", "r226", "r228", "r268", "r273" ] }, "ifrs-full_ProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossAbstract", "lang": { "en-us": { "role": { "label": "Profit (loss) [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossAttributableToAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossAttributableToAbstract", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Attributable to:", "label": "Profit (loss), attributable to [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME", "http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTSummaryofCalculationsofBasicandDilutedLossperShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Ordinary equity holders of the parent", "terseLabel": "Loss attributable to ordinary equity holders of the parent, used in the basic earnings per share calculation", "label": "Profit (loss), attributable to owners of parent" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r35" ] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME", "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "LOSS BEFORE TAX", "terseLabel": "Loss before tax", "label": "Profit (loss) before tax" } }, "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r196", "r239", "r240", "r284", "r285" ] }, "legn_ProfitLossBeforeTaxArrivedAfterChargingAndCreditingMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ProfitLossBeforeTaxArrivedAfterChargingAndCreditingMember", "presentation": [ "http://legendbiotech.com/role/LOSSBEFORETAXDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Profit Loss Before Tax Arrived After Charging And Crediting", "label": "Profit Loss Before Tax Arrived After Charging And Crediting [Member]", "documentation": "Profit loss before tax arrived after charging and crediting." } } }, "auth_ref": [] }, "legn_ProfitLossBeforeTaxLineItems": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ProfitLossBeforeTaxLineItems", "presentation": [ "http://legendbiotech.com/role/LOSSBEFORETAXDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Profit Loss Before Tax [Line Items]", "label": "Profit Loss Before Tax [Line Items]", "documentation": "Line items represent profit loss before tax." } } }, "auth_ref": [] }, "legn_ProfitLossBeforeTaxTable": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ProfitLossBeforeTaxTable", "presentation": [ "http://legendbiotech.com/role/LOSSBEFORETAXDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Profit Loss Before Tax [Table]", "label": "Profit Loss Before Tax [Table]", "documentation": "Schedule disclosing information related to profit loss before tax." } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "periodStartLabel": "Property, plant and equipment, beginning balance", "periodEndLabel": "Property, plant and equipment, ending balance", "label": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r10", "r59" ] }, "ifrs-full_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipmentMember", "presentation": [ "http://legendbiotech.com/role/LEASESAdditionalInformationDetails", "http://legendbiotech.com/role/LEASESRightofuseAssetsDetails", "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails", "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment [member]", "label": "Property, plant and equipment [member]" } }, "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r60", "r255", "r272" ] }, "legn_PropertyPlantAndEquipmentRollForward": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PropertyPlantAndEquipmentRollForward", "presentation": [ "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Roll Forward]", "label": "Property, Plant and Equipment [Roll Forward]", "documentation": "Property, Plant and Equipment" } } }, "auth_ref": [] }, "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProportionOfOwnershipInterestInSubsidiary", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATIONInformationAboutSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of equity interest attributable to the Company", "label": "Proportion of ownership interest in subsidiary" } }, "en": { "role": { "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r85", "r88", "r134" ] }, "legn_ProvisionsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ProvisionsPolicyTextBlock", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "label": "Provisions Policy [Text Block]", "documentation": "Provisions" } } }, "auth_ref": [] }, "legn_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of financial assets measured at fair value through profit or loss", "label": "Purchase Of Financial Assets At Fair Value Through Profit Or Loss Classified As Investing Activities", "documentation": "Purchase of financial assets at fair value through profit or loss classified as investing activities." } } }, "auth_ref": [] }, "legn_PurchaseOfFinancialAssetsMeasuredAtAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "PurchaseOfFinancialAssetsMeasuredAtAmortizedCost", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of financial assets measured at amortized cost", "label": "Purchase Of Financial Assets Measured At Amortized Cost", "documentation": "Purchase of financial assets measured at amortized cost." } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of intangible assets", "label": "Purchase of intangible assets, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r260" ] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property, plant and equipment", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r260" ] }, "ifrs-full_PurchasesOfGoodsRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PurchasesOfGoodsRelatedPartyTransactions", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases from related parties", "label": "Purchases of goods, related party transactions" } }, "en": { "role": { "documentation": "The amount of goods purchased by the entity in related party transactions. [Refer: Related parties [member]]" } } }, "auth_ref": [ "r253" ] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueValuationofWarrantLiabilityDetails", "http://legendbiotech.com/role/LEASESAdditionalInformationDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSAdditionalInformationDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofFairValueofEquitySettledShareOptionsGrantedDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyPlantandEquipmentDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsAmortizedonStraightLineBasisoverUsefulEconomicLivesDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRightofuseAssetsDepreciatedonStraightlineBasisoverLeaseTermsandEstimatedUsefulLivesDetails", "http://legendbiotech.com/role/TRADERECEIVABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [axis]", "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r149", "r173", "r190", "r269", "r270", "r327" ] }, "ifrs-full_RangesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RangesMember", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueValuationofWarrantLiabilityDetails", "http://legendbiotech.com/role/LEASESAdditionalInformationDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSAdditionalInformationDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofFairValueofEquitySettledShareOptionsGrantedDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyPlantandEquipmentDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsAmortizedonStraightLineBasisoverUsefulEconomicLivesDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRightofuseAssetsDepreciatedonStraightlineBasisoverLeaseTermsandEstimatedUsefulLivesDetails", "http://legendbiotech.com/role/TRADERECEIVABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ranges [member]", "label": "Ranges [member]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r149", "r173", "r190", "r269", "r270", "r327" ] }, "ifrs-full_RawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RawMaterials", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/COLLABORATIONINVENTORIESSummaryofInventoriesDetails": { "parentTag": "ifrs-full_Inventories", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINVENTORIESSummaryofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Current raw materials" } }, "en": { "role": { "documentation": "A classification of current inventory representing the amount of assets to be consumed in the production process or in the rendering of services. [Refer: Inventories]" } } }, "auth_ref": [ "r244", "r313" ] }, "legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue": { "xbrltype": "sharesItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of vesting of restricted share units (in shares)", "label": "Reclassification Of Vested Restricted Stock Units Number Of Shares In Issue", "documentation": "Reclassification of vested restricted stock units, number of shares in issue." } } }, "auth_ref": [] }, "legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of vesting of restricted share units", "label": "Reclassification Of Vested Restricted Stock Units Share Capital And Share Premium", "documentation": "Reclassification of vested restricted stock units, share capital and share premium." } } }, "auth_ref": [] }, "legn_ReconciliationOfChangesInDeferredTaxAssetsAndLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ReconciliationOfChangesInDeferredTaxAssetsAndLiabilitiesLineItems", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXAdditionalInformationDetails", "http://legendbiotech.com/role/DEFERREDTAXDisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation Of Changes In Deferred Tax Assets and Liabilities [Line Items]", "label": "Reconciliation Of Changes In Deferred Tax Assets and Liabilities [Line Items]", "documentation": "Reconciliation of changes in deferred tax assets and liabilities." } } }, "auth_ref": [] }, "legn_ReconciliationOfChangesInDeferredTaxAssetsAndLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ReconciliationOfChangesInDeferredTaxAssetsAndLiabilitiesTable", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXAdditionalInformationDetails", "http://legendbiotech.com/role/DEFERREDTAXDisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation Of Changes In Deferred Tax Assets and Liabilities [Table]", "label": "Reconciliation Of Changes In Deferred Tax Assets and Liabilities [Table]", "documentation": "Reconciliation of changes in deferred tax assets and liabilities table." } } }, "auth_ref": [] }, "legn_RegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "RegisteredDirectOfferingMember", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Registered Direct Offering", "label": "Registered Direct Offering [Member]", "documentation": "Registered Direct Offering" } } }, "auth_ref": [] }, "ifrs-full_RelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RelatedPartiesMember", "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSAdditionalInformationDetails", "http://legendbiotech.com/role/TRADEPAYABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Parties", "label": "Related parties [member]" } }, "en": { "role": { "documentation": "This member stands for related parties. Related parties are persons or entities that are related to the entity that is preparing its financial statements (the reporting entity). (a) A person or a close member of that person\u2019s family is related to a reporting entity if that person: (i) has control or joint control over the reporting entity; (ii) has significant influence over the reporting entity; or (iii) is a member of the key management personnel of the reporting entity or of a parent of the reporting entity. (b) An entity is related to a reporting entity if any of the following conditions applies: (i) The entity and the reporting entity are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others). (ii) One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member). (iii) Both entities are joint ventures of the same third party. (iv) One entity is a joint venture of a third entity and the other entity is an associate of the third entity. (v) The entity is a post-employment benefit plan for the benefit of employees of either the reporting entity or an entity related to the reporting entity. If the reporting entity is itself such a plan, the sponsoring employers are also related to the reporting entity. (vi) The entity is controlled or jointly controlled by a person identified in (a). (vii) A person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity). (viii) The entity, or any member of a group of which it is a part, provides key management personnel services to the reporting entity or to the parent of the reporting entity. [Refer: Joint ventures [member]; Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r78" ] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "negatedLabel": "Research and development expenses", "label": "Research and development expense" } }, "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } } }, "auth_ref": [ "r106" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation reserve", "label": "Reserve of exchange differences on translation [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r71", "r241" ] }, "ifrs-full_ReserveOfSharebasedPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReserveOfSharebasedPaymentsMember", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation reserves", "label": "Reserve of share-based payments [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity resulting from share-based payments." } } }, "auth_ref": [ "r241" ] }, "legn_RestrictedStockPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "RestrictedStockPlanMember", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Scheme", "label": "Restricted Stock Plan [Member]", "documentation": "Restricted stock plan." } } }, "auth_ref": [] }, "legn_RestrictedStockUnitsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "RestrictedStockUnitsAbstract", "lang": { "en-us": { "role": { "label": "Restricted Stock Units [Abstract]", "documentation": "Restricted stock units." } } }, "auth_ref": [] }, "legn_RestrictedStockUnitsExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "RestrictedStockUnitsExplanatoryTextBlock", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITS" ], "lang": { "en-us": { "role": { "terseLabel": "RESTRICTED SHARE UNITS", "label": "Restricted Stock Units Explanatory [Text Block]", "documentation": "Restricted stock units." } } }, "auth_ref": [] }, "legn_RestrictedStockUnitsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "RestrictedStockUnitsLineItems", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSAdditionalInformationDetails", "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSSummaryofMovementinNumberofRSUOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units [Line Items]", "label": "Restricted Stock Units [Line Items]", "documentation": "Restricted stock units line items" } } }, "auth_ref": [] }, "legn_RestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "RestrictedStockUnitsMember", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSAdditionalInformationDetails", "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSSummaryofMovementinNumberofRSUOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSU", "label": "Restricted Stock Units [Member]", "documentation": "Restricted stock units member." } } }, "auth_ref": [] }, "legn_RestrictedStockUnitsTable": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "RestrictedStockUnitsTable", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSAdditionalInformationDetails", "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSSummaryofMovementinNumberofRSUOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units [Table]", "label": "Restricted Stock Units [Table]", "documentation": "Restricted stock units table." } } }, "auth_ref": [] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Distributable retained earnings", "label": "Retained earnings" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r245", "r247" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings/(accumulated losses)", "label": "Retained earnings [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r5", "r241" ] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 1.0 }, "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofRevenueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME", "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofRevenueDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofAnalysisofRevenueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total revenue", "label": "Revenue" } }, "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } } }, "auth_ref": [ "r37", "r140", "r196", "r224", "r227", "r231", "r232", "r235", "r239", "r240", "r268" ] }, "ifrs-full_RevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueAbstract", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUE", "label": "Revenue [abstract]" } } }, "auth_ref": [] }, "ifrs-full_RevenueFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueFromContractsWithCustomers", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofRevenueDetails": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenue and other revenue", "label": "Revenue from contracts with customers" } }, "en": { "role": { "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration." } } }, "auth_ref": [ "r151", "r152" ] }, "legn_RevenueFromLicensingOfIntellectualProperty": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "RevenueFromLicensingOfIntellectualProperty", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME", "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONAdditionalInformationDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofAnalysisofRevenueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "License revenue", "terseLabel": "Licensing of intellectual property", "label": "Revenue From Licensing Of Intellectual Property", "documentation": "Revenue from licensing of intellectual property." } } }, "auth_ref": [] }, "legn_RevenueFromLicensingOfIntellectualPropertyTransitionalAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "RevenueFromLicensingOfIntellectualPropertyTransitionalAdjustmentMember", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXDisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License revenue - transitional adjustment", "label": "Revenue From Licensing Of Intellectual Property, Transitional Adjustment [Member]", "documentation": "Revenue From Licensing Of Intellectual Property, Transitional Adjustment" } } }, "auth_ref": [] }, "legn_RevenueFromLicensingOfPatentsRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "RevenueFromLicensingOfPatentsRelatedPartyTransactions", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing of patents to related parties", "label": "Revenue From Licensing Of Patents Related Party Transactions", "documentation": "Revenue from licensing of patents related party transactions." } } }, "auth_ref": [] }, "legn_RevenueFromSaleOfProductsAndSalesBasedRoyaltiesFromRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "RevenueFromSaleOfProductsAndSalesBasedRoyaltiesFromRelatedPartyTransactions", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofTransactionswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales of products and sales-based royalties from related parties", "label": "Revenue From Sale Of Products And Sales Based Royalties From Related Party Transactions", "documentation": "Revenue From Sale Of Products And Sales Based Royalties From Related Party Transactions" } } }, "auth_ref": [] }, "legn_RightOfUseAssetsExcludingCollaborationMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "RightOfUseAssetsExcludingCollaborationMember", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Collaboration Assets Leased", "label": "Right Of Use Assets Excluding Collaboration [Member]", "documentation": "Right Of Use Assets Excluding Collaboration" } } }, "auth_ref": [] }, "legn_RightOfUseAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "RightOfUseAssetsRollForward", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-Use Assets [Roll Forward]", "label": "Right-of-Use Assets [Roll Forward]", "documentation": "Right-of-Use Assets" } } }, "auth_ref": [] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://legendbiotech.com/role/LEASESRightofuseAssetsDetails", "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Right-of-use assets" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r158", "r165" ] }, "ifrs-full_RightofuseAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RightofuseAssetsMember", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXDisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use assets", "label": "Right-of-use assets [member]" } }, "en": { "role": { "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r157" ] }, "ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RiskExposureAssociatedWithInstrumentsSharingCharacteristic", "presentation": [ "http://legendbiotech.com/role/TRADERECEIVABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of trade receivables subject to concentration of credit risk", "label": "Risk exposure associated with instruments sharing characteristic" } }, "en": { "role": { "documentation": "The amount of risk exposure associated with financial instruments with a shared characteristic that identifies a concentration of risks. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r221" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r287" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r289" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXAdditionalInformationDetails", "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofNoncurrentAssetsDetails", "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofRevenueDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Domain]" } } }, "auth_ref": [] }, "legn_SellingAndDistributionExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "SellingAndDistributionExpenses", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "negatedLabel": "Selling and distribution expenses", "label": "Selling And Distribution Expenses", "documentation": "Selling and distribution expenses." } } }, "auth_ref": [] }, "ifrs-full_ServiceConcessionArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ServiceConcessionArrangementsAxis", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service concession arrangements [axis]", "label": "Service concession arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r238" ] }, "ifrs-full_ServiceConcessionArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ServiceConcessionArrangementsMember", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service concession arrangements [member]", "label": "Service concession arrangements [member]" } }, "en": { "role": { "documentation": "This member stands for arrangements in which an entity (the operator) may enter into an arrangement with another entity (the grantor) to provide services that give the public access to major economic and social facilities. The grantor may be a public or private sector entity, including a governmental body. Examples of service concession arrangements involve water treatment and supply facilities, motorways, car parks, tunnels, bridges, airports and telecommunication networks. Examples of arrangements that are not service concession arrangements include an entity outsourcing the operation of its internal services (for example, employee cafeteria, building maintenance, and accounting or information technology functions). It also represents the standard value for the 'Service concession arrangements' axis if no other member is used. [Refer: Government [member]]" } } }, "auth_ref": [ "r238" ] }, "ifrs-full_ServicesReceivedRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ServicesReceivedRelatedPartyTransactions", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration paid for shared services", "label": "Services received, related party transactions" } }, "en": { "role": { "documentation": "The amount of services received in related party transactions. [Refer: Related parties [member]]" } } }, "auth_ref": [ "r254" ] }, "legn_ShareCapitalAndSharePremium": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ShareCapitalAndSharePremium", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Share Capital And Share Premium", "documentation": "Share capital and share premium." } } }, "auth_ref": [] }, "legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue": { "xbrltype": "sharesItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ShareCapitalAndSharePremiumNumberOfSharesInIssue", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share Capital And Share Premium Number Of Shares In Issue", "documentation": "Share capital and share premium, number of shares in issue." } } }, "auth_ref": [] }, "legn_ShareCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ShareCapitalMember", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Share Capital [Member]", "documentation": "Share capital." } } }, "auth_ref": [] }, "legn_ShareCapitalRollForward": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ShareCapitalRollForward", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Capital [Roll Forward]", "label": "Share Capital [Roll Forward]", "documentation": "Share Capital" } } }, "auth_ref": [] }, "ifrs-full_ShareIssueRelatedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShareIssueRelatedCost", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance costs", "label": "Share issue related cost" } }, "en": { "role": { "documentation": "The amount of cost related to the issuance of shares." } } }, "auth_ref": [ "r300" ] }, "legn_ShareOptionAndRestrictedStockUnitSchemeMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "ShareOptionAndRestrictedStockUnitSchemeMember", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Option and Restricted Stock Unit Scheme", "label": "Share Option And Restricted Stock Unit Scheme [Member]", "documentation": "Share option and restricted stock unit scheme." } } }, "auth_ref": [] }, "legn_SharePremiumBeforeIssueExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "SharePremiumBeforeIssueExpenses", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMEAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share premium before issue expenses", "label": "Share Premium Before Issue Expenses", "documentation": "Share premium before issue expenses." } } }, "auth_ref": [] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share premium", "label": "Share premium [member]" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r5" ] }, "ifrs-full_SharebasedPaymentArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SharebasedPaymentArrangementsMember", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSAdditionalInformationDetails", "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSSummaryofMovementinNumberofRSUOutstandingDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMEAdditionalInformationDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment arrangements [member]", "label": "Share-based payment arrangements [member]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r191" ] }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Less: Pledged deposits", "label": "Short-term deposits, classified as cash equivalents" } }, "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r325" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesAxis", "presentation": [ "http://legendbiotech.com/role/CORPORATEINFORMATIONInformationAboutSubsidiariesDetails", "http://legendbiotech.com/role/DEFERREDTAXAdditionalInformationDetails", "http://legendbiotech.com/role/INCOMETAXAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiaries [axis]", "label": "Subsidiaries [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r86", "r89", "r144" ] }, "legn_SpecifiedDevelopmentMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "SpecifiedDevelopmentMilestonesMember", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Specified development milestones", "label": "Specified Development Milestones [Member]", "documentation": "Specified development milestones." } } }, "auth_ref": [] }, "legn_SpecifiedManufacturingMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "SpecifiedManufacturingMilestonesMember", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Specified manufacturing milestones", "label": "Specified Manufacturing Milestones [Member]", "documentation": "Specified manufacturing milestones." } } }, "auth_ref": [] }, "legn_SpecifiedNetTradeSalesMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "SpecifiedNetTradeSalesMilestonesMember", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Specified net trade sales milestones", "label": "Specified Net Trade Sales Milestones [Member]", "documentation": "Specified net trade sales milestones." } } }, "auth_ref": [] }, "legn_SpecifiedRegulatoryMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "SpecifiedRegulatoryMilestonesMember", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Specified regulatory milestones", "label": "Specified Regulatory Milestones [Member]", "documentation": "Specified regulatory milestones." } } }, "auth_ref": [] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXAdditionalInformationDetails", "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofNoncurrentAssetsDetails", "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofRevenueDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Axis]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of changes in equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/WARRANTLIABILITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement Of Changes In Equity [Line Items]", "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "legn_StatementOfChangesInEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "StatementOfChangesInEquityRollForward", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Changes in Equity [Roll Forward]", "label": "Statement of Changes in Equity [Roll Forward]", "documentation": "Statement of Changes in Equity" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/role/WARRANTLIABILITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement Of Changes In Equity [Table]", "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r5" ] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "legn_StatutoryBlendedIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "StatutoryBlendedIncomeTaxRate", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails": { "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "At the statutory blended US federal and state income tax rate of 24.3% (2022 and 2021: 28.1%)", "label": "Statutory Blended Income Tax Rate", "documentation": "Statutory blended income tax rate." } } }, "auth_ref": [] }, "ifrs-full_SubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SubsidiariesMember", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiaries", "label": "Subsidiaries [member]" } }, "en": { "role": { "documentation": "This member stands for entities that are controlled by another entity." } } }, "auth_ref": [ "r77", "r86", "r89", "r144" ] }, "legn_SummaryOfNatureOfRelatedPartyRelationshipTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "SummaryOfNatureOfRelatedPartyRelationshipTableTextBlock", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Nature of Related Party Relationship", "label": "Summary Of Nature Of Related Party Relationship [Table Text Block]", "documentation": "Summary of nature of related party relationship." } } }, "auth_ref": [] }, "legn_SummaryOfSignificantAccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "SummaryOfSignificantAccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary Of Significant Accounting Policies [Abstract]", "documentation": "Summary of significant accounting policies." } } }, "auth_ref": [] }, "legn_SurchargeRate": { "xbrltype": "percentItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "SurchargeRate", "presentation": [ "http://legendbiotech.com/role/INCOMETAXAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Surcharge rate", "label": "Surcharge Rate", "documentation": "Surcharge rate." } } }, "auth_ref": [] }, "ifrs-full_TaxEffectFromChangeInTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxEffectFromChangeInTaxRate", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State rate change", "label": "Tax effect from change in tax rate" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]" } } }, "auth_ref": [ "r46" ] }, "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of non-deductible expenses", "label": "Tax effect of expense not deductible in determining taxable profit (tax loss)" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]" } } }, "auth_ref": [ "r46" ] }, "legn_TaxEffectOfForeignPreferentialTaxRates": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TaxEffectOfForeignPreferentialTaxRates", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferential tax rate in other countries and regions", "label": "Tax Effect Of Foreign Preferential Tax Rates", "documentation": "Tax Effect Of Foreign Preferential Tax Rates" } } }, "auth_ref": [] }, "ifrs-full_TaxEffectOfForeignTaxRates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxEffectOfForeignTaxRates", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of tax rate differences in other countries and regions", "label": "Tax effect of foreign tax rates" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]" } } }, "auth_ref": [ "r46" ] }, "legn_TaxEffectOfOptionIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TaxEffectOfOptionIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation income tax charge/(benefit)", "label": "Tax Effect Of Option Income Tax Expense Benefit", "documentation": "Tax effect of option income tax expense (benefit)." } } }, "auth_ref": [] }, "legn_TaxEffectsResearchAndDevelopmentCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TaxEffectsResearchAndDevelopmentCredit", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development credit", "label": "Tax Effects Research And Development Credit", "documentation": "Tax effects research and development credit." } } }, "auth_ref": [] }, "legn_TaxExpenseIncomeAmountAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TaxExpenseIncomeAmountAbstract", "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax expense (income), amount [Abstract]", "label": "Tax expense (income), amount [Abstract]", "documentation": "Tax expense (income), amount" } } }, "auth_ref": [] }, "legn_TaxExpenseIncomeAtStatutoryBlendedIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TaxExpenseIncomeAtStatutoryBlendedIncomeTaxRate", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "At the statutory blended US federal and state income tax rate of 24.3% (2022 and 2021: 28.1%)", "label": "Tax Expense Income At Statutory Blended Income Tax Rate", "documentation": "Tax expense income at statutory blended income tax rate." } } }, "auth_ref": [] }, "legn_TaxExpenseIncomeRateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TaxExpenseIncomeRateAbstract", "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax expense (income), effective tax rate [Abstract]", "label": "Tax expense (income), rate [Abstract]", "documentation": "Tax expense (income), rate" } } }, "auth_ref": [] }, "legn_TaxLossesAndDeductibleTemporaryDifferencesNotRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TaxLossesAndDeductibleTemporaryDifferencesNotRecognized", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax losses and deductible temporary differences not recognized", "label": "Tax Losses And Deductible Temporary Differences Not Recognized", "documentation": "Tax losses and deductible temporary differences not recognized." } } }, "auth_ref": [] }, "ifrs-full_TaxRateEffectFromChangeInTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxRateEffectFromChangeInTaxRate", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails": { "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State rate change", "label": "Tax rate effect from change in tax rate" } }, "en": { "role": { "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from a change in tax rate. [Refer: Average effective tax rate; Applicable tax rate]" } } }, "auth_ref": [ "r47" ] }, "ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails": { "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of non-deductible expenses", "label": "Tax rate effect of expense not deductible in determining taxable profit (tax loss)" } }, "en": { "role": { "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the expenses not deductible in determining taxable profit. [Refer: Average effective tax rate; Applicable tax rate]" } } }, "auth_ref": [ "r47" ] }, "legn_TaxRateEffectOfForeignPreferentialTaxRates": { "xbrltype": "percentItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TaxRateEffectOfForeignPreferentialTaxRates", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails": { "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferential tax rate in other countries and regions", "label": "Tax Rate Effect Of Foreign Preferential Tax Rates", "documentation": "Tax Rate Effect Of Foreign Preferential Tax Rates" } } }, "auth_ref": [] }, "ifrs-full_TaxRateEffectOfForeignTaxRates": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxRateEffectOfForeignTaxRates", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails": { "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of tax rate differences in other countries and regions", "label": "Tax rate effect of foreign tax rates" } }, "en": { "role": { "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the application of foreign tax rates. [Refer: Average effective tax rate; Applicable tax rate]" } } }, "auth_ref": [ "r47" ] }, "legn_TaxRateEffectOfOptionIncomeTaxBenefit": { "xbrltype": "percentItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TaxRateEffectOfOptionIncomeTaxBenefit", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails": { "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation income tax charge/(benefit)", "label": "Tax Rate Effect Of Option Income Tax Benefit", "documentation": "Tax rate effect of option income tax benefit." } } }, "auth_ref": [] }, "ifrs-full_TaxRateEffectOfTaxLosses": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxRateEffectOfTaxLosses", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails": { "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax losses and deductible temporary differences not recognized", "label": "Tax rate effect of tax losses" } }, "en": { "role": { "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from tax losses. [Refer: Average effective tax rate; Applicable tax rate]" } } }, "auth_ref": [ "r47" ] }, "legn_TaxRateEffectOnResearchAndDevelopmentCredit": { "xbrltype": "percentItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TaxRateEffectOnResearchAndDevelopmentCredit", "calculation": { "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails": { "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/INCOMETAXSummaryofReconciliationofTaxExpenseApplicabletoLossBeforeTaxattheStatutoryRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development credit", "label": "Tax Rate Effect On Research And Development Credit", "documentation": "Tax rate effect on research and development credit." } } }, "auth_ref": [] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXDisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryDetails", "http://legendbiotech.com/role/LOSSBEFORETAXDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]", "label": "Temporary difference, unused tax losses and unused tax credits [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r51" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXDisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryDetails", "http://legendbiotech.com/role/LOSSBEFORETAXDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary difference, unused tax losses and unused tax credits [member]", "label": "Temporary difference, unused tax losses and unused tax credits [member]" } }, "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r51" ] }, "legn_TimeDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TimeDepositsMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Time deposits", "label": "Time Deposits [Member]", "documentation": "Time deposits." } } }, "auth_ref": [] }, "legn_TimeDepositsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TimeDepositsPolicyTextBlock", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Time deposits", "label": "Time Deposits Policy [Text Block]", "documentation": "Time deposits." } } }, "auth_ref": [] }, "legn_TimesDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TimesDeposits", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Time deposits", "label": "Times Deposits", "documentation": "Times deposits." } } }, "auth_ref": [] }, "legn_TimesDepositsCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TimesDepositsCurrentAndNoncurrent", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Time deposits", "label": "Times Deposits Current And Noncurrent", "documentation": "Times deposits current and noncurrent." } } }, "auth_ref": [] }, "legn_TimesDepositsNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TimesDepositsNonCurrent", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Time deposits", "label": "Times Deposits Non Current", "documentation": "Times deposits, non-current." } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueValuationofWarrantLiabilityDetails", "http://legendbiotech.com/role/LEASESAdditionalInformationDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSAdditionalInformationDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofFairValueofEquitySettledShareOptionsGrantedDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyPlantandEquipmentDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsAmortizedonStraightLineBasisoverUsefulEconomicLivesDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRightofuseAssetsDepreciatedonStraightlineBasisoverLeaseTermsandEstimatedUsefulLivesDetails", "http://legendbiotech.com/role/TRADERECEIVABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Top of Range", "label": "Top of range [member]" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r149", "r173", "r190", "r269", "r270", "r327" ] }, "legn_TradeAndNotesPayablesLineItem": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TradeAndNotesPayablesLineItem", "presentation": [ "http://legendbiotech.com/role/TRADEPAYABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade And Notes Payables [Line Items]", "label": "Trade And Notes Payables Line Item", "documentation": "Trade and notes payables." } } }, "auth_ref": [] }, "legn_TradeAndNotesPayablesTable": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TradeAndNotesPayablesTable", "presentation": [ "http://legendbiotech.com/role/TRADEPAYABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade And Notes Payables [Table]", "label": "Trade And Notes Payables [Table]", "documentation": "Trade and notes payables." } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherPayablesAbstract", "lang": { "en-us": { "role": { "label": "Trade and other payables [abstract]" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherPayablesToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherPayablesToRelatedParties", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other payables due to related parties", "label": "Payables to related parties" } }, "en": { "role": { "documentation": "The amount of payables due to related parties. [Refer: Related parties [member]]" } } }, "auth_ref": [ "r305" ] }, "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/role/TRADEPAYABLESAdditionalInformationDetails", "http://legendbiotech.com/role/TRADEPAYABLESSummaryofTradeandNotesPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables", "label": "Trade payables" } }, "en": { "role": { "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business." } } }, "auth_ref": [ "r305" ] }, "ifrs-full_TradeAndOtherReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Trade and other receivables [abstract]" } } }, "auth_ref": [] }, "legn_TradePayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TradePayablesMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialLiabilitiesDetails", "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables", "label": "Trade Payables [Member]", "documentation": "Trade payables." } } }, "auth_ref": [] }, "legn_TradePayablesTerm": { "xbrltype": "durationItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TradePayablesTerm", "presentation": [ "http://legendbiotech.com/role/TRADEPAYABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables, term", "label": "Trade Payables Term", "documentation": "Trade payables, term." } } }, "auth_ref": [] }, "legn_TradeReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TradeReceivableMember", "presentation": [ "http://legendbiotech.com/role/RELATEDPARTYTRANSACTIONSSummaryofOutstandingBalanceswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables", "label": "Trade Receivable [Member]", "documentation": "Trade receivable." } } }, "auth_ref": [] }, "ifrs-full_TradeReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeReceivablesMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialAssetsDetails", "http://legendbiotech.com/role/TRADERECEIVABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables", "label": "Trade receivables [member]" } }, "en": { "role": { "documentation": "This member stands for trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r204", "r208", "r277", "r301" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://legendbiotech.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "legn_TransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TransactionPrice", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSAdditionalInformationDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceAllocationtoPerformanceObligationsDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceCompositionDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Transaction price", "terseLabel": "Total", "label": "Transaction Price", "documentation": "Estimated transaction price related to contract." } } }, "auth_ref": [] }, "ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TransactionPriceAllocatedToRemainingPerformanceObligations", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSSummaryofTransactionPriceAllocationtoPerformanceObligationsDetails", "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSTransactionPriceAmountsAllocatedtoRemainingPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Remaining unsatisfied performance obligation", "netLabel": "Amounts expected to be recognized as revenue", "label": "Transaction price allocated to remaining performance obligations" } }, "en": { "role": { "documentation": "The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]" } } }, "auth_ref": [ "r155" ] }, "legn_TransactionPriceConstrainedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TransactionPriceConstrainedAmount", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction price, amount constrained at inception", "label": "Transaction Price, Constrained Amount", "documentation": "Transaction Price, Constrained Amount" } } }, "auth_ref": [] }, "legn_TransactionPriceVariableConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TransactionPriceVariableConsideration", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/REVENUEOTHERINCOMEANDGAINSAdditionalInformationDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable consideration", "label": "Transaction Price, Variable Consideration", "documentation": "Transaction Price, Variable Consideration" } } }, "auth_ref": [] }, "legn_TransferOfIntellectualPropertyLicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "TransferOfIntellectualPropertyLicenseMember", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer Of Intellectual Property License", "label": "Transfer Of Intellectual Property License [Member]", "documentation": "Transfer Of Intellectual Property License" } } }, "auth_ref": [] }, "ifrs-full_TypesOfRisksAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfRisksAxis", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESAdditionalInformationDetails", "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMonitoringCapitalUsingGearingRatioDetails", "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofSensitivitytoReasonablyPossibleChangeinExchangeRatesDetails", "http://legendbiotech.com/role/TRADERECEIVABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of risks [axis]", "label": "Types of risks [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r174", "r175", "r176", "r178", "r198", "r202", "r203" ] }, "ifrs-full_TypesOfRisksMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfRisksMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESAdditionalInformationDetails", "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMonitoringCapitalUsingGearingRatioDetails", "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofSensitivitytoReasonablyPossibleChangeinExchangeRatesDetails", "http://legendbiotech.com/role/TRADERECEIVABLESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risks [member]", "label": "Risks [member]" } }, "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } } }, "auth_ref": [ "r174", "r175", "r176", "r178", "r198", "r202", "r203" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSAdditionalInformationDetails", "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSSummaryofMovementinNumberofRSUOutstandingDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMEAdditionalInformationDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of share-based payment arrangements [axis]", "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r191" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXAdditionalInformationDetails", "http://legendbiotech.com/role/INCOMETAXAdditionalInformationDetails", "http://legendbiotech.com/role/INCOMETAXSummaryofTaxChargesDetails", "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofNoncurrentAssetsDetails", "http://legendbiotech.com/role/OPERATINGSEGMENTINFORMATIONSummaryofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States of America", "verboseLabel": "United States of America", "label": "UNITED STATES" } } }, "auth_ref": [] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "USD", "presentation": [ "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominated in USD", "label": "United States of America, Dollars" } } }, "auth_ref": [] }, "legn_USDollarStrengthensAgainstEURMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "USDollarStrengthensAgainstEURMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofSensitivitytoReasonablyPossibleChangeinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "If US$ strengthens against EUR", "label": "U S Dollar Strengthens Against E U R [Member]", "documentation": "US$ strengthens against EUR." } } }, "auth_ref": [] }, "legn_USDollarStrengthensAgainstRMBMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "USDollarStrengthensAgainstRMBMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofSensitivitytoReasonablyPossibleChangeinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "If US$ strengthens against RMB", "label": "U S Dollar Strengthens Against R M B [Member]", "documentation": "US$ strengthens against RMB." } } }, "auth_ref": [] }, "legn_USDollarWeakensAgainstEURMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "USDollarWeakensAgainstEURMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofSensitivitytoReasonablyPossibleChangeinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "If US$ weakens against EUR", "label": "U S Dollar Weakens Against E U R [Member]", "documentation": "US$ weakens against EUR." } } }, "auth_ref": [] }, "legn_USDollarWeakensAgainstRMBMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "USDollarWeakensAgainstRMBMember", "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofSensitivitytoReasonablyPossibleChangeinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "If US$ weakens against RMB", "label": "U S Dollar Weakens Against R M B [Member]", "documentation": "US$ weakens against RMB." } } }, "auth_ref": [] }, "ifrs-full_UndiscountedFinanceLeasePaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UndiscountedFinanceLeasePaymentsToBeReceived", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/LEASESSummaryofUndiscountedMinimumLeasePaymentsReceivablesinFuturePeriodsunderNoncancellableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Undiscounted finance lease payments to be received", "label": "Undiscounted finance lease payments to be received" } }, "en": { "role": { "documentation": "The amount of undiscounted finance lease payments to be received. Finance lease is a lease that transfers substantially all the risks and rewards incidental to ownership of an underlying asset." } } }, "auth_ref": [ "r167" ] }, "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "calculation": { "http://legendbiotech.com/role/DEFERREDTAXSummaryofItemswithRespecttoDeferredTaxAssetshavenotbeenRecognizedDetails": { "parentTag": "legn_DeferredTaxAssetNotYetRecognized", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXSummaryofItemswithRespecttoDeferredTaxAssetshavenotbeenRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax losses and credits", "label": "Unused tax losses for which no deferred tax asset recognised" } }, "en": { "role": { "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]" } } }, "auth_ref": [ "r48" ] }, "ifrs-full_UnusedTaxLossesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnusedTaxLossesMember", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXDisclosureOfMovementsInDeferredTaxAssetsAndLiabilitiesExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Losses available for offsetting against future taxable profits", "label": "Unused tax losses [member]" } }, "en": { "role": { "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit." } } }, "auth_ref": [ "r51" ] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsAmortizedonStraightLineBasisoverUsefulEconomicLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Useful economic lives of intangible assets", "label": "Useful life measured as period of time, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r98" ] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "presentation": [ "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Useful life of property, plant and equipment", "label": "Useful life measured as period of time, property, plant and equipment" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r53" ] }, "ifrs-full_ValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ValueAddedTaxReceivables", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSSummaryofPrepaymentsOtherReceivablesandOtherAssetsDetails": { "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSSummaryofPrepaymentsOtherReceivablesandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "VAT recoverable", "label": "Value added tax receivables" } }, "en": { "role": { "documentation": "The amount of receivables related to a value added tax." } } }, "auth_ref": [ "r304" ] }, "ifrs-full_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "VehiclesMember", "presentation": [ "http://legendbiotech.com/role/PROPERTYPLANTANDEQUIPMENTDetails", "http://legendbiotech.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transportation equipment", "label": "Vehicles [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing vehicles used in the entity's operations, specifically to include aircraft, motor vehicles and ships. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r308" ] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/LOSSBEFORETAXDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wages and salaries", "label": "Wages and salaries" } }, "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } } }, "auth_ref": [ "r312" ] }, "legn_WarrantExercisePeriod": { "xbrltype": "durationItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "WarrantExercisePeriod", "presentation": [ "http://legendbiotech.com/role/WARRANTLIABILITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise period", "label": "Warrant Exercise Period", "documentation": "Warrant Exercise Period" } } }, "auth_ref": [] }, "ifrs-full_WarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WarrantLiability", "crdr": "credit", "calculation": { "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://legendbiotech.com/role/FINANCIALRISKMANAGEMENTOBJECTIVESANDPOLICIESSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/role/SIGNIFICANTACCOUNTINGJUDGEMENTSANDESTIMATESDetails", "http://legendbiotech.com/role/WARRANTLIABILITYScheduleofMovementofWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant liability", "periodStartLabel": "Balance, beginning of the period", "periodEndLabel": "Balance, end of the period", "label": "Warrant liability" } }, "en": { "role": { "documentation": "The amount of warrant liabilities." } } }, "auth_ref": [ "r303" ] }, "legn_WarrantLiabilityFairValueLossGainRecorded": { "xbrltype": "monetaryItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "WarrantLiabilityFairValueLossGainRecorded", "crdr": "debit", "presentation": [ "http://legendbiotech.com/role/WARRANTLIABILITYAdditionalInformationDetails", "http://legendbiotech.com/role/WARRANTLIABILITYScheduleofMovementofWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value loss on warrant", "verboseLabel": "Fair value loss/(gain) of the warrant liability", "label": "Warrant Liability Fair Value Loss (Gain) Recorded", "documentation": "Warrant liability fair value loss recorded." } } }, "auth_ref": [] }, "legn_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "WarrantMember", "presentation": [ "http://legendbiotech.com/role/WARRANTLIABILITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant", "label": "Warrant [Member]", "documentation": "Warrant" } } }, "auth_ref": [] }, "ifrs-full_WarrantyContingentLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WarrantyContingentLiabilityMember", "presentation": [ "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueMeasurementHierarchyofFinancialInstrumentsDetails", "http://legendbiotech.com/role/FAIRVALUEANDFAIRVALUEHIERARCHYOFFINANCIALINSTRUMENTSSummaryofFairValueValuationofWarrantLiabilityDetails", "http://legendbiotech.com/role/FINANCIALINSTRUMENTSBYCATEGORYSummaryofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant liability", "label": "Warranty contingent liability [member]" } }, "en": { "role": { "documentation": "This member stands for a contingent liability for estimated costs of making good under warranties for products sold. [Refer: Contingent liabilities [member]]" } } }, "auth_ref": [ "r256" ] }, "legn_WarrantyLiabilitiesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "WarrantyLiabilitiesRollForward", "presentation": [ "http://legendbiotech.com/role/WARRANTLIABILITYScheduleofMovementofWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warranty Liabilities [Roll Forward]", "label": "Warranty Liabilities [Roll Forward]", "documentation": "Warranty Liabilities" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSSummaryofMovementinNumberofRSUOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested during the year (in dollars per share)", "label": "Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r326" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSSummaryofMovementinNumberofRSUOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited during the year (in dollars per share)", "label": "Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r326" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSSummaryofMovementinNumberofRSUOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted during the year (in dollars per share)", "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r326" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSSummaryofMovementinNumberofRSUOutstandingDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at January 1 (in dollars per share)", "periodEndLabel": "Outstanding at December 31 (in dollars per share)", "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r326" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofShareOptionsOutstandingUndertheSchemeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at December 31 (in dollars per share)", "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r187" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofShareOptionsOutstandingUndertheSchemeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised during the year (in dollars per share)", "label": "Weighted average exercise price of share options exercised in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r185" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofShareOptionsOutstandingUndertheSchemeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited during the year (in dollars per share)", "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r184" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofShareOptionsOutstandingUndertheSchemeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted during the year (in dollars per share)", "label": "Weighted average exercise price of share options granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r183" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMEAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average share price for share options in share-based payment arrangement exercised during period (in dollars per share)", "label": "Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise" } }, "en": { "role": { "documentation": "The weighted average share price at the date of exercise for share options that are exercised in a share-based payment arrangement. [Refer: Share-based payment arrangements [member]; Weighted average [member]]" } } }, "auth_ref": [ "r189" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofShareOptionsOutstandingUndertheSchemeDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "At January 1 (in dollars per share)", "periodEndLabel": "At December 31 (in dollars per share)", "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r182", "r186" ] }, "legn_WeightedAverageExercisePriceRollForward": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "WeightedAverageExercisePriceRollForward", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofShareOptionsOutstandingUndertheSchemeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price", "label": "Weighted Average Exercise Price [Roll Forward]", "documentation": "Weighted Average Exercise Price" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of share options granted", "label": "Weighted average fair value at measurement date, other equity instruments granted" } }, "en": { "role": { "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r194" ] }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted", "crdr": "credit", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMEAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of share options granted", "label": "Weighted average fair value at measurement date, share options granted" } }, "en": { "role": { "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r193" ] }, "legn_WeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "WeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSSummaryofMovementinNumberofRSUOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value", "label": "Weighted Average Grant Date Fair Value [Roll Forward]", "documentation": "Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMESummaryofFairValueofEquitySettledShareOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life of options (year)", "label": "Weighted average remaining contractual life of outstanding share options" } }, "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r190" ] }, "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageSharePriceShareOptionsGranted2019", "presentation": [ "http://legendbiotech.com/role/RESTRICTEDSHAREUNITSAdditionalInformationDetails", "http://legendbiotech.com/role/SHAREOPTIONSCHEMEAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value per share of options granted (in dollars per share)", "label": "Weighted average share price, share options granted" } }, "en": { "role": { "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]" } } }, "auth_ref": [ "r192" ] }, "legn_WeightedAverageSharePriceUsedInShareOptionFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "WeightedAverageSharePriceUsedInShareOptionFairValue", "presentation": [ "http://legendbiotech.com/role/SHAREOPTIONSCHEMEAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average share price used in share option fair value valuation model (in dollars per share)", "label": "Weighted Average Share Price Used In Share Option Fair Value", "documentation": "Weighted average share price used in share option fair value." } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTAdditionalInformationDetails", "http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTSummaryofCalculationsofBasicandDilutedLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of ordinary shares in issue during the year used in the basic earnings per share calculation (in shares)", "label": "Weighted average number of ordinary shares used in calculating basic earnings per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r92" ] }, "legn_WithholdingTaxPercentage": { "xbrltype": "percentItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "WithholdingTaxPercentage", "presentation": [ "http://legendbiotech.com/role/DEFERREDTAXAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Withholding tax percentage", "label": "Withholding Tax Percentage", "documentation": "Withholding tax percentage." } } }, "auth_ref": [] }, "legn_WithholdingTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://legendbiotech.com/20231231", "localname": "WithholdingTaxRate", "presentation": [ "http://legendbiotech.com/role/INCOMETAXAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Withholding tax rate", "label": "Withholding Tax Rate", "documentation": "Withholding tax rate." } } }, "auth_ref": [] }, "ifrs-full_WorkInProgress": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WorkInProgress", "crdr": "debit", "calculation": { "http://legendbiotech.com/role/COLLABORATIONINVENTORIESSummaryofInventoriesDetails": { "parentTag": "ifrs-full_Inventories", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://legendbiotech.com/role/COLLABORATIONINVENTORIESSummaryofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Current work in progress" } }, "en": { "role": { "documentation": "A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]" } } }, "auth_ref": [ "r244", "r313" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard", "URIDate": "2023-03-23" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2023-03-23" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2023-03-23" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard", "URIDate": "2023-03-23" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "136", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_136&doctype=Standard", "URIDate": "2023-03-23" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2023-03-23" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "138", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_138_b&doctype=Standard", "URIDate": "2023-03-23" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2023-03-23" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2023-03-23" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2023-03-23" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2023-03-23" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_n&doctype=Standard", "URIDate": "2023-03-23" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2023-03-23" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "r", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_r&doctype=Standard", "URIDate": "2023-03-23" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard", "URIDate": "2023-03-23" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_56&doctype=Standard", "URIDate": "2023-03-23" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2023-03-23" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "61", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_b&doctype=Standard", "URIDate": "2023-03-23" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard", "URIDate": "2023-03-23" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard", "URIDate": "2023-03-23" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard", "URIDate": "2023-03-23" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2023-03-23" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_b&doctype=Standard", "URIDate": "2023-03-23" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard", "URIDate": "2023-03-23" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2023-03-23" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2023-03-23" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2023-03-23" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2023-03-23" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2023-03-23" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2023-03-23" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2023-03-23" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "98", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_c&doctype=Standard", "URIDate": "2023-03-23" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard", "URIDate": "2023-03-23" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2023-03-23" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard", "URIDate": "2023-03-23" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_a&doctype=Standard", "URIDate": "2023-03-23" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2023-03-23" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_e&doctype=Standard", "URIDate": "2023-03-23" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2023-03-23" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2023-03-23" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2023-03-23" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2023-03-23" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2023-03-23" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2023-03-23" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2023-03-23" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_viii&doctype=Standard", "URIDate": "2023-03-23" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2023-03-23" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard", "URIDate": "2023-03-23" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2023-03-23" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2023-03-23" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2023-03-23" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard", "URIDate": "2023-03-23" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "36", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_a&doctype=Standard", "URIDate": "2023-03-23" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2023-03-23" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI", "URIDate": "2023-03-23" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "20", "IssueDate": "2023-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2023-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2023-03-23" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "20", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS20_g39-39_TI", "URIDate": "2023-03-23" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2023-03-23" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2023-03-23" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2023-03-23" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2023-03-23" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard", "URIDate": "2023-03-23" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2023-03-23" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "18", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18&doctype=Standard", "URIDate": "2023-03-23" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "19", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_c&doctype=Standard", "URIDate": "2023-03-23" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard", "URIDate": "2023-03-23" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard", "URIDate": "2023-03-23" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2023-03-23" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2023-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2023-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_vi&doctype=Standard", "URIDate": "2023-03-23" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2023-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2023-03-23" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2023-03-23" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2023-03-23" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard", "URIDate": "2023-03-23" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard", "URIDate": "2023-03-23" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2023-03-23" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2023-03-23" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "126", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126_a&doctype=Standard", "URIDate": "2023-03-23" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard", "URIDate": "2023-03-23" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "129", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_129_a&doctype=Standard", "URIDate": "2023-03-23" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "130", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_a&doctype=Standard", "URIDate": "2023-03-23" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2023-03-23" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2023-03-23" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vi&doctype=Standard", "URIDate": "2023-03-23" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vii&doctype=Standard", "URIDate": "2023-03-23" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2023-03-23" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard", "URIDate": "2023-03-23" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard", "URIDate": "2023-03-23" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2023-03-23" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2023-03-23" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard", "URIDate": "2023-03-23" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2023-03-23" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2023-03-23" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard", "URIDate": "2023-03-23" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2023-03-23" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard", "URIDate": "2023-03-23" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2023-03-23" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard", "URIDate": "2023-03-23" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard", "URIDate": "2023-03-23" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard", "URIDate": "2023-03-23" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_a&doctype=Standard", "URIDate": "2023-03-23" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_c&doctype=Standard", "URIDate": "2023-03-23" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "46", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_46&doctype=Standard", "URIDate": "2023-03-23" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2023-03-23" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Section": "Presentation of a statement of cash flows", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS07_g10-17_TI", "URIDate": "2023-03-23" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "29", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_29&doctype=Standard", "URIDate": "2023-03-23" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "30", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_30_b&doctype=Standard", "URIDate": "2023-03-23" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2023-03-23" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2023-03-23" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "12", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_a&doctype=Standard", "URIDate": "2023-03-23" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "19B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_a&doctype=Standard", "URIDate": "2023-03-23" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "19B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_c&doctype=Standard", "URIDate": "2023-03-23" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B4", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2023-03-23" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2023-03-23" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2023-03-23" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard", "URIDate": "2023-03-23" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2023-03-23" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard", "URIDate": "2023-03-23" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2023-03-23" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard", "URIDate": "2023-03-23" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "116", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_116_a&doctype=Standard", "URIDate": "2023-03-23" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_119&doctype=Standard", "URIDate": "2023-03-23" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "120", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_a&doctype=Standard", "URIDate": "2023-03-23" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard", "URIDate": "2023-03-23" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2023-03-23" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2023-03-23" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2023-03-23" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2023-03-23" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_c&doctype=Standard", "URIDate": "2023-03-23" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_g&doctype=Standard", "URIDate": "2023-03-23" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2023-03-23" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2023-03-23" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard", "URIDate": "2023-03-23" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard", "URIDate": "2023-03-23" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard", "URIDate": "2023-03-23" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI", "URIDate": "2023-03-23" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI", "URIDate": "2023-03-23" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard", "URIDate": "2023-03-23" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2023-03-23" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard", "URIDate": "2023-03-23" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_124&doctype=Standard", "URIDate": "2023-03-23" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_125&doctype=Standard", "URIDate": "2023-03-23" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard", "URIDate": "2023-03-23" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "128", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2023-03-23" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2023-03-23" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2023-03-23" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_44&doctype=Standard", "URIDate": "2023-03-23" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2023-03-23" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2023-03-23" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2023-03-23" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2023-03-23" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2023-03-23" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2023-03-23" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2023-03-23" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2023-03-23" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2023-03-23" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard", "URIDate": "2023-03-23" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard", "URIDate": "2023-03-23" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard", "URIDate": "2023-03-23" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2023-03-23" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2023-03-23" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2023-03-23" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35M", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2023-03-23" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_36&doctype=Standard", "URIDate": "2023-03-23" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2023-03-23" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2023-03-23" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard", "URIDate": "2023-03-23" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2023-03-23" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_e&doctype=Standard", "URIDate": "2023-03-23" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_f&doctype=Standard", "URIDate": "2023-03-23" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2023-03-23" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B11E", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11E&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B8", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B8_c&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Section": "Defined terms", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI", "URIDate": "2023-03-23" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2023-03-23" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2023-03-23" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2023-03-23" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard", "URIDate": "2023-03-23" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2023-03-23" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2023-03-23" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2023-03-23" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2023-03-23" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard", "URIDate": "2023-03-23" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2023-03-23" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2023-03-23" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard", "URIDate": "2023-03-23" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2023-01-01", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2023-03-23" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2023-01-01", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2023-03-23" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "SIC", "Number": "29", "IssueDate": "2023-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=SIC&num=29&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard", "URIDate": "2023-03-23" }, "r239": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard", "URIDate": "2023-03-23" }, "r240": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard", "URIDate": "2023-03-23" }, "r241": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard", "URIDate": "2023-03-23" }, "r242": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard", "URIDate": "2023-03-23" }, "r243": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r244": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_c&doctype=Standard", "URIDate": "2023-03-23" }, "r245": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r246": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82A&doctype=Standard", "URIDate": "2023-03-23" }, "r247": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r248": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_a&doctype=Standard", "URIDate": "2023-03-23" }, "r249": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_c&doctype=Standard", "URIDate": "2023-03-23" }, "r250": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_h&doctype=Standard", "URIDate": "2023-03-23" }, "r251": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2023-03-23" }, "r252": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2023-03-23" }, "r253": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "21", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_21_a&doctype=Standard", "URIDate": "2023-03-23" }, "r254": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "21", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_21_c&doctype=Standard", "URIDate": "2023-03-23" }, "r255": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard", "URIDate": "2023-03-23" }, "r256": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "88", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_88&doctype=Standard", "URIDate": "2023-03-23" }, "r257": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "119", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119_c&doctype=Standard", "URIDate": "2023-03-23" }, "r258": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "119", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119_e&doctype=Standard", "URIDate": "2023-03-23" }, "r259": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "14", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2023-03-23" }, "r260": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2023-03-23" }, "r261": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2023-03-23" }, "r262": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard", "URIDate": "2023-03-23" }, "r263": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B&doctype=Standard", "URIDate": "2023-03-23" }, "r264": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2023-03-23" }, "r265": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2023-03-23" }, "r266": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2023-03-23" }, "r267": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI", "URIDate": "2023-03-23" }, "r268": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r269": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r270": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2023-03-23" }, "r271": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r272": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard", "URIDate": "2023-03-23" }, "r273": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2023-03-23" }, "r274": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2023-03-23" }, "r275": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard", "URIDate": "2023-03-23" }, "r276": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2023-03-23" }, "r277": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2023-03-23" }, "r278": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "40", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_40_a&doctype=Standard", "URIDate": "2023-03-23" }, "r279": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r280": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r281": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "IG20C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG20C&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r282": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r283": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "IG32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG32&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r284": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard", "URIDate": "2023-03-23" }, "r285": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2023-03-23" }, "r286": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r287": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r288": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r291": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r292": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r293": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r295": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r296": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2023-03-23" }, "r298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard", "URIDate": "2023-03-23" }, "r299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard", "URIDate": "2023-03-23" }, "r300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2023-03-23" }, "r301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2023-03-23" }, "r302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard", "URIDate": "2023-03-23" }, "r303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard", "URIDate": "2023-03-23" }, "r304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard", "URIDate": "2023-03-23" }, "r306": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2023-03-23" }, "r307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard", "URIDate": "2023-03-23" }, "r308": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard", "URIDate": "2023-03-23" }, "r309": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2023-03-23" }, "r310": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2023-03-23" }, "r311": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "5", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_5&doctype=Standard", "URIDate": "2023-03-23" }, "r312": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_9&doctype=Standard", "URIDate": "2023-03-23" }, "r313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard", "URIDate": "2023-03-23" }, "r314": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2023-03-23" }, "r315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2023-03-23" }, "r316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2023-03-23" }, "r317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard", "URIDate": "2023-03-23" }, "r318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard", "URIDate": "2023-03-23" }, "r319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2023-03-23" }, "r320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2023-03-23" }, "r321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_c&doctype=Standard", "URIDate": "2023-03-23" }, "r322": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard", "URIDate": "2023-03-23" }, "r323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard", "URIDate": "2023-03-23" }, "r324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" } } }